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 Abstract 
 Pain is a debilitating condition that presents a problem of clinical relevance. Common 
analgesics include opioids and non-steroidal anti-inflammatory drugs (NSIADs). Despite 
different degrees of effectiveness, a major drawback of these analgesic classes is their side 
effects. For example, side effects associated with opioids include pruritus, respiratory depression, 
hyperalgesia, constipation, dependence.  In addition, chronic use of NSAIDs can cause gastric 
ulcers. Delta-9 tetrahydrocannabinol (THC), the primary psychoactive constituent of marijuana, 
produces antinociception in various preclinical models of pain. Similarly, many synthetic 
cannabinoid receptor agonists produce antinociception in preclinical models of pain. However, 
their psychomimetic effects dampen interest for their therapeutic development. THC and these 
cannabinoids act upon the endocannabinoid system, which is comprised of the cannabinoid 1 
(CB1) and cannabinoid 2 (CB2) receptors, endogenous ligands arachidonoylethanolamide 
(anandamide; AEA), 2-arachidonoyolglycerol (2-AG), and endocannabinoid biosynthetic and 
catabolic enzymes. In the present study, we evaluated the impact of inhibiting one of the major 
biosynthetic enzymes of 2-AG, diacylglycerol lipase- (DAGL-), and two primary 
endocannabinoid catabolic enzymes, monoacylglycerol lipase (MAGL), and fatty acid amide 
hydrolase (FAAH). MAGL is responsible for degrading 2-AG and FAAH is the principal 
degradative enzyme for anandamide. We hypothesized that inhibiting these enzymes will 
produce anti-edematous and anti-allodynic effects in preclinical models of inflammatory pain. 
 In Chapter 2, we tested whether the selective MAGL inhibitor JZL184 and FAAH 
inhibitor PF-3845 would reduce nociceptive behavior in the carrageenan test. JZL184 and PF-
3845 significantly attenuated carrageenan-induced paw edema and mechanical allodynia (a 
nociceptive response to normally non-noxious stimuli), whether administered before or after 
 carrageenan. Complementary genetic and pharmacological approaches revealed that JZL184’s 
anti-allodynic effects required both CB1 and CB2 receptors, but only CB2 receptors mediated its 
anti-edematous actions. Anti-edematous effects of PF-3845 were mediated through CB2 
receptors. Importantly, the anti-edematous and anti-allodynic effects of JZL184 underwent 
tolerance following repeated injections of high dose JZL184 (16 or 40 mg/kg), but repeated 
administration of low dose JZL184 (4 mg/kg) retained efficacy.  
Although the data in the first set of studies demonstrate that inhibition of MAGL or 
FAAH reduces inflammatory pain, JZL184 and PF-3845 only produced partial effects. In an 
attempt to increase efficacy, Chapter 3 tested whether combined blockade of FAAH and MAGL 
would produce enhanced anti-edematous and anti-allodynic effects in the carrageenan model of 
inflammatory pain. Partial blockade of MAGL, with a low dose of JZL184 (4 mg/kg), and full 
blockade of FAAH, with a high dose of PF-3845 (10 mg/kg), enhanced the anti-allodynic effects, 
but no further increases in the anti-edematous effects were found. Importantly, repeated 
administration of this combination did not result in tolerance. A novel FAAH-MAGL dual 
inhibitor SA-57, which is far more potent in inhibiting FAAH than MAGL, reversed 
carrageenan-induced allodynia. Taken together, these findings suggest that dual MAGL and 
FAAH inhibition represents a promising avenue for the treatment of inflammatory pain.  
 Chapter 4 of this dissertation tested whether inhibition of DAGL-a major biosynthetic 
enzyme of 2-AG, would reverse inflammatory pain. Two DAGL-inhibitors, KT109, and 
KT172, which have been previously shown to reduce arachidonic acid, prostaglandins, and TNF-
 levels in lipopolysaccharide (LPS)-stimulated murine macrophages, were used to test whether 
these compounds would elicit antinociceptive effects in the LPS model of inflammatory pain 
model. Because these drugs also inhibit ABHD6, we assessed KT195, a selective ABHD6 
 inhibitor that is inactive against DAGL-. KT109, but not KT172 or KT195, significantly 
reversed LPS-induced allodynia. Importantly, we found that DAGL-knockout mice possess an 
anti-allodynic phenotype, but KT109 did not elicit any further decrease in allodynia in these 
animals. The anti-allodynic effects of KT-109 did not require cannabinoid receptors. 
Additionally, the anti-allodynic effects of KT-109 did not undergo tolerance following repeated 
administration. KT-109 did not produce any gastric hemorrhagic effects when compared to the 
NSAID diclofenac, which significantly produced gastric hemorrhages. These results suggest that 
blockade of DAGL- leads to antinociceptive effects through a cannabinoid receptor 
independent mechanism of action, with absence of notable side effects.  
Collectively, the research presented in this dissertation suggests that the endocannabinoid 
catabolic enzymes MAGL and FAAH, and the endocannabinoid biosynthetic enzyme DAGL-, 
represent promising targets to treat inflammatory pain.  
 
 
 
 
 
 
 
 1 
Chapter 1: Introduction 
Cannabinoid Discovery and Background 
 
 The earliest evidence of the use of cannabis was in 2900 BC on the island of Taiwan, 
near the mainland of China. Since prehistoric times, cannabis has been used for various 
purposes, including as a source of fiber for clothes and paper, religious and medicinal purposes 
as a curative and an anesthetic agent (Mechoulam, 1986). Records also exist of cannabis use in 
ancient civilizations in Japan, India, Israel, and Egypt. The western world became interested in 
the plant’s therapeutic value beginning in the middle of the 19th century for use in treating 
ailments such as cough, fatigue, headache, asthma, and rheumatism (O'Shaughnessy et al., 1842; 
Lowinson et al., 1997). In 1964, Δ9-tetrahydrocannabinol (THC) was identified as the primary 
psychoactive constituent of Cannabis sativa (Gaoni and Mechoulam, 1964). The term 
“cannabinoid” (CB) was defined as a group of structurally related terpenoids responsible for the 
pharmacological effects of the plant (Gaoni and Mechoulam, 1971, Mechoulam et al., 1987). In 
addition, more than 100 other phytocannabinoids have been discovered (Appendino et al., 2011). 
Other prevalent phytocannabinoids, cannabinol and cannabidiol possess a variety of 
pharmacological properties, but display fewer central nervous system (CNS) effects than THC 
and other synthetic cannabinoids (Mechoulam et al., 2002a, Mechoulam et al., 2002b). 
Subsequent research led to the discovery of cannabinoid receptors and the endocannabinoid 
system, as described below. 
Endocannabinoid System 
 
 The endocannabinoid system consists of two G-protein coupled receptors (GPCRs), CB1 
(Devane et al., 1988, Matsuda et al., 1990, Pertwee, 1997) and CB2 (Munro et al., 1993, Pertwee 
 2 
et al., 2007) and the endogenous ligands that bind to these receptors, including N-
arachidonoylethanolamine (anandamide, AEA) (Felder et al., 1996, Martin et al., 1999b) and 2-
arachidonoylglycerol (2-AG) (Mechoulam and Deutsch, 2005, Sugiura et al., 1995). In addition 
to these endogenous cannabinoids, other lipids including virodhamine, (Porter et al., 2002) 
meadethanolamide (Priller et al., 1995) and noladin ether (Hanus et al., 2001) interact with 
cannabinoid receptors. Endocannabinoids are enzymatically produced on demand in postsynaptic 
neurons and travel retrogradely to activate the CB1 receptors that are located presynaptically 
(Katona et al., 1999). Stimulation of CB1 and CB2 receptors by endocannabinoids or other 
receptor agonists lead to decreases in cAMP production via blockade of adenylyl cyclase 
(Howlett et al., 1990), activation of inwardly rectifying potassium (GIRK) channels via Gβγ 
subunits (Mackie et al., 1995, McAllister et al., 1999), and inhibition of Ca2+ channels 
attenuating presynaptic activity. A detailed description of the cannabinoid receptors and 
endogenous cannabinoid biosynthesis and degradation is given in the following sections.  
Cannabinoid Receptors 
 
 Two main cannabinoid receptors CB1 (Devane, 1988, Matsuda, 1990, Pertwee, 1997) and 
CB2 (Munro, 1993, Pertwee, 2007) were discovered in the 1990’s. The CB1 receptor has been 
cloned from rat (Matsuda, 1990), mouse (Chakrabarti et al., 1995), and human (Gerard et al., 
1991) tissues and shows 97–99% amino acid sequence identity across species. CB1 and CB2 
receptors share approximately 44% identity with each other (Munro, 1993). The transmembrane 
regions of these two receptors share approximately 68% amino acid similarity (Galiegue et al., 
1995). THC and many other cannabinoids activate these receptors. Both CB1 and CB2 receptors 
are G-protein coupled receptors (GPCRs), which are associated with Gi/o G-proteins (Howlett, 
1995, Pertwee et al., 2010). Upon interaction with CB1 and /or CB2 receptors agonists, these 
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GPCRs undergo conformational changes. The stimulated receptors facilitate the exchange of 
GDP for GTP at the α-subunit of the G-protein, leading to its dissociation from the receptor. 
Subsequently, the α-subunit and βγ-heterodimer are released and ultimately regulate various 
downstream effectors. Upon activation, these receptors decrease cAMP production via blockade 
of adenylyl cyclase (Howlett, 1990), activation of inwardly rectifying potassium (GIRK) 
channels via Gβγ subunits (Mackie, 1995, McAllister, 1999). Furthermore, activation of the 
cannabinoid receptors inhibits N- and P/Q-type calcium channels, which reduce synaptic vesicle 
fusion to the nerve terminal thereby inhibiting the release of excitatory and inhibitory 
neurotransmitters.  
 CB1 receptors are expressed pre-synaptically at both glutamatergic (Huang et al., 2001, 
Szabo and Schlicker, 2005) and GABAergic interneurons (Katona, 1999). These receptors play a 
role in short-term synaptic plasticity. CB1 receptor agonists act as neuromodulators by inhibiting 
release of glutamate and GABA. Transient suppression of the stimulatory neurotransmitter (e.g. 
glutamate) is called depolarized-induced suppression of excitation (DSE) (Kreitzer and Regehr, 
2001). Conversely, transient suppression of the inhibitory transmission (i.e. GABA) is termed 
depolarization-induced suppression of inhibition (DSI) (Vincent et al., 1992). Both result in 
cannabinoid receptor mediated hyperpolarization of a repetitively depolarized neuron, which 
suppresses subsequent vesicular fusion and release of glutamate or GABA.  
 The CB1 receptor was originally described as the “brain type” cannabinoid receptor, 
because the level of expression was high in the brain (Herkenham et al., 1990). Autoradiography 
of CB1 receptors in brain sections from several mammalian species, including rat, mouse and 
human, reveals a unique and conserved distribution; most dense in the basal ganglia, substantia 
nigra (pars reticulata), amygdalar nuclei, internal segment of the globus pallidus, caudate and 
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putamen, and in hippocampus and cerebellum. CB1 receptors are also present in dorsal horn and 
lamina X in the spinal cord and in medium and large-sized neurons in dorsal root ganglion. 
Finally, CB1 receptors are present in sparse densities in lower brainstem areas such as medulla 
and pons, periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) (Herkenham et 
al., 1991a, Herkenham et al., 1991b, Herkenham, 1990, Hohmann and Herkenham, 1999). Most 
behavioral effects produced by cannabinoids are mediated through CB1 receptors. For example 
THC-induced catalepsy, hypolocomotion and hypothermia were completely absent in CB1 
receptor deficient mice indicating that the classical behavioral effects of THC are mediated 
through CB1 receptors (Zimmer et al., 1999). Similarly, CB1 receptors mediate the discriminative 
stimulus effects of THC in drug discrimination paradigm. In drug discrimination procedure, an 
animal is trained to perform an operant response paired with vehicle and a different operant 
response  paired with the training drug. For example, the animal learns to press the left lever 
whenever it receives an injection of the training drug and to press the right lever when it is 
injected with vehicle. Once a subject has acquired to discriminate between drug and vehicle 
conditions, novel compounds are evaluated for substitution for the training drug. If a novel drug 
produces responding on the lever associated with the training drug, it is considered to 
have discriminative stimulus effects like those of the training drug and would be predicted to 
produce subjective effects like those of the training drug. The discriminative stimulus effects of 
cannabinoids in mice, rats, and rhesus monkeys were blocked by the CB1 receptor antagonist, 
rimonabant (Rinaldi-Carmona et al., 1994), indicating a CB1 receptors mechanism of action 
(Compton et al., 1996, Wiley et al., 1995a, Wiley et al., 1995b). 
 CB2 receptors are expressed in both the CNS and periphery. These receptors are 
associated with immune cells such as B cells, T cells, macrophages, neutrophils (Carayon et al., 
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1998, Galiegue, 1995, Pettit et al., 1996, Schatz et al., 1997). They have also been detected in 
spleen, bone marrow, pancreas, uterus, and lung (Galiegue, 1995). Initially the CB2 receptors 
were described as the periphery receptors; however, these are also expressed in the CNS in 
microglial cells (Cabral and Marciano-Cabral, 2005) and in brainstem neurons  (Van Sickle et 
al., 2005).  
Biosynthesis and degradation of Endocannabinoids 
 
 The biosynthetic pathways of anandamide and 2-AG have been well-investigated (Di 
Marzo and Petrosino, 2007). Anandamide was the first endogenous cannabinoid to be isolated 
and characterized (Devane et al., 1992, Felder et al., 1993). Anandamide belongs to the N-
acylethanolamine (NAE) family of bioactive lipids. N-acylphosphatidyl ethanolamine (NAPE) is 
the precursor of anandamide, which is synthesized by transacylation of phosphatidyl 
ethanolamine (Di Marzo et al., 1994). NAPE is then hydrolyzed by a Ca 2+ sensitive NAPE–
selective phospholipase D (NAPE-PLD), a phosphodiesterase from the metallo-β-lactamase 
family. NAPE-PLD knockout mice displayed a fivefold reduction in Ca2+-dependent conversion 
of NAPEs to NAEs (Leung et al., 2006). However, NAPE-PLD knockout mice show wild type 
levels of anandamide (Leung, 2006) indicating the existence of other pathways apart from the 
transacylation and phosphodiesterase pathways that are involved in anandamide production. In 
one of the alternate pathways, NAPEs are hydrolyzed to glycerophospho-N-aryl ethanolamine 
(GP-NAEs) by a serine hydrolase, α/β-hydrolase 4 (ABHD-4). GP-NAE is then hydrolyzed to 
anandamide by glycerophospho-diesterase-1. In the second alternate pathway, phospho-N-
arachidonoyl ethanolamine (pAEA), which is synthesized from N-
arachidonoylphosphatidylethanolamine by a phospholipase-C (PLC), is hydrolyzed to 
anandamide byphosphatases such as PTPN22 (Di Marzo, 2008, 2009, Ligresti et al., 2005).  
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 2-AG and anandamide are metabolized intracellularly to arachidonic acid and other 
products. Anandamide is hydrolyzed by post-synaptically located fatty acid amide hydrolase 
(FAAH), which belongs to the serine hydrolase family of enzymes (Cravatt et al., 1996, Patricelli 
and Cravatt, 1999, 2000, Patricelli et al., 1999, Patricelli et al., 1998). FAAH is a membrane 
bound serine hydrolase, which is located in the endoplasmic reticulum and acts at an alkaline pH 
(Cravatt, 1996). The structure of FAAH has been determined by X-ray crystallography (Bracey 
et al., 2002). FAAH (-/-) mice display 15 fold elevated anandamide levels in the brain (Cravatt et 
al., 2001, Lichtman et al., 2004). FAAH also hydrolyzes several other bioactive fatty acid amides 
in vitro (Cravatt, 1996, Desarnaud et al., 1995, Maurelli et al., 1995, Ueda and Yamamoto, 
1995), including N-palmitoylethanolamine (Calignano et al., 1998), and the sleep-inducing lipid 
oleamide (Cravatt et al., 1995). In addition, another FAAH substrate, N-acyl taurines (NATs) 
were discovered in the nervous system tissues from FAAH (+/+) and (-/-) mice. NATs were 
elevated more than 10-fold in brains and spinal cords from FAAH-(-/-) mice (Saghatelian et al., 
2006). Another enzyme of the serine hydrolase family, FAAH-2 is also involved in anandamide 
hydrolysis (Wei et al., 2006) but the hydrolysis rate is 38-fold slower than FAAH. In humans, 
FAAH-2 is present in the peripheral tissues such as the liver, but this enzyme is absent in the 
rodents. FAAH-2 hydrolyzes anandamide in situations where FAAH is inactivated (Wei, 2006). 
Additionally, a third N-acylethanolamine hydrolase termed N-acyl–ethanolamine-hydrolyzing 
acid amidase (NAAA) was discovered in human megakaryoblastic cells (Ueda et al., 1999) and 
in various rat tissues including lung, spleen, and macrophages (Ueda et al., 2001). This enzyme 
is active only at acidic pH and is catalytically distinct from FAAH (Ueda and Tsuboi, 2005). 
This enzyme has shown to primarily hydrolyze N-palmitoyl ethanolamine and anandamide in 
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macrophages (Solorzano et al., 2009, Sun et al., 2005). Additionally, cyclooxygenase-2 (COX-2) 
also hydrolyses anandamide to prostaglandin ethanolamides (PGH2-EA) (Kozak et al., 2002).  
 The second discovered endogenous cannabinoid, 2-AG is synthesized via a two-step 
process. Phosphatidyl inositol is converted to Diacylglycerol (DAG) by PLC activity, which is 
then hydrolyzed by diacylglycerol lipase to 2-AG. Diacylglycerol lipases (DAGLs) are 
biosynthetic enzymes that are involved in mediating neuronal growth during development and as 
a retrograde messenger (Tanimura et al., 2010, Williams et al., 2003). Two DAGL enzymes are, 
DAGL-α (120 kDa) and DAGL-β (70 kDa). DAGL has four transmembrane domains with both 
the C and N terminus located inside the membrane (Bisogno et al., 2003). This enzyme also 
belongs to the serine hydrolase family. DAGL-β is predominantly expressed in the developing 
brain and in the periphery, while the α-isoform is mainly found in the central nervous system 
(Bisogno and Di Marzo, 2010, Gao et al., 2010). During brain development DAGL, is located on 
the axonal tract where it produces 2-AG, which mediates the axonal growth (Williams, 2003). In 
adults, DAGL is located postsynaptically (Williams, 2003). In the hippocampus, the postsynaptic 
release of 2-AG induced by depolarization results in the transient suppression of GABA-
mediated transmission at inhibitory synapses. This form of depolarization-induced suppression 
of inhibition (DSI) is completely lost in DAGL knockout animals, indicating an essential role for 
this enzyme in regulating retrograde synaptic plasticity (Gao, 2010). In addition, adult 
neurogenesis is compromised in the hippocampus and subventricular zone (SVZ) of DAGL- (-
/-) mice and in the hippocampus of DAGL- (-/-)mice (Gao, 2010). These data indicate that 
DAGL plays an important role in adult neurogenesis (Gao, 2010). A second pathway for 2-AG 
production involves an intermediate 2-arachidonoyl-lysophosphatidylinositol (lyso-PI). 
Phosphotidyl inositol preferring phospholipase A1 converts phosphatidyl inositol to the lyso-PI 
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intermediate, which in turn gets converted to 2-AG by lysophosphatidyl inositol selective PLC 
(Di Marzo, 2008, 2009, Ligresti, 2005). 
  MAGL is the main enzyme responsible for degrading 2-AG (Dinh, 2004, Dinh et al., 
2002). It hydrolyses 2-AG to arachidonic acid and glycerol (Fredrikson et al., 1986). The enzyme 
is expressed presynaptically, and the highest concentrations are found in the cell membrane, and 
in the cytosolic fraction (Blankman et al., 2007, Dinh, 2002). The physiological roles of MAGL 
appear to be tissue specific. For example in adipose tissue, monoglycerides formed from stored 
triglycerides is hydrolyzed by MAGL to fatty acid and glycerol. The released free fatty acids are 
then used as a source of energy in vivo (Chon et al., 2007). MAGL indirectly controls 
prostaglandin levels, by being a major enzyme involved in the formation of its precursor 
arachidonic acid. It has been shown that MAGL exerts control over both basal and LPS-induced 
arachidonic acid and prostaglandins in liver and lung (Nomura et al., 2011). But cytosolic 
phospholipase -A2 regulates these lipids in the gut and spleen indicating that MAGL regulates 2-
AG degradation in a tissue specific manner (Nomura, 2011). In addition, MAGL controls the 
duration of retrograde signaling mediated by 2-AG. ABHD6 and ABHD12 also hydrolyze 2-AG 
to arachidonic acid (Blankman, 2007, Marrs et al., 2010). Additionally, 2-AG can be hydrolyzed 
by COX-2 to prostaglandin glycerol ester (PGH2-G) (Di Marzo, 2008, Ligresti, 2005).  
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Figure 1: The endocannabinoid system: receptors, ligands and their regulatory pathways  
2-AG: 2-arachidonylglycerol; AEA: anandamide; AA: arachidonic acid; MAGL: 
monoacylglycerol lipase; FAAH: fatty acid amide hydrolase; DAGL: diacylglycerol lipase; CB1: 
cannabinoid receptor-1. 
Overview of Pain: 
 
 As defined by the International Association for the Study of Pain (1979),  pain is “an 
unpleasant sensory and emotional experience associated with actual or potential tissue damage, 
or described in terms of such damage” (International association for study of pain, 1979) (Pain, 
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1979). The sensory components of pain are complex and several distinct types exist, including 
nociceptive (pain in response to a noxious stimulus), inflammatory (pain in response to tissue 
damage and inflammation), neuropathic (pain associated with the damage to the nervous 
system), and functional (pain resulting from abnormal central processing of normal input) 
(Woolf, 2004). Pain may be evoked by the presence or absence of a stimulus. There are different 
types of nociceptive stimuli such as thermal, electrical, mechanical and chemical (Bennett, 2001, 
Dykstra, 1985, Le Bars et al., 2001, Mogil et al., 2001) that have been used to evoke pain in 
different pain models. Pathological pain states can produce allodynia, which is defined as pain 
produced by stimulus that is normally not painful and/or hyperalgesia, which is increased pain 
sensitivity to a stimulus that is normally painful (International association for study of pain, 
1979). Analgesia is absence of pain to a noxious stimulus (International association for study of 
pain, 1979). Millions of people suffer from pain every year and that has tremendous effects on 
the US in health care costs, rehabilitation and lost worker productivity, as well as cause 
emotional and financial burden on patients and their families (American academy of pain 
medicine). According to a recent Institute of Medicine report, pain is a significant public health 
problem that costs society at least $560-$635 billion annually, this includes the total incremental 
cost of health care due to pain from ranging between $261 to $300 billion and $297-$336 billion 
due to lost productivity (PRWEB 2011).  
Pain processing 
Peripheral: 
 While pain normally serves as a warning device and can facilitate recuperation, it can 
also represent a serious and debilitating condition. The complex physiology of pain begins with 
activation of primary sensory neurons, also known as nociceptors, by noxious stimuli (Burke, 
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2007). Nociceptors have two different kinds of axons rapidly conducting A- fibers, and slowly 
conducting, unmylinated C-fibers. A- fibers elicit the first phase of sharp pain and C-fibers 
elicit a wave of dull pain (Julius and Basbaum, 2001, Millan, 1999). Both Aδ- and C-fibers  
synapse in the dorsal horn of the spinal cord. Then their sensory inflow transfers to second-order 
neurons in the spinal cord in topographically organized manner (Costigan and Woolf, 2000, 
Markenson, 1996, Millan et al., 1996). Then the projection cells with axons in the receiving 
neuron transmitted to the brain and ultimately activate specific brain regions. (Riedel and Neeck, 
2001, Todd et al., 2006, Willis, 1991).  
Central: 
Spinal Cord 
 The neuronal organization of the spinal cord determines characteristic features of pain, 
e.g. the projection of pain into particular tissues (Schaible et al., 2006). Noxious stimuli activate 
nociceptors, which transmit the signal through the dorsal root ganglia to the dorsal horn of the 
spinal cord (Todd, 2006, Woolf, 2004). The activation of nociceptive fibers at the dorsal horn 
results in the release of excitatory neurotransmitter glutamate, aspartate, calcitonin gene peptide 
(CGRP), which are important mediators of spinal transmission (Urban and Gebhart, 1997) 
(Todd, 2006, Yaksh, 1999). The two classes of interneurons in the dorsal horn that play roles in 
the transmission of nociception are the inhibitory neurons that use γ-aminobutyric acid (GABA) 
or glycine, and excitatory neurons that are glutamatergic (Todd, 2006). The excitatory amino 
acid glutamate activates the metabotropic G-protein coupled receptor alpha-amino-3-hydroxy-5-
methyl-4- isoxazolepropionic acid (AMPA)/kainite (K) and the ionotropic receptor, N-methyl-D-
aspartate (NMDA) (Morgan et al., 1999, Ren and Dubner, 1999a, b, Todd, 2006). The AMPA/K 
receptors mediate fast synaptic transmission by activating and deactivating rapidly and 
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desensitize upon prolonged agonist exposure. On the other hand, NMDA receptors have a 
significantly slower activation and deactivation time (McBain and Mayer, 1994). NMDA 
receptor activation plays a role in inflammatory and neuropathic pain states (Price et al., 1994, 
Sindrup and Jensen, 1999)
 
and results in the activation and exacerbation of peripheral 
hyperalgesia and accountable for the changes seen during central sensitization (Costigan and 
Woolf, 2000, Morgan, 1999, Ren and Dubner, 1999a, b). 
Brain 
 Nociceptive signals in the dorsal horn project to the supraspinal sites (Almeida and Val-
Gallas, 1997, Berkley and Hubscher, 1995, Bester et al., 1995, Calvino and Grilo, 2006, Millan, 
1999). Two major pathways that project nociceptive information are the spinothalamic tract and 
the spinoreticular tract. Glutamate facilitates the transfer of the signal from the spinothalamic 
tract to the thalamus and from the spinomesencephalic tract to the periaqueductal grey (PAG) 
while other neuropeptides (i.e. SP) play a role in relaying information to the brain (Azkue et al., 
1997) (Jensen and Yaksh, 1992). The spinothalamic tract first innervates the thalamus and 
consequently the postcentral gyrus of the cortex (Apkarian et al., 1992, Berkley and Hubscher, 
1995, Casey et al., 1996, Millan, 1999). The thalamus is a major relay station in the emotional 
and cognitive processing of pain that relays information to various cortical regions via a complex 
pattern of connections (Millan, 1999). On the other hand, spinoreticular tract fibers ascend to 
reach the brainstem reticular formation and then project to thalamus and hypothalamus. This 
pathway is involved in the affective/motivational aspects of pain (Almeida et al., 2004). 
Inflammation 
 Inflammation develops in response to tissue injury and is a main contributor in pain 
perception (Costigan and Woolf, 2000, Pasero, 2004). Inflammation is triggered by macrophages 
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release at the site of tissue damage (Costigan and Woolf, 2000). Several inflammatory mediators 
such as bradykinin, prostaglandins, histamine, and cytokines are released in response to tissue 
injury (Costigan and Woolf, 2000, Millan, 1999). Bradykinin causes activation of second 
messengers resulting in increased sodium ion channel conductance and sensitization. 
Prostaglandins enhance activity of bradykinin and contribute to inflammatory responses. These 
mediators act on various receptors and ion channels of the nociceptors, causing various signal 
transduction cascades that result in modulation of effector molecules and changes in gene 
transcription (Costigan and Woolf, 2000). There are two types of inflammatory responses: acute 
inflammation, which is a short-term process and displays five major signs of inflammation: 
swelling, redness, heat, pain, and sometimes dysfunction of organs (Costigan and Woolf, 2000, 
Millan, 1999) and chronic inflammation which is of longer duration and is associated with local 
infiltration of monocytes, lymphocytes, macrophages, and proliferation of small blood vessels 
and fibroblast (Chen et al., 2008). 
Preclinical pain models 
 
 Experimental models to study pain mechanisms necessitate the use of a quantifiable and 
reproducible stimulus that elicits measurable nociceptive responses.  The different types of 
stimuli used to generate nociceptive responses include thermal, electrical, mechanical and 
chemical. Therefore, pain models can be classified based on the different kinds of stimuli.  
Common pain models that employ thermal stimuli are the tail-flick test, the paw-
withdrawal test, and the hot plate test (Le Bars, 2001). The tail-flick test involves immersing the 
tip of the tail in a warm water bath at a predetermined temperature that is typically above 50
o
 C 
or focusing a radiant heat source on the tail. The heat provokes abrupt reflexive movement of the 
tail and sometimes recoiling of the body. The latency for the response is generally determined 
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with a stopwatch or an apparatus that senses tail movement (Ben-Bassat et al., 1959, Grotto and 
Sulman, 1967, Janssen et al., 1963). In paw withdrawal test, heat is applied to the planter surface 
of an already inflamed paw of freely moving animals and the latency of withdrawing the paw 
from the stimulus is monitored (Hargreaves et al., 1988a). The limitation of this assay is that the 
position of the limb because the background level of activity in the flexors changes with the 
position of the animal. In the hot plate test, the animal is put into a cylindrical space with a floor 
consisting of a heated metallic plate (Leimbach, 1953, MacDonald, 1944, O'Callaghan and 
Holtzman, 1975). Then the reaction time of withdrawing the paw by licking or jumping is 
measured.  
 Mechanical stimuli applied to a hind paw or the tail and the threshold (weight in grams) 
am evoked behavior (lifting, stretching, and licking) are measured.  This type of stimulus has 
limitations. For example, repeated use of the stimulus can increase the sensitivity of the 
stimulated area resulting a false positive result (Fennessy and Rattray, 1971). As proposed by 
Randall and Selitto in 1957, the latter can be improved by comparing the paw withdrawal 
threshold of a non-inflamed normal paw with an inflamed paw from the same animal (Randall 
and Selitto, 1957). A mechanical stimulus is used to measure trauma, inflammation or nerve 
injury evoked pain.  
 Electrical stimulus is delivered in the paw through the floor of the cage where the animals 
are free to move (Blake et al., 1963, Bonnet and Peterson, 1975, Crocker and Russell, 1984, 
Evans, 1961). The animals respond to this noxious stimulus by and the latency is measured.  
Thermal, mechanical, and electrical are short duration stimuli that produce phasic pain 
(Le Bars, 2001) where the receptors respond to punctuate stimuli  (Le Bars, 2001). Other tests 
involve the use of variety of chemicals that produce inflammatory responses such as formalin 
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(Hwang and Wilcox, 1986, Kellgren, 1939), acetic acid (Teiger, 1976), complete Freund's 
adjuvant (Iadarola et al., 1988) and carrageenan (Okuda et al., 1984, Otsuki et al., 1986) (Butler 
et al., 1992, Coderre and Wall, 1987, Tonussi and Ferreira, 1992). These types of stimuli are 
used as a model of tonic pain where the receptors adapt slowly to the stimulus and convey 
information about the duration of the stimulus (Le Bars, 2001). Most of these assays invoke 
nociceptive behavior or increase sensitivity to the stimuli described above. These responses can 
persist for a prolonged period of time. Complete Freund's adjuvant  or carrageenan can elicit pain 
that lasts from days to weeks (Okuda, 1984, Otsuki, 1986) (Butler, 1992, Coderre and Wall, 
1987, Le Bars, 2001, Tonussi and Ferreira, 1992).  
In the models described above, a noxious stimulus is used to produce the measured 
response. The allodynic, hyperalgesic and other nociceptive responses described above are 
conceptualized as pain-stimulated behavior (Negus et al., 2006). Many preclinical models of pain 
(acute, inflammatory, and neuropathic) are based on pain-stimulated behaviors. For example, a 
noxious stimulus produces an increase in frequency and intensity of the dependant measure, 
which is used to infer pain (Dykstra, 1985, Le Bars, 2001, Negus, 2006, Stevenson et al., 2009). 
A pitfall of pain-stimulated assays is that analgesics can produce false positives by impairing 
motor function.  
 However, pain is also associated with depression of many behaviors such as feeding, 
locomotor activity and mating (Flecknell, 1994, Karas, 2002, Negus, 2006, Stevenson, 2009). 
These responses are conceptualized as pain-depressed behaviors. Accordingly, the pain stimulus 
results in a depression of learned or unconditional behaviors (Stevenson et al., 2006).  In the case 
of pain-depressed behavior, treatment efficacy is inferred by the reinstatement of the behavior 
(Negus, 2006). An advantage of models measuring pain-depressed behavior is that there is a 
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decrease of likelihood of a drug producing false positive analgesic effects. In addition, 
preclinical models measuring pain-depressed behavior possess clinical relevance because 
restoration of a function is a desired outcome in patients. 
 It is believed that pain-depressed behavior involves affective or emotional aspect of pain 
while pain stimulated behavior reflect sensory-discriminative components of pain (Negus, 2006, 
Stevenson, 2006, Stevenson, 2009). Therefore, pain-stimulated and pain-depressed behavior 
represent two complementary approaches to study the sensory-discriminative and affective-
motivational aspects of pain. The affective component of pain is clinically relevant and it is also 
studied by using condition place preference (CPP) paradigm. In this assay, the subject is 
subjected to a chronic pain condition and the effects of analgesics are tested in an apparatus 
containing two chambers; one chamber that is paired with the analgesic and the other chamber 
that is paired with vehicle. A drug that produces pain relief will lead to a preference to the 
chamber associated with it  (Cahill et al., 2013, Niikura et al., 2008, Ozaki et al., 2003, Ozaki et 
al., 2002). It is also important to test the drug in different animals that are in a pain free condition 
to assess intrinsic rewarding effects of a drug. An analgesic should be more potent in producing 
CPP in animals under the pain state than to the animals under the pain free condition. Many 
types of analgesics such as morphine and gabapentin have been shown to produce CPP in pain-
subjected animals, suggesting pain relief. 
Analgesics 
 
 Analgesics are the therapeutic compounds prescribed to control or treat the pain state, 
which include opiates and non-steroidal anti-inflammatory drugs (NSAIDs). Despite possessing 
a range in the degree of effectiveness, a major drawback of these analgesic compounds is related 
to their long-term use. For example, NSAIDs produce their antinociceptive actions by 
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inhibiting cyclooxygenases, leading to a decrease in prostaglandin production.  Untoward side 
effects of NSAIDs include  gastric ulcers, renal failure, allergic reactions, and hemorrhage by 
inhibiting platelet aggregation (i.e., aspirin). Additionally, they can cause potentially life-
threatening liver damage . Opioids produce their pharmacological effects through ,,  
receptors in the CNS and periphery and are very effective analgesics. These drugs are associated 
with serious untoward side effects both acutely and upon chronic administration. Acute 
administration of opiates can cause respiratory depression and pruritus and repeated opioid use 
can lead to tolerance, opiate-induced hyperalgesia, constipation, and the potential of addiction 
(Hojsted and Sjogren, 2007, Schug et al., 1992). Because of these significant side effects, there 
are many other drug classes under investigation for alleviating pain. Another example is 
gabapentin, which is structurally related to γ-aminobutyric acid (GABA), a neurotransmitter that 
plays a role in pain transmission and modulation, has been shown to be effective in various 
animal models of chronic neuropathic pain such as chronic constriction injury model of 
neuropathic pain in rats (Bennett, 1988).
 
Gabapentin administered intraperitoneally doses 
ranging from 10 to 75 mg/kg produces significant dose-related improvement in heat hyperalgesia 
and mechanical allodynia (Xiao and Bennett, 1995). Heat hyperalgesia was also significantly 
reduced following intrathecal gabapentin administration, indicating that the antihyperalgesic 
properties of gabapentin are at least partially modulated through spinal cord mechanisms (Xiao 
and Bennett, 1995). In addition, gabapentin was effective in significantly reducing late-phase 
tactile allodynia in both the rat formalin (Shimoyama et al., 1997) and carrageenan footpad tests 
and hyperalgesia in the rat streptozotocin model (Parke-Davis Pharmaceutical Research, 
unpublished data, 1997). However, this drug also produces significant motor and cognitive side 
effects (Backonja et al., 1998, Martin et al., 1999a).  
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Cannabis in clinical model of pain: 
 
  Studies evaluating smoked cannabis compared to placebo show significant 
improvements in pain conditions in patients. For example, smoked cannabis has been shown to 
reduce pain associated with fibromyalgia, post traumatic and postsurgical neuropathic pain, 
central peripheral neuropathic pain, human immunodeficiency virus–associated sensory 
neuropathy and cisplatin-induced pain and hyperalgesia (Abrams et al., 2007, Ellis et al., 2009, 
Fiz et al., 2011, Wallace et al., 2007, Ware et al., 2010, Wilsey et al., 2008). Approximately 15 to 
56 patients were involved in these studies and commonly reported side effects observed were dry 
mouth, headache, dizziness, dry eyes, hypotension, sedation, and concentration deficit. Another 
cannabinoid drug called Sativex/Nabiximols that consists of THC and cannabidiol (CBD) in 1:1 
ratio, has been tested in patients with rheumatoid arthritis (Blake et al., 2006), neuropathic pain 
(Nurmikko et al., 2007), central and neuropathic pain associated with multiple sclerosis (Rog et 
al., 2005, Rog et al., 2007). These studies have demonstrated significant reduction in pain 
compared to placebo, but patients have reported sedation, dizziness, and nausea as side effects. 
Similarly, high dose of THC produces analgesia in cancer patients at a dose that is equivalent to 
high dose of codeine (morphine derivative) and the side effects are dizziness, blurred vision, and 
ataxia (Noyes et al., 1975a, Noyes et al., 1975b). Another synthetic THC called 
marinol/dronabinol has not reduced chronic gastrointestinal pain or posthysterectomy pain 
(Buggy et al., 2003, Holdcroft et al., 1997, Naef et al., 2003) but has demonstrated a reduction in 
pain score in multiple sclerosis patients (Svendsen et al., 2004). These data indicate that these 
drugs are effective against limited pain conditions. Additionally, THC has shown to produce 
poor efficacy in reducing acute pain in humans (Beaulieu, 2006, Buggy, 2003, Kraft et al., 2008, 
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Naef, 2003, Raft et al., 1977). Enzymes regulating endocannabinoids are an emerging target to 
treat pain with reduced side effects.  
Role of direct cannabinoid receptor agonists on pain: 
 
 THC and other direct-acting cannabinoid receptor agonists produce analgesic effects in 
laboratory animals, but without respiratory depressant effects. For example, administration of 
synthetic cannabinoid receptor agonists (i.e. CP-55940, WIN 55-212-2 and HU210) produces 
analgesia and reduces edema in the carrageenan-induced inflammatory pain model (Elmes et al., 
2005, Nackley et al., 2003, Wise et al., 2008). Additionally, peripherally restricted cannabinoid 
receptor agonist, naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)-methanone possesses 
antihyperalgesic activity in  sciatic nerve ligation model of neuropathic pain (Dziadulewicz et al., 
2007). Compound A, another peripherally restricted potent CB1/CB2 receptor agonist, has 
produced anti-hyperalgesic activity in spinal nerve ligation model of neuropathic pain in rats as 
well as in formalin model of inflammatory pain in mice (Boyce, 2008). But this compound has 
also produced cataleptic activity at the same dose at which it has produced antinociception 
(Boyce, 2008). Two other such compounds are AZD1940 and AZ11713908. AZD1940 has been 
shown to reduce capsaicin-induced nociception in rats (Groblewski, 2010). Similarly, 
AZ11713908 has produced antinociceptive effects comparable to WIN 55, 212-2 in the 
carrageenan model of inflammatory pain and in spinal nerve ligation model of neuropathic pain 
in rats (Yu et al., 2010). It is also noteworthy that AZ11713908 has produced CNS mediated side 
effects such as catalepsy (Yu, 2010). The result indicates that this compound crosses blood brain 
barrier at a high dose. Additionally, ajulemic acid (CT-3), synthetic analogue of THC, has been 
shown to ameliorate neuropathic and inflammatory pain (Dyson et al., 2005, Mitchell et al., 
2005). Local administration of the selective CB1 receptor agonist, arachidonyl-2-chlorethylamide 
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(ACEA), in the paw suppresses the carrageenan-evoked mechanical hyperalgesia in rats 
(Gutierrez et al., 2007). Although such direct acting cannabinoid receptor agonists produce 
antinociceptive and anti-inflammatory effects, their CB1 mediated psychomimetic side effects 
such as catalepsy, hypomotility, hypothermia, hypolocomotion and abuse potential have 
dampened enthusiasm for developing drugs that act directly at CB1 receptors (Schlosburg et al., 
2009).  
On the other hand, the CB2 receptor agonist AM1241 inhibits tactile hypersensitivity to 
carrageenan and reduced spinal nerve ligation induced nociception in rats (Nackley et al., 2004), 
which indicates that targeting CB2 receptors is a viable alternative to CB1 agonists.  Similarly, 
AM1241, GW405833, and HU-308 has shown to produce antinociceptive effects in the hind paw 
incision model in rats (LaBuda et al., 2005). HU-308 has also reduced formalin-induced 
peripheral pain in mice (Hanus et al., 1999). Additionally, JWH-015 can reduce post-operative 
pain in rats (Romero-Sandoval and Eisenach, 2007). Other CB2 agonists  JWH-133 and AM1710 
have been shown to reduce neuropathic pain  in mice (Yamamoto et al., 2008) and in rats 
(Wilkerson et al., 2012) respectively. Also, L768242 and 1-(4-(pyridin-2-
yl)benzyl)imidazolidine-2,4-dione have reduced allodynia elicited by L5-L6 spinal nerve ligation 
in rats (Beltramo et al., 2006, van der Stelt et al., 2011). However, none of the CB2 selective 
agonists that have been developed so far is completely selective for CB2 receptors. Therefore, 
they produce CB2 selectivity only within a specific dose range (Pertwee, 2012). They tend to 
activate CB1 receptors at higher doses (Pertwee, 2012). Furthermore, CB2 receptor agonist 
AM1241 has been shown to produce very different effects at CB2 receptors from different 
species. For example a racemic mixture of AM1241 is an agonist at human CB2 but functions as 
an inverse agonist at rodent CB2 (Atwood and Mackie, 2010). Similarly, these exogenously 
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administered synthetic cannabinoids and THC cause a persistent inhibition of CB1 receptors and 
neurotransmitter release, and do not mimic the localized and transient effects seen with 
endocannabinoids (Vaughan and Christie, 2005). Thus, exploration of the other targets in the 
endocannabinoid system, such as endocannabinoid regulating enzymes, may possess promise in 
the clinical setting with decreased subset of marijuana-like side effects. For example altering 
endogenous cannabinoid levels by blocking DAGL- or MAGL and/or FAAH represent an 
attractive alternate approach to elicit antinociception, but without eliciting cannabimimetic 
effects (Cravatt, 2001, Gobbi et al., 2005). Hence, this dissertation focuses on the role of 
endocannabinoid catabolic and anabolic enzymes inhibition on inflammatory pain in mice.  
Role of DAGL inhibition in antinociceptive effects 
 
  DAGL represents an upstream enzyme in the production of 2-AG and arachidonic acid. 
Thus, DAGL inhibition produces a reduction of 2-AG synthesis (Gao, 2010) as a result reduces 
arachidonic acid production (Hsu et al., 2012).  Potential therapeutic applications have been 
proposed to be similar to those of cannabinoid antagonists (Di Marzo, 2008), which have been 
shown to aid in weight loss (Chaput and Tremblay, 2006, Cota et al., 2006, Di Marzo et al., 
2001, Pagotto et al., 2006), inflammation in rats (Lu et al., 2006, McVey et al., 2003), and 
Parkinson's symptoms such as dyskinesia (slight tremor of the hands to uncontrollable movement 
of the upper body but can also be seen in the lower extremities) (Brotchie, 2003, Di Marzo et al., 
2000). Yet much less is known about the physiological effects of disrupting endocannabinoid 
production in vivo due, at least in part, to a lack of selective inhibitors for the enzymes that 
biosynthesize endocannabinoids. Non-selective agents such as RHC80267 and 
tetrahydrolipstatin (THL) are known to inhibit DAGL, but have off target effects on other 
lipases. For example, RHC-80267 has been reported to inhibit FAAH (Cravatt, 1996) and acts as 
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a muscarinic receptor antagonist (Hashimotodani et al., 2008). Similarly THL has been found to 
block ABHD12 (Blankman, 2007) and pancreatic lipases in the intestine (Chevaleyre et al., 
2006). Alternatively, other selective inhibitors of the 2-AG biosynthesis, ﬂuorophosphonates O-
3841 and O-3640 show limited activity in cells (Bisogno et al., 2006, Bisogno, 2003) and are less 
potent than tetrahydrolipstatin (THL) (Ortar et al., 2008). In addition, these compounds do not 
show selectivity between the α and β forms of the enzyme (Min et al., 2010).  
 Hsu et al 2012 has recently reported the discovery of 1, 2, 3-triazole urea (1, 2, 3-TU) as 
a versatile chemotype for serine hydrolase inhibitor development. They describe discovery of 
two compounds KT109 (IC50 = 82 nM) and KT172 (IC50 = 71 nM) that potently and selectively 
inactivated DAGL- in vitro and in vivo. These compounds as well as DAGL--/-) mice (Gao, 
2010) were used to show that DAGL- is the principal 2-AG biosynthetic enzyme in peritoneal 
macrophages. The pharmacologic or genetic inactivation of DAGL- produced a remarkable 
array of metabolic changes in macrophages that included not only reductions in 2-AG levels, but 
also decreases in arachidonic acid and prostaglandins. Interestingly, inactivation of DAGL- also 
attenuated lipopolysaccharide-stimulated TNF- release from macrophages, implicating a 
DAGL- regulated endocannabinoid-eicosanoid network as an important modulator of 
proinflammatory responses in macrophages (Hsu, 2012).  
 KT109 and KT172 have a known off-target, ABHD6 (IC50 values of 16 and 5 nM, 
respectively). Hence, a negative-control probe, KT195 has been generated to address that 
problem. KT195 has shown to be a potent (IC50 = 10 nM) selective inhibitor of ABHD6 and 
structurally related to KT109 and KT172, but inactive against DAGL- (Hsu, 2012). Although 
the findings indicate that DAGL- inhibitors, KT-109 and KT-172 reduce 2-AG, AA, 
prostaglandins as well as reduce TNF- from the macrophages (Hsu, 2012), the role of this 
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inhibitors on the prolonged model of inflammatory nociception is yet to be examined. Hence, in 
the present study we have tested the role of KT-109, KT-172 and KT-195 (as a control for 
ABHD6) in the LPS model of inflammatory pain in mice. LPS is a bacterial endotoxin derived 
from the outer cell wall of gram (-) bacteria. When injected into the plantar surface of the mouse 
paw, it elicits a mild innate or non-specific inflammatory response. The innate response is 
characterized by an infiltration of immune cells, the release of cytokines and chemokines, and 
activation of complement cascades to remove the bacteria. The resulting response is the 
induction of tactile allodynia (painful response to a non-noxious stimulus) (Rowbotham and 
Fields, 1989, Staud and Domingo, 2001). Hence, in this thesis, I test the hypothesis that genetic 
or pharmacological inhibition of 2-AG synthesizing enzyme DAGL-, blocks mechanical 
allodynia associated with inflammation.  
Role of FAAH inhibition in antinociceptive effects 
 As shown in table 1, the bulk of research examining the role of endocannabinoid 
catabolic enzymes in nociception has focused on FAAH (Booker et al., 2011, Chang et al., 2006, 
Clapper et al., 2010, Jayamanne et al., 2006, Kinsey et al., 2011a, Naidu et al., 2008, 2009, 
Naidu et al., 2010, Suplita et al., 2005), largely because of a greater availability of selective 
FAAH inhibitors than selective MAGL inhibitors. Irreversible (PF-3845, URB597) and 
reversible (OL-135) inhibitors of FAAH have been demonstrated to elevate anandamide levels in 
the brain (Ahn et al., 2009, Boger et al., 2005, Fegley et al., 2005, Kathuria et al., 2003, 
Lichtman, 2004) and produce analgesia in a wide variety of animal models of pain (Schlosburg, 
2009). Systemic administration of the FAAH inhibitor URB597 reduces carrageenan-induced 
paw edema (Holt et al., 2005). URB597 also reduces both plantar thermal and mechanical 
threshold sensitivity in a dose-dependent manner in complete Freund’s adjuvant-induced 
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inflammatory pain. Repeated oral administration of URB597 attenuates chronic constriction 
injury of sciatic nerve-induced thermal hyperalgesia and mechanical allodynia (Russo et al., 
2007). The reversible FAAH inhibitor, OL-135, reverses mechanical allodynia in a spinal nerve 
ligation model (Chang, 2006), chronic constriction injury (CCI) model (Kinsey et al., 2009) and 
acetic acid (Naidu, 2009), hot plate, tail-immersion, formalin (Lichtman, 2004) and LPS 
(Booker, 2011) models of pain. Peripherally restricted FAAH inhibitor URB593 has been shown 
to reduce carrageenan-induced inflammatory pain (Okine et al., 2012) and has also reduced 
neuropathic pain in spinal nerve ligation model (Clapper, 2010). Another FAAH inhibitor JNJ-
1661010 has been shown to attenuate tactile allodynia in rat mild thermal injury model of acute 
tissue damage, in the rat spinal nerve ligation model of neuropathic pain as well as in 
carrageenan model of inflammatory pain (Karbarz et al., 2009). The long-lasting FAAH inhibitor 
PF-3845 has produced anti-allodynic effects in the complete Freund’s Adjuvant (CFA) model 
(Ahn, 2009) and has partially suppressed the hyperalgesia in the LPS mouse model of 
inflammatory pain (Booker, 2011). Similarly, deletion of the FAAH gene increases levels of 
anandamide, accompanied with CB1 receptor-mediated hypoalgesic phenotypes in models of 
acute and inflammatory pain and acetic acid-induced nociception (Booker, 2011, Chang, 2006, 
Cravatt, 2001, Lichtman, 2004).  
Recently, a novel compound ARN272 was  found  to block AEA binding to FAAH like 
anandamide transporter (FLAT). As a result it increased plasma anandamide levels which in turn 
has produced antinociception in the formalin model of pain (Fu et al., 2012). It should be noted 
that  Leung et al 2013, were unable to detect the expression of FLAT using RT-PCR and western 
blotting, in dorsal root ganglion, spinal cord, liver, and kidney.  FLAT may exhibit a low tissue 
expression profile that is below the detection limit of these approaches (Leung et al., 2013), 
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which raises serious questions about this purported anandamide transporter. The reason behind 
these two contrasting results is unclear and they question the role of ARN272 as well as FLAT 
on antinociception.  
 The beneficial effects caused by FAAH blockade in these models are predominantly 
mediated through the activation of CB1 and/or CB2 receptors, though noncannabinoid 
mechanisms of actions can also play contributory or even primary roles. The two major 
noncannabinoid receptors that play a role in antinociception are transient receptor potential 
vanilloid  (TRPV1) and peroxisome proliferator-activated receptors (PPAR). Pharmacological 
data and receptor binding data show that anandamide binds to the TRPV1 receptors in dorsal 
root ganglion (Tognetto et al., 2001) and in the sensory nerve (Zygmunt et al., 1999). Similarly, 
FAAH regulated N-acyl taurines have been shown to activate TRPV1 receptors (Saghatelian, 
2006). TRPV1 antagonists capsazepine blocked the anti-hyperalgesic effects of anandamide 
indicate the role of these receptors in antinociception (Horvath et al., 2008). Additionally, 
administration of capsazepine and CB1 receptor antagonist AM251 partially blocked the 
antinociceptive effects of URB597 in the periaqueductal gray (Maione et al., 2006). Similarly, 
anti-allodynic and anti-hyperalgesic effects of another FAAH substrate palmitoylethanolamide, 
were mediated by CB1 and TRPV1 receptors suggesting the involvement of these receptors in 
mediating the antinociceptive effects (Costa et al., 2008). However, other data suggest that 
anandamide plays opposing roles on pain through its actions at cannabinoid and TRPV1 
receptors (Singh Tahim et al., 2005). It has been shown that elevation of anandamide by 
inhibiting FAAH, at the periphery produces a TRPV1-mediated, exacerbation of visceral 
hyperactivity (Dinis et al., 2004, Singh Tahim, 2005).  
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 PPAR-α also plays a vital role in mediating the anti-inflammatory and antinociceptive 
effects of URB597 (Sagar et al., 2008). PPAR-α receptor antagonist GW6471 blocked the anti-
hyperalgesic effects of URB597 in the carrageenan model in rats (Sagar, 2008). Additionally, 
palmitoylethanolamide produced anti-inflammatory effects through PPAR-α. 
Palmitoylethanolamide also attenuated carrageenan-induced paw edema and phorbol ester-
induced ear edema in PPAR-α wild type animals but had no effects in PPAR-α deficient mice 
(Lo Verme et al., 2005). Another naturally occurring PPAR-α agonist oleoylethanolamide and 
synthetic PPAR-α agonist GW7647 have replicated these effects in a PPAR-α dependent manner 
(Lo Verme, 2005). These data suggest that PPAR-α plays a role in mediating the antinociceptive 
effects of FAAH inhibitors and FAAH substrates. The table shows a review of studies examining 
FAAH inhibitors in preclinical pain assays. 
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Review of studies examining FAAH inhibitors in preclinical pain assays. 
 
Compound Type of assay/Dose Tests (animal) Effects Reference 
 
 
 
 
 
 
OL-135 
 
Inflammatory pain (MTI) 
10 mg/kg (i.p.) 
 Paw pressure 
test (rats) 
Anti-allodynic 
effects  
(Chang, 2006)  
Neuropathic pain (SNL) 
20 mg/kg (i.v.) 
 Paw pressure 
test (rats) Von 
Frey test 
Anti-allodynic 
effects 
Thermal nociception 
10 mg/kg (i.p.) 
 Tail immersion 
test (mice) 
Increase in latency (Lichtman, 2004) 
 HPT (mice) Increase in latency 
Visceral pain (Formalin) 
10 mg/kg (i.p.) 
 Paw licking test 
(mice) 
Decreased 
response 
Neuropathic pain (CCI 
model) 
10 mg/kg (i.p.) 
 Paw pressure 
test (mice) 
Anti-allodynic 
effects 
(Kinsey, 2009) 
Paw lifting test Anti-allodynic 
effects 
 
 
 
 
 
 
 
 
 
 
 
 
 
URB597 
 
Neuropathic pain (CCI 
model) 
10 mg/kg (i.p.) 
 Paw pressure 
test (mice) 
 Von Frey test 
Anti-allodynic 
effects 
(Kinsey, 2009) 
 Paw lifting test 
(mice) 
 Cold acetone 
test 
Anti-allodynic 
effects 
Inflammatory pain (CFA; 
i.pl.) 
0.3 mg/kg (i.p.) 
Paw pressure 
test (rats) 
 Von Frey test 
Anti-allodynic 
effects 
(Jayamanne, 2006) 
Plantar test 
(rats) 
Anti-allodynic 
effects 
Neuropathic pain (CCI 
model) 
0.3 mg/kg (i.p.) 
Paw pressure 
test (rats) Von 
Frey test 
No effect 
Visceral pain 
(Acetic acid) 
1–10 mg/kg (s.c.) 
 Acetic acid-
induced 
stretching test 
(mice) 
Stretching 
decreased   
(Naidu, 2009) 
Inflammatory pain 
(Lipopolysaccharide; i.pl.) 
10 mg per/kg (s.c.) 
 Hot plate test 
(mice) 
Hyperalgesia 
decreased 
(Naidu, 2010) 
 Paw thickness 
test 
No reduction in 
edema 
 Paw thickness 
test 
Anti-edematous 
effects 
 
 
 
 
 
Neuropathic pain (CCI 
model) 
10–50 mg/kg (p.o.) 
 Paw pressure 
test 
Anti-allodynic 
effects 
(Russo, 2007) 
 Electronic Von 
Frey test 
Anti-allodynic 
effects 
Neuropathic pain (CCI  Thermal Hyperalgesia 
 28 
 
 
 
 
 
 
URB597 
 
model) 
10 mg/kg (p.o.) 
hyperalgesia 
 Paw withdrawal 
latency 
decreased 
Inflammatory pain 
(Iodoacetic acid-induced 
osteoarthritis) 
5 mg/kg (s.c.) 
Paw pressure in 
capacitance test 
19% MPE (Schuelert et al., 
2011) 
Inflammatory pain 
(Carrageenan i.pl.) 
3 mg/kg (i.p.) 
Paw edema 
measurement 
(mice) 
Anti-edematous 
effects 
(Holt, 2005) 
Bone cancer pain 
9 μg per bone infusion 
Paw pressure 
test 
Anti-allodynic 
effects 
(Khasabova et al., 
2008) 
Tail flick test (TFT) 
40 mg/kg (i.p.) 
TFT (mice) No effect (Haller et al., 
2008) 
URB597 plus 
anandamide 
Tail flick test (TFT) 
10 and 40 mg/kg (i.p.)  
TFT (mice) 68% MPE 
 
 
URB597 
Chemotherapy-induced 
peripheral neuropathy 
0.1 and 1 mg/kg 
  
Von Frey test 
Cold acetone 
test (rats) 
Anti-allodynic 
effects 
(Guindon et al., 
2013) 
 
 
 
 
 
 
 
URB937 
(peripherally 
restricted FAAH 
inhibitor)  
Chemotherapy-induced 
peripheral neuropathy 
0.1 and 1 mg/kg 
 
Von Frey test 
Cold acetone 
test (rats) 
Anti-allodynic 
effects 
Inflammatory pain 
(Carrageenan s.c.) 
0.3 mg/kg (i.p.) 
Hyperalgesia 
Paw thickness 
test 
Hyperalgesia 
decreased 
(Okine, 2012) 
Neuropathic pain (SNL) 
1 mg/kg (i.p.) 
Paw pressure 
test; 
Withdrawal 
latency 
Hyperalgesia 
decreased 
(Clapper, 2010) 
Thermal 
stimulation; 
Withdrawal 
latency 
Hyperalgesia 
decreased 
Paw pressure 
tests,Von Frey 
test 
Hyperalgesia 
decreased 
 
 
 
URB937 
Neuropathic pain (SNL) 
1 mg/kg (i.p.) 
Paw pressure 
and withdrawal 
latency; Thermal 
stimulation and 
withdrawal 
latency; Paw 
pressure and 
Von Frey tests 
Long-lasting 
similar effects 
(lack of tolerance) 
(Clapper, 2010) 
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                                                                                                             Table modified from Roques et al., 2012 
Role of MAGL inhibition in antinociceptive effects 
 Table 2 shows the pharmacological effects of MAGL inhibitors on different nociceptive 
assays in the preclinical models. Initial studies investigating the in vivo consequences of 
inhibiting MAGL employed URB602 (Burston et al., 2008, Comelli et al., 2007, Desroches et 
al., 2008, Guindon et al., 2007a, Guindon et al., 2007b, Guindon et al., 2011, Guindon and 
Hohmann, 2008, Hohmann et al., 2005, Vandevoorde et al., 2007) and N-arachidonyl maleimide 
(Burston, 2008). For example, systemic or peripheral administration of URB602 suppressed 
formalin-induced nociception, carrageenan-induced inflammatory nociception, and partial sciatic 
nerve ligation-induced nociception in rats (Comelli, 2007, Desroches, 2008, Guindon, 2011). 
Although URB602 (for MAGL IC50 = 28 IC50 = ~ 5 μM ) and N-arachidonyl 
 
 
 
JNJ-1661010 
Mild thermal injury 
20 mg/kg (i.v.) 
Paw pressure 
test (rats); Von 
Frey test 
Anti-allodynic 
effects 
(Karbarz, 2009) 
Neuropathic pain (SNL) 
20 mg/kg (i.v.) 
Paw pressure 
test (rats)Von 
Frey test 
Anti-allodynic 
effects 
(Karbarz, 2009) 
 
 
 
 
 
 
 
PF-3845 
 
 
 
 
 
Inflammatory pain (CFA; 
i.p.) 
0.1–10 mg per kg (p.o.) 
Paw pressure 
test, Von Frey 
test (rats) 
Anti-allodynic 
effects 
(Ahn et al., 2011) 
Osteoarthritis (MIA-
induced injury in knee) 
0.3 mg/kg and 3 mg/per kg 
(p.o.) 
 Joint 
compression 
threshold (rats) 
Hyperalgesia 
decreased 
Inflammatory pain 
(Carrageenan) 
10 mg/kg (i.p.) 
Von Frey test 
(mice) 
Anti-allodynic 
effects 
(Ghosh et al., 
2013) 
Inflammatory pain (LPS) 
10 mg/kg (i.p.) 
 
Von Frey test 
(mice) 
Anti-allodynic 
effects 
(Booker, 2011) 
Neuropathic pain (CCI) 
10 mg/kg (i.p.) 
Von Frey test 
(mice) 
Anti-allodynic 
effects 
(Kinsey et al., 
2010) 
 
ARN272 
Inflammatory pain 
(Formalin) 
0.01–1 mg/per kg (i.p.) 
 Paw withdrawal 
latency (mice) 
Hyperalgesia 
decreased 
(Fu, 2012) 
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maleimide (for MAGL IC50 = 140 nM; for FAAH IC50 = 2.31 nM ) inhibit MAGL in the brain, 
these compound are nonselective and inhibit other serine hydrolases, including FAAH (Burston, 
2008, Hohmann, 2005, Makara et al., 2005, Saario et al., 2005, Vandevoorde, 2007). Thus, it is 
unclear whether antinociceptive effects of these nonselective MAGL inhibitors are mediated 
through MAGL blockade, inhibition of other enzymes (e.g., FAAH), or inhibition of multiple 
enzymes.  
 The development of JZL184, a piperidine carbamate that preferentially and irreversibly 
inhibits MAGL, provided the first pharmacological tool that when administered acutely increases 
2-AG levels in the brain, without altering anandamide brain levels (Long et al., 2009a). Despite 
showing greater than 300-fold selectivity for MAGL over FAAH in vitro, JZL184 still partially 
blocked FAAH activity in vivo. This partial inhibition, however, did not result in elevated levels 
of anandamide (Long, 2009a). Systemic administration of JZL184 reduces nociceptive behaviors 
in the warm water tail withdrawal, formalin and acetic acid stretching tests (Busquets-Garcia et 
al., 2011, Long, 2009a) and also reduces mechanical and cold allodynia in the CCI model of 
neuropathic pain in mice (Kinsey, 2009). Intraplantar injection of JZL184 reduces nociceptive 
behaviors in the formalin test (Guindon, 2011), capsaicin-induced nociceptive behavior and 
thermal hyperalgesia (Spradley et al., 2010), chemotherapy-induced peripheral neuropathy 
(Guindon, 2013). KML29 shows increased selectivity for MAGL over FAAH (Chang et al., 
2012). This MAGL inhibitor has been shown to reduce carrageenan and CCI-induced 
nociception in mice (Ignatowska-Jankowska et al., 2013). In Chapter 2 of this dissertation, we 
report on the effects of JZL184 in the carrageenan model of inflammatory pain. Similar to FAAH 
inhibitors, inhibition of MAGL predominantly mediates its effects through the activation of 
CB1 and/or CB2 receptors.  
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Table 2: Review of studies with different MAGL inhibitors on acute and chronic preclinical 
pain assays. 
 
Compound Type of 
Assay/dose  
Dose/Route/Species Effect  Reference  
 
 
 
 
 
 
 
URB602  
  
Mechanical 
allodynia and 
thermal 
hyperalgesia 
0.1, 1, 10, 100,  
1000 mg (i.pl.); 
(Rat) 
Dose-dependent 
anti-allodynic 
effect 
(Desroches, 2008) 
radiant-heat, tail-
flick test (TFT) 
0.1 nmol (i.c.v); 
(Rat) 
Reduced Stress 
induced 
analgesia 
(Hohmann, 2005) 
 λ-carrageenan 1, 5, 10 mg/kg, (i.p.); 
(Rat) 
dose-dependent 
anti-edematous 
and anti-
nociceptive 
effect 
(Guindon, 2007b) 
Formalin 0.001-600 µg (i.pl.); 
(Rat) 
composite pain 
score-weighted 
scores 
technique 
(Guindon, 2011) 
N-
arachidonyl ma
leimide 
Tail withdrawal 1, 3, 10 mg/kg (i.p.); 
(Mouse) 
Dose dependant 
antinociception 
(Burston, 2008) 
 
 
 
 
 
 
 
 
JZL184  
  
Acetic acid 
stretching  
8, 16 mg/kg (i.p.);  
8 mg/kg (i.p.) 
Mouse 
Antinociception  (Busquets-Garcia, 
2011, Long, 
2009a) 
CCI (mechanical 
& cold 
allodynia)  
16, 40 mg/kg (i.p.); 
Mouse 
Anti-allodynic  (Kinsey, 2010, 
Kinsey, 2009)  
Carrageenan-
induced paw 
inflammation  
4-40 mg/kg (i.p.); 
Mouse 
Partial anti-
allodynic and 
anti-edema  
(Ghosh, 2013) 
Bone cancer pain  10 μg (i.p.l); 
Mouse 
 
Anti-
hyperalgesic  
(Khasabova et al., 
2011) 
Cisplatin-
induced 
peripheral 
neuropathy 
(mechanical and 
cold allodynia) 
1, 3, 8 mg/kg (i.p.); 
Rat 
Anti-allodynic (Guindon, 2013) 
Formalin pain 
test  
16 mg/kg (i.p); 
Mouse 
0.001-300 μg ( i.pl); 
Antinociceptive 
at both early 
and late phase  
(Guindon, 2011, 
Long, 2009a) 
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Rat 
Capsaicin-
induced  
100μg (i.p.);  
Rat 
Antinociception  (Spradley, 2010)  
Postoperative 
pain 
0.016–16 mg/kg 
(i.p.); 
Mouse 
Mechanical and 
thermal 
hyperalgesia 
(Martins et al., 
2013) 
Carrageenan 25, 50, 100 g (i.p.); 
Rat 
Mechanical 
allodynia 
(Woodhams et al., 
2012) 
 
 
KML29  
 
Carrageenan 5,20, 40 mg/kg (i.p.); 
Mouse 
Anti-allodynic (Ignatowska-
Jankowska, 2013) 
CCI (mechanical 
& cold allodynia 
5, 20, 40 mg/kg 
(i.p.); 
Mouse 
Anti-allodynic (Ignatowska-
Jankowska, 2013) 
                                                                                        Table modified from Ramesh et al., 2012  
Rational and Hypothesis: 
Overall hypothesis: 
Inhibition of endocannabinoid regulating enzymes will reduce nociceptive behavior in mouse 
inflammatory pain models. 
Carrageenan model of inflammatory pain 
 
 The present study examined the anti-edematous and anti-allodynic effects of FAAH and 
MAGL inhibitors in the carrageenan model of inflammatory pain which has been used to assess 
cannabinoids and may other drugs. It is a common preclinical inflammatory pain model (Guay et 
al., 2004, Hargreaves, 1988a, Henriques et al., 1987). The stimulus is a sulfated glycoprotein 
derived from red seaweed. This is a neutrophil mediated acute inflammatory model (Fecho et al., 
2005). Carrageenan administration leads to biphasic events, the early 1-6 hours phase and late 12 
and 24 hours phase. The initial phase of inflammation (0-1 hrs post carrageenan injection) is due 
to activation of inflammatory agents such as bradykinin, nitric oxide, and histamine in the 
injected area (Crunkhorn and Meacock, 1971, Garcia Leme et al., 1973, Hargreaves et al., 1988b, 
 33 
Salvemini et al., 1996, Vinegar et al., 1987). The second sustained phase of swelling is correlated 
with the activation of neutrophils, cytokines, prostaglandins, and cyclooxygenase-2 (COX-2) 
(Loram et al., 2007, Seibert et al., 1994, Vinegar, 1987). In addition, immune response such as 
activation of macrophages, mast cells, endothelial cells which results in release proinflammatory 
cytokines such as TNF-, IL-6, IL-1 (Fecho et al., 2007) are observed in this phase. This phase 
is usually termed the acute phase, and occurs 2-4 hours after injection (Hargreaves, 1988a). The 
carrageenan assay involves the administration of carrageenan into the dorsal surface of the hind 
paw of mice/rats resulting in edema (increased in paw volume) and an increase in sensitivity to 
mechanical (allodynia) and thermal stimuli (hyperalgesia). Many electrophysiological studies 
have shown that carrageenan-induced edema and hyperalgesia last for 1 to 4 days (Hargreaves, 
1988a, Kayser and Guilbaud, 1987, Vinegar et al., 1969, Vinegar, 1987). Stimulating the paw 
with mechanical (von Frey filaments) or thermal stimuli (Hargreaves, radiant heat tests) elicits 
behavioral responses, such as licking, flexing and flinching of the paw (Guay, 2004, Nantel et 
al., 1999). These responses can be reliably measured in carrageenan assay (Fecho, 2005, Ferreira 
et al., 1988). Thus, carrageenan is widely used as a model for localized inflammatory pain. 
Additionally, FAAH (-/-) mice exhibited reduced inflammatory responses compared to wild 
types in carrageenan model of inflammatory pain (Lichtman, 2004). Similarly, anandamide, 
palmitoylethanolamide and oleoylethanolamide have been shown to reduce carrageenan-induced 
edema in FAAH (-/-) mice (Wise, 2008). A nonselective MAGL inhibitor URB602 has been 
shown to reduce carrageenan-induced edema and allodynia in mice (Comelli, 2007). These 
studies indicate that carrageenan is a reliable model for inflammatory pain. Therefore, we have 
chosen carrageenan as a model to assess edema and allodynia. 
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Selection of DAGL MAGL and FAAH inhibitors  
 We selected MAGL and FAAH for our study because MAGL and FAAH are the 
primary degradative enzymes of endocannabinoids (Cravatt, 1996, Dinh, 2004, Dinh, 2002). As 
Endocannabinoids are produced on demand and are then rapidly degraded. Inhibition of their 
degradative enzymes prolongs their action at CB1 and CB2 receptors. We selected DAGL- 
because it is one of the major biosynthetic enzymes for 2-AG. It is present in the periphery and 
plays an important role in the production of arachidonic acid. Thus, its inhibition reduces 
arachidonic acid and leads to a reduction in prostaglandin synthesis and other pro-inflammatory 
mediators. Hence, we wanted to examine the impact of inhibiting this enzyme in an 
inflammatory pain model. In addition, inhibiting endocannabinoid regulating enzymes avoids 
cannabimimetic effects of direct cannabinoid receptor agonist. We specifically chose the 
following compounds:  KT-109, and KT-172 for DAGL-, JZL184 for MAGL, PF-3845 for 
FAAH, and SA-57 for dual FAAH-MAGL inhibition, since they are amongst the most selective 
inhibitors presently available (Ahn, 2009, Hsu, 2012, Long, 2009a). The inhibitors are highly 
selective and irreversible for DAGL-, MAGL, and FAAH respectively and have a long half-life 
(up to 24 h). DAGL- inhibitors have been shown to reduce 2-AG and arachidonic acid in the 
liver. In contrast, mice treated with KT109 and KT172 or DAGL-−/−) mice did not show 
changes in 2-AG or arachidonic acid in brain tissue. It should be noted that KT-109 and KT-172 
inhibit ABHD-6 with respective IC50 values of 16 and 5 nM (Hsu, 2012). Hence, we have used 
the selective ABHD6 inhibitor KT-195 as a control for this off-target. MAGL and FAAH 
inhibitors produce profound (up to 10-fold) elevations of the appropriate endocannabinoids. 
However, JZL184 also inhibits FAAH, although in vitro the compound is approximately 500-
fold more selective as a MAGL inhibitor (IC50 = 8 nM) than as a FAAH inhibitor (IC50 = 4,000 
 35 
nM) (Long, 2009a). Nonetheless, acute treatment with JZL184 in mice does not elevate 
anandamide levels in the brain. However, repeated treatment with JZL184 leads to augmented 
brain levels of anandamide in mice (Schlosburg et al., 2010). 
 
Overview of Chapter 2. Impact of MAGL and FAAH inhibitors on carrageenan-induced 
inflammatory pain 
 In initial studies, we examined the consequences of MAGL and FAAH inhibition on 
carrageenan-induced inflammatory nociception in mice. We have taken a complementary genetic 
and pharmacological approach to determine the involvement of cannabinoid receptor system to 
mediate the effects of MAGL and FAAH inhibitors. We hypothesized that CB1and CB2 receptor 
mediated the antinociceptive effects of MAGL inhibitors. This prediction is based on the results 
of previous studies demonstrating the effects of JZL184 has mediated its antinociceptive effects 
through CB1 and CB2 receptors in formalin-induced inflammatory pain (Guindon, 2011) and in 
bone cancer pain (Khasabova, 2011). JZL184 has also shown to mediate its antinociceptive 
effects through CB1 receptors on acetic acid induced stretching (Busquets-Garcia, 2011, Long, 
2009a), tail withdrawal assay (Long, 2009a, Schlosburg, 2010), CCI-induced neuropathic pain 
(Kinsey, 2010, Kinsey, 2009), and formalin-induced inflammatory pain (Long, 2009a). As 
carrageenan-induced inflammation triggers cytokine release (Loram, 2007, Seibert, 1994, 
Vinegar, 1987) and CB2 receptors are predominantly present in the immune cells (Cabral, 2006), 
we predicted the involvement of CB1 as well as CB2 in carrageenan-induced inflammatory pain. 
Similarly, anti-allodynic effects of FAAH inhibition is predicted to be mediated by CB1 and CB2 
receptors. This is based on the previous literature showing both CB1 and CB2 receptors are 
required for the anti-allodynic effects of FAAH inhibition in chronic constriction injury model 
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(Kinsey, 2010, Kinsey, 2009), (Russo, 2007), partial sciatic and spinal nerve injury models of 
pain (Desroches, 2008, Jhaveri et al., 2006) as well as in LPS-induced inflammatory pain model 
(Booker, 2011).  
 Chronic pharmacological blockade or genetic deletion of MAGL, unlike FAAH 
inhibition, leads to functional antagonism and loss of cannabinoid-mediated effects and produces 
cross-tolerance to CB1 agonists in mice. Chronic MAGL blockade with high dose of JZL-184 
also causes physical dependence, impaired endocannabinoid-dependent synaptic plasticity, and 
desensitized brain CB1 receptors (Chanda et al., 2010, Schlosburg, 2010), but the effects were 
maintained following repeated administration of low dose JZL184 (Kinsey et al., 2013, Sciolino 
et al., 2011). Hence, in our next experiments we examined the role of repeated administration of 
low versus high dose of JZL184 in carrageenan pain model. As genetic deletion or prolonged 
pharmacological inhibition of MAGL is known to produce CB1 receptor functional tolerance 
(Chanda, 2010, Schlosburg, 2010), we assessed the dose-response relationship of JZL184 after 
acute and repeated administration in the carrageenan assay. We predicted based on previous 
literature that MAGL inhibition with high of JZL184 (Schlosburg, 2010) but not low dose 
(Sciolino, 2011), will show tolerance to the antinociceptive effects of JZL-184.  
 Overview of Chapter 3. Effects of partial MAGL and complete FAAH blockade on 
carrageenan-induced inflammatory pain 
 In Chapter 3, we described the role of dual FAAH and MAGL inhibition. Previous work 
reported that JZL195, a dual MAGL-FAAH inhibitor, that equipotently raised both 2-AG and 
anandamide levels and produced a greater antinociceptive response in tail immersion acetic acid 
abdominal stretching tests than inhibitors of either FAAH or MAGL alone (Long et al., 2009b). 
However, JZL195 also elicits cannabimimetic activity in the tetrad test, causing analgesia, 
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hypomotilty, catalepsy and THC-like drug discrimination responses (Long, 2009b). Additionally, 
repeated administration of high dose JZL184 or genetic deletion of MAGL, unlike FAAH 
inhibition, leads to desensitization and down regulation of brain CB1 receptors (Chanda, 2010, 
Schlosburg, 2010). On the other hand, the antinociceptive and anxiolytic-like effects of low dose 
JZL184 are maintained after repeated administration (Kinsey, 2013, Sciolino, 2011). Hence, our 
experiments evaluated whether differential elevation of 2-AG and anandamide, by partially 
inhibiting MAGL and completely inhibiting FAAH produced augmented antinociceptive effects 
compared with individual enzyme blockade. We have used two pharmacological approaches for 
these studies. First, we have used low dose JZL-184 and high dose PF-3845 and second we have 
used a novel differential MAGL and FAAH inhibitor SA-57 (Niphakis et al., 2012). We also 
evaluated whether the simultaneous blockade of MAGL and FAAH would produce 
cannabimimetic effects in the tetrad test, as well as whether repeated administration of FAAH 
and MAGL inhibitors produce cross-tolerance to THC. We predicted that elevating endogenous 
cannabinoids by inhibiting their hydrolytic enzymes offer potential therapeutic benefits, without 
the undesirable cannabimimetic actions. We investigated the efficacy of these inhibitors to 
reduce carrageenan-induced edema and allodynia. Selective CB1 and CB2 receptor antagonists 
were employed to assess cannabinoid receptor involvement of the anti-inflammatory effects of 
combined JZL184 and PF-3845. Anandamide and 2-AG levels were quantified in whole brain 
following administration of these enzymes inhibitors. Finally, we evaluated the role of prolonged 
dual blockade of MAGL and FAAH on carrageenan-induced allodynia and edema. Changes in 
CB1 receptor binding and G- protein activation were assessed in brains of mice repeatedly that 
were treated repeatedly with MAGL and FAAH inhibitors. We hypothesize that the combination 
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of JZL184 and PF-3845and SA-57 will also enhance the antinociceptive effects without inducing 
cannabimimetic behavioral effects and receptor adaptations.  
Overview of Chapter 4. Effects of DAGL-, a major 2-AG biosynthesizing enzyme, inhibitors 
on LPS-induced inflammatory pain  
 In Chapter 4, we examined the role of selective DAGL- inhibitors on LPS model of  
inflammatory pain. In comparison to the consequences of inhibiting FAAH and MAGL in 
laboratory animal models of pain, much less is known about the physiological effects of 
inhibiting the endocannabinoid biosynthetic enzymes on pain. As discussed above, 2-AG 
biosynthesis is regulated by two sequence-related enzymes, DAGL-α and DAGL-β (Bisogno, 
2003). Biochemical studies have provided evidence that these are multi-domain, transmembrane 
serine hydrolases. Recent genetic studies with constitutive knockout mice have confirmed that 
both DAGL-α and DAGL-β regulate 2-AG production in vivo. The relative contribution made by 
each enzyme depends on tissue type. For example, DAGL- is responsible for adult 
neurogenesis in subventricular zone, while both isoforms are responsible for adult neurogenesis 
in the hippocampus (Gao, 2010, Tanimura, 2010). Recently, two compounds, KT109 and 
KT172, that potently and selectively inactivated DAGL-β in vitro and in vivo, were developed. 
In Chapter 4, we test whether these two compounds reverse LPS-induced allodynia. We 
predicted that these compounds would reduce allodynia in cannabinoid independent manner. On 
the other hand, one may predict that decreased 2-AG levels will lead to increased inflammatory 
pain. But we based our prediction on the in vitro findings that demonstrate that KT-109 and KT-
172 reduces 2-AG, arachidonic acid, prostaglandins, and TNF - release from peritoneal 
macrophages (Hsu, 2012). Reducing the pool of 2-AG results in less available precursor of 
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arachidonic acid, and consequently decreasing prostaglandin levels. Finally, we examined if 
DAGL inhibition cause any gastric ulcerogenic effects due to reduction in prostaglandin levels. 
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Chapter 2. The monoacylglycerol lipase inhibitor JZL184 suppresses 
inflammatory pain in the mouse carrageenan model 
This chapter has been published as a research report in a peer-review journal (Ghosh et al., 2013). 
Introduction 
 The endogenous cannabinoid system consists of two G-protein-coupled cannabinoid (i.e., 
CB1 and CB2) receptors (Gerard, 1991, Matsuda, 1990), the lipid endogenous ligands N-
arachidonoylethanolamine (anandamide; AEA) (Devane, 1992) and 2-2-AG (Mechoulam et al., 
1995, Sugiura, 1995), and the enzymes that synthesize and degrade anandamide and 2-AG (Ahn 
et al., 2008). These endogenous cannabinoids are produced and released on demand, and are then 
rapidly metabolized by their respective degradative enzymes, fatty acid amide hydrolase (FAAH) 
(Cravatt, 2001, Cravatt, 1996) and monoacylglycerol lipase (MAGL) (Blankman, 2007, Dinh, 
2004). The cannabinoid receptors and the endocannabinoid catabolic enzymes represent potential 
therapeutic targets to treat obesity, psychiatric disorders, neuroinflammatory diseases, cancer, 
and pain and inflammatory conditions (Pacher, 2006). Accordingly, a growing body of research 
has focused on investigating whether elevating endogenous levels of anandamide or 2-AG, via 
inhibition of their degradative enzymes, reduces nociceptive behavior in laboratory animal 
models of pain.  
 The bulk of research examining the role of endocannabinoid catabolic enzymes in 
nociception has focused on FAAH (Booker, 2011, Chang, 2006, Clapper, 2010, Jayamanne, 
2006, Kinsey, 2011a, Naidu, 2008, 2009, Naidu, 2010, Suplita, 2005) largely because of a 
greater availability of selective FAAH inhibitors than selective MAGL inhibitors. Initial studies 
investigating the in vivo consequences of inhibiting MAGL employed URB602 (Burston, 2008, 
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Comelli, 2007, Desroches, 2008, Guindon, 2007a, Guindon, 2007b, Guindon, 2011, Guindon 
and Hohmann, 2008, Hohmann, 2005, Vandevoorde, 2007) and N-arachidonyl maleimide 
(Burston, 2008). For example, systemic or peripheral administration of URB602 suppressed 
formalin-induced nociception, carrageenan-induced inflammatory nociception, and partial sciatic 
nerve ligation-induced nociception in rats (Comelli, 2007, Desroches, 2008, Guindon, 2011). 
Although URB602 and N-arachidonyl maleimide inhibit MAGL in the brain, these compounds 
are nonselective and inhibit other serine hydrolases, including FAAH (Burston, 2008, Hohmann, 
2005, Vandevoorde, 2007).  
 The development of JZL184, a piperidine carbamate that preferentially and irreversibly 
inhibits MAGL, provided the first pharmacological tool that when administered acutely increases 
2-AG brain levels, without altering anandamide brain levels (Long, 2009a). Systemic 
administration JZL184 reduces nociceptive behaviors in the warm water tail withdrawal, 
formalin, and acetic acid stretching tests (Busquets-Garcia, 2011, Long, 2009a) and reduces 
mechanical and cold allodynia in the CCI model of neuropathic pain in mice (Kinsey, 2009). 
Intraplantar injection of JZL184 reduces nociceptive behaviors in the formalin test (Guindon, 
2011), capsaicin-induced nocifensive behavior, and thermal hyperalgesia (Spradley, 2010). 
  Although these findings indicate that MAGL inhibition produces antinociceptive effects 
in multiple pain models, the effects of JZL184 have yet to be evaluated in a prolonged model of 
inflammatory nociception. Thus, in the present study we tested whether JZL184 would attenuate 
paw edema and mechanical allodynia in the carrageenan model of inflammatory pain. In an 
initial study, we evaluated the dose-response effects of JZL184 in this assay. For comparison, we 
tested the nonsteroidal anti-inflammatory diclofenac as well as the FAAH inhibitor PF-3845, 
which has been shown to possess anti-inflammatory and anti-allodynic effects in complete 
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Freund’s adjuvant (Ahn, 2009), LPS (Booker, 2011), and CCI pain (Kinsey, 2010, Kinsey, 2009) 
models. In order to determine whether cannabinoid receptors mediate the anti-allodynic and anti-
edematous effects of JZL184, we used complementary genetic and pharmacological tools to 
assess the contribution of CB1 and CB2 receptors to JZL184-induced decreases in nociception 
and paw edema. Repeated administration of JZL184 or genetic deletion of MAGL results in CB1 
receptor downregulation and desensitization as well as CB1 functional tolerance (Chanda, 2010, 
Schlosburg, 2010). Therefore, we also tested whether the anti-edematous and anti-allodynic 
responses elicited by JZL184 in the carrageenan model would be retained after repeated 
administration of low and high doses of JZL184. Finally, we tested whether systemic 
administration of JZL184 after intraplantar carrageenan injections reverses edema and allodynia 
to infer whether this compound possesses efficacy to treat nociceptive behavior and edema 
following an inflammatory insult. 
Methods 
Subjects 
 Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) as well as male and female 
CB1 (-/-) and CB2 (-/-) mice and their respective littermate controls, CB1 (+/+) and CB2 (+/+) 
mice from the Center Transgenic Colony at Virginia Commonwealth University served as 
subjects. CB1 (-/-) and CB2 (-/-) mice were backcrossed onto a C57BL/6J background for 13 and 
6 generations, respectively. The subjects weighed between 18 and 25 g, and were housed four-
five mice per cage in a temperature (20–22 °C) and humidity controlled AAALAC-approved 
facility. Mice were given unlimited access to food and water in their home cages and were 
maintained on a 12/12 h light/dark cycle. The sample size for each treatment group was 6 to 10 
mice/group and for knockout studies was 4 to 9 mice/group. All animal protocols were approved 
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by the Virginia Commonwealth University Institutional Animal Care and Use Committee and 
were in accordance with the National Institutes of Health guide for the care and use of 
Laboratory animals (Institute of Laboratory and Animal Resources, 1996). After testing was 
completed, all mice were humanely euthanized via CO2 asphyxia, followed by rapid cervical 
dislocation. 
Drugs 
 JZL184 and PF-3845 were synthesized as described previously (Ahn, 2009, Long, 2009a) 
by Organix, Inc. (Woburn, MA). JZL184, PF-3845, the CB1 receptor antagonist rimonabant 
(SR141716, National Institute on Drug Abuse, Bethesda, MD), and the CB2 receptor antagonist 
SR144528 (National Institute on Drug Abuse) were dissolved in a vehicle that consisted of a 
mixture of ethanol, alkamuls-620 (Rhone-Poulenc, Princeton, NJ), and saline in a ratio of 1:1:18. 
The nonselective cyclooxygenases (COX) inhibitor diclofenac (DIC; Tocris, Ellisville, MO) was 
dissolved in saline. Each drug was given via the i.p. route of administration in a volume of 10 
μl/g body weight. 
Induction of Paw Edema with Carrageenan  
 Edema was induced by giving an intraplantar injection of 0.3% carrageenan (Sigma, St 
Louis) in a 20-l volume using a 30-gauge needle into the hind left paw. Paw thickness was 
measured with electronic digital calipers (Traceable Calipers, Friendswood, TX), prior to and 5 h 
following carrageenan administration, which corresponds to peak edema (Wise et al. 2007). This 
procedure has been used previously by our laboratory (Cravatt, 2001, Cravatt and Lichtman, 
2004, Lichtman, 2004, Wise, 2008).  
Mechanical Allodynia 
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 The mice were placed inside ventilated polycarbonate chambers on an elevated aluminum 
mesh table and allowed to acclimate to the apparatus for 60 min before testing. Mechanical 
allodynia was assessed with von Frey filaments (North Coast Medical, Morgan Hill, CA), using 
the “up-down” method (Chaplan et al., 1994) 5 h after carrageenan administration. The plantar 
surface of each hind paw was stimulated five times with each filament (0.16–6.0 g), at a 
frequency of approximately 2 Hz, starting with the 0.6-g filament and increasing until the mouse 
responded by licking and/or lifting the paw off the surface of the test apparatus. Three or more 
responses out of five stimulations were coded as a positive response. Once a positive response 
was detected, sequentially lower weight filaments were used to assess the sensory threshold for 
each paw. 
Testing Procedures 
 Mice were transported to the testing room, weighed, randomly assigned to the different 
treatment regimens, and allowed to acclimate for at least 1 h before injections. The time course 
for carrageenan-induced paw edema was assessed in an initial experiment. Peak edema occurred 
at 1 h, which was sustained for 5 h (figure 2). Mechanical allodynia was assessed at the 5 h time 
point. For consistency with our previous studies, the 5 h time point was selected to assess paw 
edema and mechanical allodynia. The pre-treatment times for each drug were as follows: 30 min 
for diclofenac (5 mg/kg), 2 h for PF-3845 (1, 3, or 10 mg/kg), and 2 h for JZL184 (1.6, 4, 16, or 
40 mg/kg). In experiments assessing cannabinoid receptor mechanism of action, the CB1 receptor 
antagonist rimonabant (1 mg/kg) and the CB2 receptor antagonist SR144528 (3 mg/kg) were 
administered 30 min prior to JZL184 (16 mg/kg) or vehicle. It should be noted that in initial 
experiments, 3 mg/kg rimonabant reduced paw edema. In contrast, 1 mg/kg rimonabant 
administered alone did not affect the dependent measures and was employed for the antagonism 
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studies. Previous studies have shown that these doses of rimonabant (Lichtman et al., 1996, 
Lichtman and Martin, 1991, Lichtman, 2004) and SR144528 (Lichtman, 2004, Malan et al., 
2002) block the pharmacological effects of cannabinoid receptor agonists. The anti-edematous 
and anti-allodynic effects of 16 mg/kg JZL184 were evaluated in CB1 (+/+), CB1 (-/-), CB2 (+/+), 
and CB2 (-/-) mice to further assess receptor involvement. In addition, we determined whether 
administration of the antagonists after carrageenan would reverse the anti-edematous and anti-
allodynic effects JZL184. In this experiment, rimonabant (1 mg/kg) or SR144528 (3 mg/kg) was 
injected 4 h after carrageenan and edema and allodynia were measured at 5 h. 
 In order to assess the impact of repeated administration of JZL184 on paw edema and 
mechanical allodynia, the following groups of mice were tested: (Group 1) vehicle for 6 days, 
(Groups 2-5) vehicle for 5 days and challenged with 1.6, 4, 16 or 40 mg/kg JZL184 on day 6, 
and (Groups 6-9) 1.6, 4, 16 or 40 mg/kg JZL184 for 6 days. Mice were administered their 
respective treatments 2 h before carrageenan was injected. Edema and mechanical allodynia 
were then assessed 5h later. In the final experiment, JZL184 (16 mg/kg) was administered 3 h 
after carrageenan to examine whether carrageenan-induced edema and allodynia would be 
reversed at 5 h.  
Data Analyses 
 Paw edema data are expressed as the difference in paw thickness between the 5 h and 
pre-injection measures. Paw withdrawal thresholds to the von Frey filaments in the carrageenan-
injected and contralateral (i.e., control) paws at the 5 h time point were used to assess mechanical 
allodynia. All data are depicted as mean + standard error of the mean (SEM). Data were analyzed 
using t-tests, one-way analysis of variance (ANOVA), or two-way ANOVA. Dunnett’s test was 
used for post hoc analysis in the dose-response experiments in which the effects of each drug 
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dose were compared to those of vehicle. Tukey-Kramer post hoc analysis was used for all tests 
comparing different treatment groups. Bonferroni planned comparisons were used to assess 
genotype differences. Differences were considered significant at the p < 0.05 level. 
Results: 
Induction of Edema and allodynia by carrageenan 
Intraplantar administration of carrageenan induced paw edema and allodynia over an 
extended time. In the time course study, carrageenan induced edema peaked at 1 h, which was 
sustained for 5 h [F (4, 25) = 536.5, p < 0.001; Figure 2A. Allodynia was first tested at 5 h time 
point and it was found to persist at least 24 h after carrageenan [F (5, 30) = 9.009, p < 0.001] 
(Figure 2B). As shown in Figure 2C, 3 mg/kg rimonabant produced anti-edematous effects when 
administered alone [F (2, 14) = 47.85, p < 0.001]. On the other hand, administration of 1mg/kg 
rimonabant did not alter paw thickness [p = 0.09].  
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Figure 2: Time course for the edematous and allodynic effects of carrageenan.  
Edema peaked at 1 h and persisted for at least 5 h (Panel A), ***, p < 0.001 versus 1, 3, and 5 h. 
Allodynia reduced in 48 h (Panel B), +++, p < 0.001 versus contralateral paw; ###, p < 0.001 
versus 5 h. Values represented the mean (± SEM) mechanical paw withdrawal threshold and 
difference in paw thickness. N=6 /group. Panel C showed that the CB1 antagonist rimonabant 
produced an effects of its own at a high dose (3mg/kg) but 1 mg/kg did not have an effect of its 
own ***, p < 0.001 versus vehicle; ###, p < 0.001 versus 3mg/kg rimonabant. N = 5-6/group. 
 Anti-edematous and anti-allodynic effects of diclofenac, JZL184, and PF-3845 in the 
carrageenan model 
Intraplantar administration of carrageenan induced paw edema and decreased paw 
withdrawal threshold over an extended time (Figure 3). In contrast, the withdrawal threshold for 
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the control paw remained constant throughout all of the studies (Table 3). As shown in Figure 
3A, JZL184 [F (4, 33) = 24.64, p < 0.001], PF-3845 [F (3, 20) = 25.76, p < 0.001], and 
diclofenac [t (12) = 5.51, p < 0.001] significantly attenuated carrageenan-evoked edema. As 
shown in Figure 3B, carrageenan-induced allodynia was significantly attenuated by JZL184 [F 
(4, 37) = 11.95, p < 0.001], PF-3845 [F (3, 20) = 6.596, p < 0.05] and diclofenac [t (12) = 6.03, p 
< 0.001]. None of the treatments altered the paw withdrawal threshold in the contralateral paw 
(Table 3).  
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Figure 3: JZL184, PF3845, and diclofenac (5 mg/kg) partially reduced edema and allodynia in 
the carrageenan model. 
JZL184 significantly reduced carrageenan-induced paw edema (A) and allodynia (B). Diclofenac 
(Dic) and PF-3845, shown on the same graph and both significantly reduced edema (C). 
Diclofenac (Dic) and PF-3845, shown on the same graph and both of them partially reduced 
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allodynic (D). Values represented the mean (± SEM) mechanical paw withdrawal threshold and 
difference in paw thickness. ***, p < 0.001 versus vehicle, +++, p < 0.001 versus vehicle. N=6-7 
mice/group.  
Cannabinoid receptors mediate the anti-allodynic and anti-edematous of JZL184  
To determine whether CB1 and CB2 receptors mediate the anti-allodynic effects of 
JZL184, mice were pretreated with rimonabant (1 mg/kg), SR144528 (3 mg/kg), or vehicle 30 
min prior to JZL184 (16 mg/kg) injection. As shown in Figure 4A, rimonabant [F (1, 20) = 
10.07, p < 0.001] and SR144528 [F (1, 20) = 19.21, p < 0.001; Figure 4B] completely blocked 
the anti-allodynic effects of JZL184. There was a significant interaction between JZL184 and 
pretreatment with the rimonabant and SR144528 on mechanical allodynia, indicating the 
involvement of CB1 and CB2 receptors. Neither rimonabant nor SR144528 significantly affected 
allodynia when given alone. CB1 (-/-) [F (1, 19) = 5.73, p < 0.001; Figure 4C] and CB2 (-/-) [F 
(1, 24) = 8.74, p < 0.01; Figure 4D] mice were resistant to the anti-allodynic effects of JZL184. 
In the absence of drugs, both CB1 (-/-) and CB2 (-/-) mice showed similar nociceptive behavior 
as the wild type control mice. All the F ratios in this section represent the statistical interaction 
between drug treatment and genotype in the two-ANOVAs. 
The data depicted in Figure 5, revealed that CB2 receptors mediate the anti-edematous 
effects of JZL184. Whereas rimonabant did not affect the anti-edematous effects of JZL184 
[p=0.22; Figure 5A]. SR144528 completely blocked the anti-edematous effects of JZL184, as 
revealed by a significant interaction between JZL184 and SR145528 [F (1, 20) = 8.73, p < 0.001; 
Figure 5B]. Consistent with the cannabinoid receptor antagonist data, JZL184 retained its anti-
edematous effects in CB1 (-/-) mice [p = 0.84; Figure 5C], but CB2 (-/-) mice were completely 
resistant to the anti-edematous effects of JZL184, as indicated by a significant interaction 
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between JZL184 and the genotype [F (1, 21) = 59.97, p < 0.001; Figure 5D]. As shown in Figure 
5E, the anti-edematous effects of PF-3845 were reversed by SR144528 [F (1, 26) = 74.08, p < 
0.001]. On the other hand, rimonabant did not change the anti-edematous effects of PF-3845 [F 
(1, 20) = 24.01, p < 0.001; Figure 5F]. 
 In the next series of experiments, we examined whether rimonabant or SR144528 
injected 4 h after carrageenan would reverse the anti-edematous and anti-allodynic effects of 
JZL184 (16 mg/kg). The anti-edematous effects of JZL184 were not reversed by either drug 
[p=0.53; Figure 6A], but rimonabant as well as SR144528 completely reversed the anti-allodynic 
effects of JZL184 [F (1, 36) = 5.27, p < 0.01; Figure 6B]. 
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Figure 4: The anti-allodynic effect of JZL184 is mediated by a CB1 and CB2 mechanism of 
action. Rimonabant blocked the anti-allodynic effect of (A) JZL184. ***, p < 0.001 versus 
vehicle/vehicle (veh/veh), ###, p < 0.001 versus veh/JZL184. SR144528 also blocked the anti-
allodynic effect of JZL184 (B). ***, p < 0.001 versus veh/veh. ###, p < 0.001 versus 
veh/JZL184. The anti-allodynic effect of JZL184 did not occur in (C) CB1 knockout mice (-/-). 
**, p < 0.05 versus WT/veh. ###, p<0.001 versus CB1 (-/-)/JZL184. The anti-allodynic effect of 
(D) JZL184 did not occur in CB2 knockout mice. **, p < 0.001 versus wild type or WT/veh. ###, 
p < 0.001 versus CB2 (-/-)/JZL184. Values represented the mean (± SEM) mechanical paw 
withdrawal threshold. N=6/group.  
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Figure 5: The anti-edematous effect of JZL184 is mediated by a CB2, but not a CB1, receptor 
mechanism of action. Rimonabant did not block the anti-edema effect of JZL184 (A). ***, p < 
0.001 versus veh/veh; SR144528 blocked the anti-edematous effect of JZL184. ***, p < 0.001 
versus Vehicle/Vehicle (veh/veh). ## p < 0.01 versus veh/JZL184, the anti-edematous effect of 
JZL184 was present in CB1 knockout mice (-/-). **, p < 0.01, ***, p < 0.001 versus WT/veh. 
The anti-edematous effect of JZL184 does not occur in CB2 knockout mice (D). ***, p < 0.001 
versus WT/Veh and ### p < 0.001versus CB2 (-/-)/JZL. Values represented the mean (± SEM) 
difference in paw thickness. N=5-9/group. Panel E showed that anti-edematous effects of PF-
3845 were antagonized by SR144528, ***, p < 0.001 versus veh/veh; ###, p < 0.001 versus 
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Veh/PF-3845 and panel F showed that the anti-edematous effects were maintained in 
rimonabant-treated animals, ***, p < 0.001 versus veh/veh. Rimonabant has produced an anti-
edematous effects by itself at 3mg/kg dose ***, p < 0.001 versus veh/veh.  
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Figure 6: JZL184-induced anti-allodynia occurs independently of its anti-edematous effect.  
Neither rimonabant nor SR144528 blocked the anti-edematous effect of JZL184 when injected 
approximately 4 h after carrageenan (A). Both rimonabant and SR144528 blocked the anti-
allodynic effect of JZL184 when injected approximately 1 hour before determining mechanical 
allodynia (B). Values represented the mean (± SEM) mechanical paw withdrawal threshold and 
difference in paw thickness. **, p < 0.01, ***, p < 0.001 versus veh/veh; #, p < 0.05 versus 
JZL184/veh. N=6-9/group. 
Differential tolerance following repeated administration of low dose and high dose JZL184 
As genetic deletion or prolonged pharmacological inhibition of MAGL is known to 
produce CB1 receptor functional tolerance (Chanda, 2010, Schlosburg, 2010), we assessed the 
dose-response relationship of JZL184 (1.6, 4, 16, or 40 mg/kg) after acute and repeated 
administration in the carrageenan assay. JZL184 dose-dependently attenuated carrageenan-
induced paw edema and allodynia. As shown in Figure 7, acute administration of 4, 16, and 40 
mg/kg JZL184 significantly attenuated carrageenan-induced edema [F (8, 65) = 11.62, p < 0.001] 
(Figure 7A). While the anti-edematous effects of 4 and 16 mg/kg JZL184 were maintained 
following repeated dosing, the anti-edematous effects of 40 mg/kg JZL184 underwent tolerance 
upon repeated administration. Acute administration of 4, 16, and 40 mg/kg JZL184 also 
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significantly attenuated mechanical allodynia [F (8, 65) = 7.953, p < 0.001; Figure 7B]. The anti-
allodynic effects of 4 mg/kg JZL184 were maintained after repeated dosing; however, repeated 
administration of high doses of JZL184 (16 and 40 mg/kg) led to tolerance. The lowest dose of 
JZL184, 1.6 mg/kg, tested in this study, remained ineffective regardless of whether it was 
administered acutely or repeatedly. There was no allodynia seen in the contralateral paw (Table 
3). 
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Figure 7: The anti-edematous and anti-allodynic effects of JZL184 undergo tolerance following 
repeated administration of high dose, but not low dose of the drug. A. The anti-edematous effects 
of low doses of JZL184 remain effective after repeated administration. B. The anti-allodynic 
effects of low doses of JZL184 remain effective after repeated administration, when the high 
dose produced tolerance.*, p < 0.05, **, p < 0.01, ***, p < 0.001 versus veh/veh; ###, p < 0.001 
versus acute 40 mg/kg JZL184. Values represented the mean (± SEM) mechanical paw 
withdrawal threshold and difference in paw thickness. N = 6-8/group.  
JZL184 reverses carrageenan-induced anti-edema and allodynia 
 
To test whether JZL184 retains efficacy when given after the induction of edema, 
subjects received vehicle or JZL184 (16 mg/kg) 3 h after carrageenan. Edema was measured 3 
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and 5 h after carrageenan injection and allodynia was assessed at 5 h. As shown in Figure 8A, 
JZL184 produced a significant partial reversal of carrageenan-induced edema. JZL184 
significantly reduced edema at 5 h compared with the 3 h time point [F (1, 10) = 58.58, p < 
0.001]. JZL184 given after the induction of carrageenan-induced paw edema also significantly 
attenuated the mechanical allodynia at 5 h [t (10) = 2.90, p < 0.0; Figure 8B]. JZL184 did not 
affect paw withdrawal thresholds in control paws (Table 3). 
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Figure 8: JZL184 given after carrageenan reverses paw edema and mechanical allodynia. 
JZL184 reversed edema (A) and allodynia (B) when administered 3 h post carrageenan. Values 
represented the mean (± SEM) mechanical paw withdrawal threshold and difference in paw 
thickness. **, p < 0.01 versus JZL184 at 3 h. T test was done for allodynia. **, p < 0.01, versus 
veh; N=6 /group  
Table 3: Paw withdrawal thresholds in the contralateral paw 
The paw withdrawal thresholds for the control paw were not altered by any of the 
treatments as measured with von Frey filaments. Values represent the mean (± SEM) mechanical 
paw withdrawal threshold. 
Experiment  Mean 
(g) 
± SEM Sample 
Size 
JZL184 acute dose 3.27  0.142 35 
 JZL184 chronic dose 3.11 0.119 70 
 PF-3845 acute dose 3.20  0.276  24 
 Diclofenac  3.14  0.40 12 
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Rimonabant 3.35  0.165  27 
 SR144528 2.90  0.248  26 
CB1 (-/-) mice 3.37  0.297  24 
 CB2 (-/-) mice 2.96  0.217 23 
 Rimonabant or SR144528 after carrageenan  3.44  0.189  28 
 JZL184 after carrageenan  3.50  0.435  12 
 Combination of low dose of JZL184 and high dose of PF-
3845 
3.13 0.053 32 
Repeated administration low dose of JZL184 and high dose 
of PF-3845 
3.32 0.165 27 
 
Discussion 
 JZL184 represents the first selective MAGL inhibitor that elevates brain 2-AG, but not 
anandamide, levels upon acute administration (Long, 2009a). This compound reduces 
nociceptive behavior in a wide range of laboratory animal models of pain, including warm water 
tail withdrawal, acetic acid stretching, formalin, mechanical and cold allodynia following chronic 
constrictive injury of the sciatic nerve, capsaicin-induced mechanical allodynia, and bone cancer 
tests (Khasabova, 2011; Kinsey, 2010; Kinsey, 2009; Spradley, 2010; Busquets-Garcia, 2011; 
Guindon, 2011). The present study increases the understanding that MAGL inhibition plays a 
role in nociception by demonstrating that JZL184 reduces carrageenan-induced paw edema and 
associated mechanical allodynia. These effects were similar in magnitude to those produced by 
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the FAAH inhibitor PF-3845, as well as the nonselective COX inhibitor diclofenac. The anti-
edematous effects of JZL184 were mediated through CB2 receptors, while the anti-allodynic 
effects required both CB1 receptors and CB2 receptors. In addition, repeated administration of 
high dose JZL184 resulted in tolerance to its anti-allodynic and anti-edematous effects, but a low 
dose of JZL184 retained efficacy after repeated administration.  
 A key finding in the present study was that JZL184 administration 3 h after carrageenan 
significantly reversed the magnitude of paw edema and mechanical allodynia. The purpose of 
administering JZL184 pre versus post carrageenan is to identify the therapeutic significance of 
the drug. Reversal of anti-allodynic effects by JZL184 indicates that the drug can reverse already 
exist edema and allodynia. Similarly, URB602 reversed carrageenan-induced paw edema and 
paw withdrawal latency when administered after carrageenan in mice (Comelli, 2007). These 
findings suggest that endocannabinoid catabolic inhibitors may possess therapeutic utility in 
treating clinical symptoms associated with inflammatory disease states. 
 The observations that JZL184 did not attenuate carrageenan-induced edema in 
SR144528-treated wild type mice and CB2 (-/-) mice indicate a necessary role of CB2 receptors. 
In contrast, complementary pharmacological and genetic approaches indicated that CB1 receptors 
are expendable for the anti-edematous effects of JZL184. Likewise, the anti-edematous effect of 
URB602, which inhibits FAAH and MAGL with similar potency, has also been reported to be 
blocked by SR144528, but not by rimonabant. Studies have shown that systemic and local 
administration of the CB2 receptor agonist AM1241 suppressed the development of mechanical 
stimulation in the carrageenan model of inflammation. This suppression was blocked by 
SR144528, but not by rimonabant. Previous studies have also reported that elevation of 2-AG 
attenuates inflammatory and immune response in vitro. Thus, inhibiting 2-AG degradation in 
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vivo offers a strategy to augment levels of this endogenous cannabinoid to elicit anti-
inflammatory effects through the stimulation of CB2 receptors.  
 Conversely, complementary genetic and pharmacological approaches revealed that the 
anti-allodynic effects of JZL184 required both CB1 and CB2 receptors. Similarly, the suppressive 
effects of JZL184 on capsaicin-induced thermal hyperalgesia and nocifensive behavior required 
both CB1 and CB2 receptors. Likewise, intra-paw administration of JZL184 or URB602 
produced antinociceptive effects in the formalin model, which were blocked by CB1 and CB2 
receptor antagonists. In contrast, CB2 receptors did not play a necessary role in the anti-allodynic 
effects of JZL184 in the chronic constriction injury model. Two related questions are raised by 
these observations. First, why do both CB1 and CB2 receptors play a necessarily role in the 
antinociceptive effects of JZL184 in some types of nociceptive assays (e.g., carrageenan, 
formalin, and capsaicin), but only CB1 receptors are required in other models (e.g., warm water 
tail withdrawal, acetic acid stretching, CCI)? Second, what is the mechanism by which both 
cannabinoid receptors are required for the anti-allodynic effects of JZL184 in the carrageenan 
assay? It is unlikely that the method to assess nociception accounts for these disparate findings 
because von Frey filaments were used to assess mechanical allodynia in both CCI and 
carrageenan assays. Instead, this differential involvement of CB2 receptors may be related to the 
degree to which inflammatory responses contribute to the nociception as well as the 
concentration of cannabinoid receptors and 2-AG at the critical sites of action. Indeed, these 
actions could occur at the site of inflammation in the paw, within the dorsal root ganglia or 
dorsal horn of the spinal cord, or in multiple supraspinal regions (e.g., PAG or the rostral 
ventromedulla). It has been shown that CB2 receptors are upregulated in the dorsal root ganglia 
and paw tissue of rodents administered complete Freund’s adjuvant, suggesting that CB2 
 61 
receptors in these regions could contribute to the findings reported here. For example, 
intraplantar carrageenan could lead to the infiltration of immune cells, such as macrophages or 
neutrophils, at the site of injection, that express CB2 receptors (Galiegue, 1995). 2-AG activation 
of CB2 receptors on infiltrating cells might synergize with the well-described antinociceptive 
actions of CB1 receptor stimulation on peripheral nociceptors within the spinal cord and within 
supraspinal sites of action. It will be important to examine whether JZL184 alters inflammatory 
mediators (e.g., pro- and anti- inflammatory cytokines and prostaglandins, as well as infiltrating 
immune cells) caused by carrageenan. In order, to ascertain the relative contribution of CB1 and 
CB2 receptors in these effects, we also evaluated the ability of rimonabant and SR144528 
administered 4 h after carrageenan to reverse the anti-allodynic and anti-edematous effects of 
JZL184. Neither antagonist reversed the anti-edematous effects of JZL184 but both rimonabant 
and SR144528 reversed the anti-allodynic effects of JZL184, indicating that these effects can be 
dissociated.  
 Another important finding in the present study was that the anti-allodynic and anti-
edematous effects of JZL184 were maintained following repeated low dose administration, but 
the effects underwent tolerance after repeated high dose JZL184. Similarly, prolonged 
inactivation of MAGL via administration of high dose JZL184 (40 mg/kg) results in the loss of 
analgesic responses in the CCI model, cross-tolerance to exogenous cannabinoid receptor 
agonists (i.e., THC, and WIN55, 212-2), CB1 receptor downregulation and desensitization in 
cingulate cortex, hippocampus, somatosensory cortex, and PAG. Additionally, 2-AG elevation in 
MAGL (-/-) mice caused tonic activation and partial desensitization of CB1 receptors 
(Schlosburg, 2010). The findings that the anti-edematous and anti-allodynic effects of low dose 
JZL184 were maintained after repeated dosing are consistent with a previous report in which 
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repeated administration of 8 mg/kg JZL184 maintained its anxiolytic-like effects under high 
illumination conditions in the rat elevated plus maze assay (Guindon, 2011).   
 In conclusion, the present study demonstrates that the selective MAGL inhibitor, JZL184, 
significantly inhibits inflammatory pain, as assessed in the carrageenan assay. More specifically, 
JZL184 attenuated the development of paw edema and mechanical allodynia and reversed edema 
and allodynia when administered after carrageenan. Complementary genetic and 
pharmacological approaches revealed that the anti-allodynic effects of JZL184 required both CB1 
and CB2 receptors, whereas only CB2 receptors had a necessary role in mediating its anti-
edematous effect. We also found that the anti-allodynic and anti-edematous effects of low, but 
not high, doses of JZL184 do not undergo tolerance when administered repeatedly. These results 
indicate that the activation of CB1 and/or CB2 receptors by low doses of MAGL inhibitors may 
have beneficial effects on inflammatory pain that include the ability to prevent inflammation and 
reverse established inflammatory pain states. 
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Chapter 3. Combined inhibition of MAGL and FAAH 
suppresses edema and produces augmented anti-allodynic 
effects in the carrageenan mouse model 
Introduction: 
 Direct cannabinoid receptor agonists have long been known to reduce pain and 
inflammation in acute and chronic preclinical animal models (Kinsey, 2009, Lichtman, 2004, 
Long, 2009b, Russo, 2007); however, the psychomimetic side effects produced by these drugs 
dampen enthusiasm for clinical development (Lichtman, 2004). An alternative approach that 
promises to retain the beneficial effects and to minimize the untoward cannabimimetic side 
effects associated with CB1 receptor agonists is to inhibit the primary enzymes responsible for 
the hydrolysis of the endogenous cannabinoids (endocannabinoids), monoacylglycerol lipase 
(MAGL) and fatty acid amide hydrolase (FAAH) (Blankman, 2007, Cravatt, 2001, Cravatt, 
1996, Dinh, 2002). Pharmacological inhibition of MAGL and FAAH elevates the respective 
endocannabinoids,  anandamide;  and 2-AG in brain and spinal cord tissue (Cravatt, 1996, 
Kinsey, 2009, Long, 2009a). Blockade of these endocannabinoid catabolic enzymes produce 
analgesic and anti-inflammatory effects in vivo in carrageenan, tail withdrawal, CFA, CCI, LPS 
and formalin pain assay (Ahn, 2009, Guindon, 2011, Guindon and Hohmann, 2009, Kinsey, 
2010, Kinsey, 2009, Lichtman, 2004, Long, 2009a, Long, 2009b, Naidu, 2010, Sasso et al., 2012, 
Schlosburg, 2009, Sciolino, 2011, Spradley, 2010).  
Irreversible (PF-3845, URB597) and reversible (OL-135) inhibitors of FAAH have been 
demonstrated to elevate anandamide levels in the brain (Ahn, 2009, Boger, 2005, Fegley, 2005) 
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and attenuate neuropathic pain (Clapper, 2010, Jhaveri, 2006, Kinsey, 2009, Lichtman, 2004, 
Russo, 2007), inflammatory pain (Booker, 2011), and collagen-induced arthritis (Kinsey, 2011a). 
Similarly, MAGL inhibitors attenuate nociception to radiant heat and acetic acid-induced 
abdominal stretching (Long, 2009a), as well as reverse allodynic and hyperalgesic states in 
neuropathic (Kinsey, 2009) and inflammatory (Ghosh, 2013, Guindon, 2011) pain models. 
However, these inhibitors are not fully efficacious in producing antinociceptive effects in 
neuropathic and inflammatory pain models.  
 It is also important for drugs used to treat chronic pain conditions to maintain their 
antinociceptive effects following chronic administration. The consequences of prolonged and 
complete inhibition of MAGL contrast with the consequences of prolonged and complete 
blockade of FAAH.  Repeated administration of high doses of FAAH inhibitors produce 
sustained analgesia and without loss of CB1 receptor function (Falenski et al., 2010, Schlosburg, 
2010)  and FAAH deficient mice display a CB1 receptor-mediated hypoalgesic phenotype in 
thermal nociceptive tests, in both phases of the formalin test, thermal anti-hyperalgesic and anti-
inflammatory effects in the carrageenan model (except in chronic constriction injury model) 
(Lichtman et al., 2004). Complete blockade of MAGL leads to tolerance, physical dependence, 
impaired endocannabinoid-dependent synaptic plasticity, and CB1 receptor down-regulation and 
desensitization in select brain regions (Chanda, 2010, Schlosburg, 2010). However, partial 
MAGL blockade with low dose JZL184 maintains its antinociceptive actions in the CCI of the 
sciatic nerve neuropathic pain model (Kinsey, 2013) as well as in formalin-induced and 
carrageenan-induced inflammatory pain model (Ghosh, 2013, Sciolino, 2011). [3H] SR141716A 
binding reveals that mice show normal CB1 receptor expression and function following repeated 
administration of low dose JZL184 (≤ 8 mg/kg) (Kinsey, 2013). Although, antinociceptive 
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effects of low dose JZL184 are maintained following repeated administration, it produced a 
partial anti-edematous and anti-allodynic effects in the carrageenan model (Ghosh, 2013). 
Similarly, the FAAH inhibitor, PF-3845 only partially reduced mechanical allodynia in CCI and 
carrageenan models (Ghosh, 2013). Thus, it would be advantageous to develop an approach to 
augment the efficacy of FAAH and MAGL inhibitors in reversing carrageenan-induced 
allodynia, but without the occurrence of CB1 receptor functional tolerance, dependence, or 
cannabimimetic side effects. 
 Interestingly, the dual FAAH/MAGL inhibitor, JZL195 produced enhanced 
antinociceptive effects in tail immersion assay of thermal pain sensation, acetic acid writhing test 
of visceral pain compared with individual inhibition of these enzymes (Long, 2009b). However, 
JZL195, an equipotent MAGL and FAAH inhibitor also produced hypomotilty, catalepsy, 
substituted for THC in the drug discrimination assay, and impaired spatial memory performance 
in the Morris water maze task (Long, 2009b, Wise et al., 2012), which are drawbacks for the 
strategy of completely inhibiting both FAAH and MAGL in combination. Hence, in this chapter, 
we tested whether partial inhibition of MAGL and full inhibition of FAAH would elicit enhanced 
antinociceptive effects in mouse models of inflammatory and neuropathic pain. Two approaches 
were used to produce a differential blockade of these two enzymes. In Chapter 3A, we tested 
whether co-administration of low dose JZL184 (4 mg/kg) and high dose PF-3845 (10 mg/kg) 
block nociceptive behavior in the carrageenan model of inflammatory pain and chronic 
constriction injury model of neuropathic pain. In Chapter 3B, we tested a novel dual FAAH-
MAGL inhibitor, SA-57, which is considerably more potent in elevating brain anandamide levels 
than in elevating brain 2-AG levels (Niphakis, 2012). 
Part A. 
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 Endocannabinoid levels in the brain upon acute and repeated administration of JZL184 
and PF-3845 given alone and in combination were quantified. The 4 mg/kg dose was chosen for 
JZL184 because this is the lowest effective dose that produces anti-edematous and anti-allodynic 
effects and these effects did not undergo tolerance following repeated administration. In addition, 
this dose maintained its gastro-protective effects upon repeated administration i .e repeated 
administration of JZL184 (4 mg/kg) produces protective effects in diclofenac-induced gastric 
hemorrhages (Kinsey, 2013). The 10 mg/kg dose of PF-3845 was chosen because effective in the 
carrageenan assay (Ghosh, 2013) and its repeated administration did not lead to CB1 receptor 
functional tolerance (Schlosburg, 2010). Accordingly, we also evaluated whether the 
antinociceptive effects of this combination would be retained following repeated administration. 
Subjects were given repeated administration of this combination and tested for cross-tolerance to 
THC in the tetrad assay. Moreover, CB1 receptor expression and function were assessed using 
[3H] SR141716A binding and CP55, 940-stimulated [35S] GTPγS-stimulated binding assays as 
well as inhibition of IPSCs induced by the full CB1 receptor agonist WIN55, 212-2 in cingulate 
cortex. Finally, we tested whether the combination of low dose JZL184 and high dose PF-3845 
would produce cannabimimetic side effects as assessed in the tetrad. 
Methods: 
Subjects 
 Subjects were male C57BL/6J mice from Jackson Laboratory, Bar Harbor, ME. CB1 (-/-) 
and CB2 (-/-) mice and their respective littermate controls, CB1 (+/+) and CB2 (+/+) mice from 
the Center Transgenic Colony at Virginia Commonwealth University served as subjects. CB1 (-/-
) and CB2 (-/-) mice were backcrossed onto a C57BL/6J background for 13 and 6 generations, 
respectively. The subjects weighed between 18 and 25 g, and were housed four-five mice per 
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cage in a temperature (20–22 °C) and humidity controlled AAALAC-approved facility. Mice 
were given unlimited access to food and water in their home cages and were maintained on a 
12/12 h light/dark cycle. The sample size for each treatment group was 6 to 20 mice/group. All 
animal protocols were approved by the Virginia Commonwealth University Institutional Animal 
Care and Use Committee and were in accordance with the National Institutes of Health guide for 
the care and use of Laboratory animals (Institute of Laboratory and Animal Resources, 1996). 
After testing was completed, all mice were humanely euthanized via CO2 asphyxia, followed by 
rapid cervical dislocation except for the binding and endocannabinoid quantification studies 
where the animals were euthanized by decapitation without anesthesia. 
Drugs 
 JZL184 and PF-3845 were synthesized as described previously (Ahn et al. 2009; Long et 
al. 2009) by Organix, Inc. (Woburn, MA). JZL184, PF-3845, delta 9-THC, the CB1 receptor 
antagonist rimonabant (SR141716) and the CB2 receptor antagonist SR144528 were obtained 
from National Institute on Drug Abuse. Previous studies have shown that these doses of 
rimonabant (Lichtman, 1996, Lichtman, 2004) and SR144528 (Conti et al., 2002, Lichtman, 
2004, Malan, 2002) blocked the pharmacological effects of cannabinoid receptor agonists. All 
the drugs were dissolved in a vehicle that consisted of a mixture of ethanol, alkamuls-620 
(Rhone-Poulenc, Princeton, NJ), and saline in a ratio of 1:1:18. Each drug was given via the i.p. 
route of administration in a volume of 10 μl/g body weight. 
Induction of paw edema with carrageenan  
 Edema was induced by giving an intraplantar injection of 0.3% carrageenan (Sigma, St 
Louis), in a 20 l volume using a 30 gauge needle, into the hind left paw. Paw thickness was 
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measured with electronic digital calipers (Traceable Calipers, Friendswood, TX) prior to and 5 h 
following carrageenan administration, which corresponds to peak edema (Wise, 2008). This 
procedure has been used previously by our laboratory (Cravatt and Lichtman, 2004, Ghosh, 
2013, Lichtman, 2004, Wise, 2008).  
Neuropathic pain model 
 Mice were subjected to CCI of the sciatic nerve, as described previously (Kinsey et al., 
2009). Under isoflurane anesthesia, the right hind leg was shaved and the area swabbed with 
betadine solution, followed by ethanol. A small incision was made in the skin posterior to the 
femur, the muscle was separated, and the sciatic nerve was isolated and ligated twice with 5-0 
(1.0 metric) black silk braided suture (Surgical Specialties Corporation, Reading, PA). The 
surrounding muscle and skin were then sutured with 6-0 nylon. Mice were placed in a heated 
cage to recover from anesthesia before being returned to the vivarium. Mice were tested for 
allodynia prior to, and 10 days after, CCI surgery to establish baseline levels of allodynia. 
Mechanical allodynia 
 The mice were placed inside ventilated polycarbonate chambers on an elevated aluminum 
mesh table and allowed to acclimate to the apparatus for 60 min before testing. Mechanical 
allodynia was assessed with von Frey filaments (North Coast Medical, Morgan Hill, CA), using 
the “up-down” method (Chaplan, 1994). The plantar surface of each hind paw was stimulated 
five times with each filament (0.16–6.0 g), at a frequency of approximately 2 Hz, starting with 
the 0.6-g filament and increasing until the mouse responded by licking and/or lifting the paw off 
the surface of the test apparatus. Three or more responses out of five stimulations were coded as 
a positive response. Once a positive response was detected, sequentially lower weight filaments 
were used to assess the sensory threshold for each paw. 
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Testing procedures for the carrageenan and CCI studies 
 Mice were transported to the testing room, weighed, randomly assigned to the different 
treatment regimens, and allowed to acclimate for at least 1 h before injections. The time course 
for carrageenan-induced paw edema was assessed previously and peak edema occurred at 1 h 
(chapter 2 figure 2) and sustained for 5 h (Ghosh, 2013). Hence, all the edema data presented in 
this study represent the results obtained at the 5 h time point. Mechanical allodynia was assessed 
at the 5 h time point for carrageenan model and prior to, and 10 days after, CCI surgery to 
establish baseline levels of allodynia. The pre-treatment times for each drug were as follows: 2 h 
for PF-3845 (10 mg/kg), and 2 h for JZL184 (4 mg/kg), 2 h for PF-3845 (10 mg/kg) +JZL184 
(4mg/kg) except for the reversal study where all the drugs were administered 3 h after 
carrageenan. In experiments assessing cannabinoid receptor mechanism of action, the CB1 
receptor antagonist rimonabant (1 mg/kg) and the CB2 receptor antagonist SR144528 (3 mg/kg) 
were administered 30 min prior to JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) or vehicle. JZL184 
(4 mg/kg) + PF-3845 (10 mg/kg) or vehicle were administered 2 h before carrageenan. Edema 
was measured prior to and 5 h after and allodynia was assessed 5 h after carrageenan. Previous 
studies have shown that these doses of rimonabant (Lichtman, 1996, Lichtman, 2004) and 
SR144528 (Conti, 2002, Lichtman, 2004, Malan, 2002) blocked the pharmacological effects of 
cannabinoid receptor agonists. We have also measured the levels of endocannabinoids in brain, 
receptor binding, and receptor activity, cross-tolerance to THC as well as electrophysiology after 
acute as well as repeated administration of the combination. Following all the experiments, the 
animals were subjected to humane method of euthanasia and their brain tissues were collected 
for the analysis of brain endocannabinoid levels, binding and activity of the cannabinoid 
receptors in the same animals. 
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 In order to assess the impact of repeated administration of JZL184 (4 mg/kg) + PF-3845 
(10 mg/kg) on paw edema and mechanical allodynia in the carrageenan study, the following 
groups of mice were tested: (Group 1) vehicle for 6 days, (Group 2) vehicle for 5 days and 
challenged with JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) on day 6, and (Group 3) JZL184 (4 
mg/kg) + PF-3845 (10 mg/kg) for 6 days. On test days, mice were administered their respective 
treatments 2 h before carrageenan was injected. Edema and mechanical allodynia were then 
assessed 5 h later.  
Measurement of brain lipids 
 Following decapitation, brains were rapidly removed and frozen on dry ice and stored at-
80°C. On the day of processing, the pre-weighed tissues were homogenized with 1.4 ml 
chloroform: methanol (2:1 v/v containing 0.0348g phenylmethylsulfonyl fluoride/ml) after the 
addition of internal standards to each sample (2-pmol anandamide –d8, 1 nmol 2-AG-d8 and 1 
nmol AA-d8). Homogenates were mixed with 0.3 ml of 0.73% w/v NaCl, vortexed and 
centrifuged for 10 min at 3220 g (4°C). The aqueous phase and debris were collected and 
extracted again twice with 0.8 ml chloroform. The organic phases from the three extractions 
were pooled and the organic solvents were evaporated under nitrogen gas. Dried samples were 
reconstituted with 0.1 ml chloroform and mixed with 1 ml cold acetone. The mixtures were 
centrifuged for 5 min at 1811 g and (4 °C) to precipitate protein. The upper layer of each sample 
was collected and evaporated under nitrogen. Dried samples were reconstituted with 0.1 ml 
methanol and placed in auto sample vials for analysis. LC/MS/MS was used to quantify 
anandamide, 2-AG, and AA. The mobile phase consisted of methanol (90:10): 0.1% ammonium 
acetate and 0.1% formic acid. The column used was a Discovery ® HS C18, 4.6* 15 cm, 3 
micron (Supelco, USA). Ions were analyzed in multiple reaction monitoring mode and the 
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following transitions were monitored in positive mode: (348>62) and (348>91) for anandamide; 
(356>62) for anandamide-d8; (379>287) and(279>269) for 2- AG ; (387>96) for 2AG-d8; 
(300>62) and (300>283) in negative mode: (303>259) and (303>59) for AA and (311>267) for 
AA-d8. A calibration curve was constructed for each assay based on linear regression using the 
peak area ratios of the calibrators. The extracted standard curves ranged from 0.039 to 40 pmol 
for anandamide, from 0.0625 to 64 nmol for 2-AG and from 0.1 to 32 nmol for AA. 
Agonist-stimulated [35S] GTPγS binding 
 Mice were injected with JZL184 + PF-3845 or vehicle for five consecutive days and were 
humanely euthanized 24 h after the final injection. The brains were removed, hemisected along 
the midsagital plane, flash frozen in liquid nitrogen, and stored at - 80°C, as described previously 
(Selley et al., 1996). One half of each brain was placed in 15 mL of cold TME membrane buffer 
(50 mMTris-HCl, 3 mM MgCl2, 1 mM EGTA, pH 7.4) and homogenized. The other half of each 
brain was processed for radioligand binding, as described below. The samples were then 
centrifuged at 50,000 x g for 10 min at 5°C. The supernatant was removed and samples were 
resuspended in 15 ml of TME membrane buffer. Centrifugation was repeated, the pellet re-
suspended in TME buffer, and the protein concentration determined. Membranes then were 
pretreated with adenosine deaminase (10 mU/ml) for 15 min at 30 °C. Membrane protein (10 μg) 
was incubated in TME/Na (assay buffer with 100 mM NaCl) with 0.1% BSA, 30 μM GDP, 0.1 
nM [35S] GTPγS, and varying concentrations of CP55, 940 (0.01–10 μM) for 2 h at30°C. Non-
specific binding was determined using 20 μM unlabeled GTPγS. Basal binding was determined 
in the absence of agonist. The incubation was terminated by rapid filtration through GF/B glass 
fiber filters and three washes with ice-cold Tris–HCl (pH 7.4). Liquid scintillation 
spectrophotometry was used to evaluate bound radioactivity after the extraction of filters in 
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Budget-Solve TM (Research Products International Corp., Mount Prospect, IL) scintillation 
fluid. 
[3H] SR141716A binding 
 Half of each brain from mice treated with JZL184 or vehicle for five consecutive days, as 
described above, was placed in 15 mL of cold TME membrane buffer (50 mMTris-HCl, 3 
mMMgCl2, 1 mM EGTA, and pH 7.4) and homogenized, as described above. Saturation 
analysis was performed by incubating 30 μg membrane protein with 0.2–3 nM [3H] SR141716A 
(rimonabant; CB1 receptor antagonist) in assay buffer A + BSA (0.5 per g) with 2 μM of 
unlabeled rimonabant for 90 min at 30°C to determine non-specific binding. Total binding was 
determined in the absence of unlabeled rimonabant. The reactions were terminated using vacuum 
filtration through Whatman GF/B glass fiber filter pre-soaked in Tris buffer containing 5 g L-1 
BSA(Tris–BSA) and three washes with 4 °C Tris–BSA. Bound radioactivity was evaluated by 
liquid scintillation spectrophotometry at 45% efficiency after extraction in Budget-Solve TM 
scintillation fluid. 
Cannabimimetic behavior assessments 
 Mice were treated for five consecutive days with vehicle + vehicle or4 mg/kg JZL184 + 
10 mg/kg PF-3845 and tested for cross-tolerance to THC on day six. Prior to testing all mice 
were acclimated to the test room for at least 1 h (Martin et al., 2003). Baseline nociception and 
rectal temperature were assessed. Cross-tolerance to THC (3, 10, 30 or 100 mg/kg) was then 
tested using a within-subjects cumulative dosing design. Specifically, mice were injected with an 
increasing dose of THC every 40 min and tested 30 min after each injection (Falenski, 2010, 
Kinsey, 2013) for catalepsy, nociception, and rectal temperature. Catalepsy was assessed using 
the bar test, in which the forelimbs of each mouse were placed on a horizontal bar during a 60s 
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test in which time immobile was measured. Hypothermia was determined by change in rectal 
body temperature from baseline. The tail immersion test was used to measure antinociception. 
The distal 2 cm of the tail was immersed in 52.0 °C water and the tail withdrawal latency 
determined. A maximum cutoff of 10 s was used to minimize possible tissue damage. Maximum 
percent effect was using the formula [(test value - base line value)/ (10 - baseline value)]*100. 
 In separate groups of mice, the cannabimimetic behavioral effects of treatment with 
vehicle + vehicle, 4 mg/kg JZL184 + 10 mg/kg PF-3845, or 40 mg/kg JZL184 + 10 mg/kg PF-
3845 were evaluated in the tetrad test. Baseline rectal temperature and nociception were first 
determined. Two hours after injections, locomotor activity was measured in a 5 min test. Mice 
were then evaluated for catalepsy, nociception, and rectal temperature as described above. 
Locomotor activity was quantified using Any-Maze 
TM
 software.  
Measurements of IPSCs in the cingulate cortex 
 C57BL/6J mice (~10 weeks old) were intraperitoneally injected with (1) Vehicle + 
Vehicle (2) Repeated 4 mg/kg JZL184 + vehicle (3) repeated 4 mg/kg JZL184 + 10 mg/kg PF-
3845 and (4) repeated 40 mg/kg JZL184 + 10 mg/kg PF-3845 for six days. 2 h after the final 
injection, mice were anaesthetized by isoflurane inhalation and decapitated. Cortical slices (300 
µm thick) were cut using a vibrating slicer (Leica) and prepared as described in our previous 
studies (Pan et al., 2011, Schlosburg, 2010). Briefly, slices were prepared at 4-6°C in a solution 
containing (in mM): 220 sucrose, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 7 MgSO4, 26 NaHCO3, 10 
glucose, and 1 sodiumascorbate. The slices were transferred in artificial cerebrospinal fluid 
(ACSF) containing (in mM): 119 NaCl, 2.5 KCl, 2.5 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 26 
NaHCO3, and 10 glucose and were allowed to recover at least 1 hour at room temperature. All 
solutions were saturated with 95% O2 and 5% CO2.  
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 Whole-cell voltage-clamp recordings were made using patch clamp amplifier 
(Multiclamp 700B) under infrared-differential contrast interference microscopy. Data acquisition 
and analysis were performed using a digitizer (DigiData 1440A) and analysis software pClamp 
10 (Molecular Devices). Pyramidal neurons in layer V of the cingulate cortex were identified 
visually based upon pyramidal shaped soma with a prominent apical dendrite. Additionally, the 
pyramidal neurons exhibit spike frequency adaptation in response to depolarizing current 
injections (Satake et al., 2008). To evoke IPSCs in layer V pyramidal neurons, the stimulation 
electrode was placed in layer V of cingulate cortex. The pipettes were filled with an internal 
solution containing (in mM): 80 K-gluconate, 60 KCl, 10 HEPES, 0.2 EGTA, 2 MgCl2, 4 
MgATP, 0.3 Na2GTP, and 10 Na2-phosphocreatine (pH 7.2 with KOH). Glutamate receptor 
antagonists 6-cyano-7-nitroquinoxaline-2, 3-dione (CNQX, 20 µM) and D-2-amino-5-
phosphonovaleric acid (D-AP-5, 20 µM) were present in the ACSF throughout the experiments. 
Series resistance (15-30 MΩ) was monitored throughout the recordings, and data were discarded 
if the resistance changed by more than 20%. All recordings were performed at 32 ± 1°C by using 
an automatic temperature controller.  
Data analyses 
 Paw edema data are expressed as the difference in paw thickness between the 5 h and 
pre-injection measures. Paw withdrawal thresholds to the von Frey filaments in the carrageenan-
injected and contralateral (i.e., control) paws at the 5 h time point were used to assess mechanical 
allodynia and prior to, and 10 days after, CCI surgery. All data are depicted as mean +/- standard 
error of the mean (SEM). Data were analyzed using t-tests, one-way analysis of variance 
(ANOVA), or two-way ANOVA. Tukey-Kramer post hoc analysis was used for all tests 
comparing different treatment groups. Bonferroni planned comparisons were used to assess the 
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data in the mechanism of action study. [3H] SR141716A and [35S] GTPγS binding data were fit 
by nonlinear regression analysis to obtain Bmax and KD or Emax values, respectively. The 
pharmacological effects of THC were analyzed using a mixed design ANOVA vehicle + vehicle 
and JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) pretreatment was the between subjects variable, 
and THC dose was the within subjects variable followed by Bonferroni post hoc test to compare 
each pretreatment with vehicle at individual THC doses. Differences of p < 0.05 were considered 
statistically significant. IPSC amplitude was normalized to the baseline. The depression 
(percentage) of IPSCs by WIN55, 212-2 was calculated as follows: 100 × [mean amplitude of 
IPSCs during the last 5 min treatment/mean amplitude of baseline IPSCs]. Data sets were 
compared with Student's t-test. All the results were considered significant at p< 0.05. 
Results: 
Co-administration of JZL184 and PF-3845 elevates endocannabinoids without decreasing 
arachidonic acid in the brain. 
 To assess the impact of partial MAGL inhibition combined with full FAAH inhibition on 
brain endocannabinoid levels, male C57BL/6 mice were assigned to one of the following five 
groups: (1) vehicle + vehicle, (2) vehicle + 4 mg/kg JZL184, (3) vehicle + 10 mg/kg PF-3845, 
(4) 4 mg/kg JZL184 + 10 mg/kg PF-3845, or (5) 40 mg/kg JZL184 + vehicle (i.e., full MAGL 
blockade). 40 mg/kg JZL184 was included to compare the impact of low dose high dose JZL184 
on the endocannabinoid level. It has been shown in the literature that 40 mg/kg elevates brain 2-
AG level by 10 folds (Long, 2009a). Hence, including this condition in our experiment serves the 
purpose of validating that the assay is working. The mice were sacrificed immediately after 
assessment of edema and allodynia at 5h that is 7 h after the drug treatment. Brain levels of 
anandamide, 2-AG, and arachidonic acid (AA) 7 h following the injections are shown in Figure 
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9A-C. PF-3845 given alone or in combination with JZL184 led to a 10-fold increase in 
anandamide levels [F (4, 35) = 389.0, p < 0.001; Figure 9A]. JZL184 (4 mg/kg) given alone or 
in combination with PF-3845 produced a 3-fold elevation in 2-AG levels [F (4, 35) = 99.10, p < 
0.001; Figure 9B]. The elevation in brain 2-AG was not accompanied by significant reductions 
in the levels of arachidonic acid (AA) [p > 0.41] Figure 9C]. On the other hand, full blockade of 
MAGL using 40 mg/kg JZL184 elevated 2-AG levels eight fold [Figure 9B] and reduced brain 
AA levels by two fold [F (4,35)= 18.92, p < 0.001; Figure 9C]. Dr. Rehab Abdulla performed 
this experiment.  
 
Figure 9. Anandamide, 2-AG levels were elevated by single as well as dual enzyme inhibition. 
However, arachidonic acid (AA) levels remained unaffected by single enzyme inhibition versus 
dual enzyme inhibition. Only high dose of JZl184 has decreased the level of arachidonic acid. 
Acute administration of JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) significantly increased brain 
levels of (A) anandamide and (B) 2-AG, but did not affect (C) arachidonic acid (AA) levels. ***, 
p < 0.001 versus vehicle (Tukey-Kramer post hoc tests). Data presented as mean ± SEM (N = 7-
8). 
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Partial MAGL and complete FAAH inhibition produce augmented anti-allodynic effects in the 
carrageenan model of inflammatory pain 
 We have previously reported that JZL184 (4, 16, or 40 mg/kg) or PF-3845 (3 or10 
mg/kg) (Ghosh, 2013) only partially reversed the anti-allodynic effects in carrageenan and CCI 
assays  (Ghosh, 2013, Kinsey, 2010). Hence, a main goal of this experiment was to test whether 
the combined administration of low dose JZL184 and high dose PF-3845 would produce 
augmented anti-allodynic effects compared with each drug given alone. As shown in Figure 10A 
combined administration of JZL184 (4 mg/kg) and PF-3845 (10 mg/kg) produced augmented the 
anti-allodynic effects compared with administration of either inhibitor given alone [F (4, 35) = 
17.2, p < 0.001; Figure 10A]. JZL184 (4 mg/kg), PF-3845 (10 mg/kg), or JZL184 (4 mg/kg) + 
PF-3845(10 mg/kg) significantly reduced paw threshold values as compared to vehicle. 
Additionally, the paw threshold responses following combined administration of JZL184 + PF-
3845 produced threshold values that did not differ from the contralateral control paw, indicating 
full reversal of carrageenan-induced allodynia. The combination did not affect paw withdrawal 
thresholds in the control paws. However, JZL184 (4 mg/kg), PF-3845 (10 mg/kg), or combined 
administration of JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) given 2 h before carrageenan 
partially reduced paw edema [F (3, 28) = 51.2, p < 0.001; Figure 10B]. To test whether JZL184 
+ PF-3845 retains efficacy when given after the induction of edema, subjects received vehicle or 
JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) 3 h after carrageenan. Edema was measured prior to 
and 5 h after carrageenan injection and allodynia was assessed at 5 h. As shown in Figure 10 C, 
the combination produced a significant reversal of carrageenan-induced edema at 5 h [F (3, 20) = 
15.30, p < 0.001]. The combination also significantly reversed mechanical allodynia at this time 
point [F (4, 25) = 9.21, p < 0.001; Figure 10D]. JZL184 + PF-3845 did not affect paw 
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withdrawal thresholds in control paws. Thus, the combination partially reverses carrageenan-
induced edema and completely reverses carrageenan-induced allodynia. 
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Figure 10. Combined administration of JZL184 and PF-3845 produced enhanced anti-allodynic, 
but not anti-edematous effects, compared with single enzyme inhibition in the carrageenan 
model. (A) Co-administration of low dose JZL184 (4mg/kg) and high dose PF-3845 (10 mg/kg) 
augmented the anti-allodynic effects of JZL184 (4mg/kg) and high dose of PF-3845 (10 mg/kg) 
alone. (B) JZL184 (4 mg/kg), PF-3845 (10 mg/kg), and a co-administration of JZL184 (4mg/kg) 
+ PF-3845 (10 mg/kg) produce anti-edematous effects of similar magnitude.JZL184 and/or PF- 
3845 were administered 2 h before carrageenan. Paw thickness was measured prior to and 5 h 
after carrageenan injection and mechanical allodynia was assessed at 5 h post carrageenan 
injection. **, p < 0.01, ***, p <0.001 versus vehicle; # p < 0.05 versus control paw (Tukey-
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Kramer post hoc tests). Data presented as mean ± SEM (n = 8). Administration of JZL184 (4 
mg/kg) + PF-3845 (10 mg/kg) reversed (C) edema and (D) allodynia when administered 3 h post 
carrageenan. Paw thickness was measured prior to and 5 h after carrageenan administration and 
mechanical allodynia was measured 5 h after carrageenan.*, p < 0.05, **, p < 0.01, ***, p < 
0.001 versus vehicle; #, p < 0.05 versus control paw (Tukey-Kramer post hoc tests). Data 
presented as mean ± SEM (N = 6). 
Partial MAGL and complete FAAH inhibition produce augmented anti-allodynic effects in the 
chronic constriction injury model of neuropathic pain 
 Similarly, we have tested the effects of this combination is chronic constriction injury 
model of neuropathic pain. Each of the inhibitors injected 2 h before testing produced significant 
anti-allodynic effects in the CCI model of neuropathic pain [F(4,29) = 27.52; p < 0.001; Figure 
11]. While combined administration of JZL184 (4 mg/kg) + PF-3845(10 mg/kg) produced 
augmented anti-allodynic compared with JZL184 (4 mg/kg) or PF-3845 (10 mg/kg) alone. 
Allodynia was partially reversed in this assay. In addition, JZL184 + PF-3845 did not affect paw 
withdrawal thresholds in control paws. Dr. Steven Kinsey performed this experiment. 
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Figure 11. Combined administration of JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) produced 
enhanced anti-allodynic effects in the CCI model of neuropathic pain. Low dose JZL184 
(4mg/kg) and high dose PF-3845 (10 mg/kg) produced augmented anti-allodynic effects when 
administered together as compared to either JZL184 or PF-3845 alone. Mechanical allodynia 
was assessed 2 h post drug administration. **, p < 0.01, ***, p <0.001 versus vehicle; #, p < 0.05 
versus JZL184 (Tukey-Kramer post hoc tests). Data presented as mean ± SEM (N = 20). 
Combination JZL184 and PF-3845 mediates its anti-allodynic effects through cannabinoid 
receptors 
 To determine cannabinoid receptors mediate the anti-allodynic effects of JZL184 + PF-
3845, mice were pretreated with rimonabant (1 mg/kg), SR144528 (3 mg/kg), or vehicle 150 min 
prior to carrageenan/ JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) was administered 120 min before 
carrageenan. The data depicted in Figure 12 A, reveal that CB2 receptors mediate the anti-
edematous effects of JZL184 (4 mg/kg) + PF-3845 (10 mg/kg). Whereas rimonabant was without 
effect [p= 0.73], SR144528 completely blocked the anti-edematous effects of the combination as 
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revealed by a significant interaction between JZL184+ PF-3845 and SR145528 [F (1, 21) = 23.0, 
p < 0.001]. In contrast, either rimonabant [F (1, 21) = 21.9, p < 0.001] or SR144528 [F (1, 21) 
=20.5, p < 0.001] completely prevented the anti-allodynic effects of combined administration 
JZL184 + PF-3845, indicating that both CB1 and CB2 receptors were required (Figure 12B). 
Neither rimonabant nor SR144528 significantly affected carrageenan-induced edema or 
allodynia in the absence of an endocannabinoid catabolic enzyme inhibitor. 
 
Figure 12. The anti-edematous effect of JZL184 and PF-3845 was mediated by CB2 but not CB1 
receptors and the anti-allodynic effect of the combination was mediated by CB1 and CB2 
mechanism of action. (A) Rimonabant (1 mg/kg) did not block the anti-edematous effects of 
JZL184 (4 mg/kg) and PF-3845 (10 mg/kg). ***, p < 0.001 versus vehicle/vehicle. SR144528 (3 
mg/kg) blocked the anti-edematous effects of JZL184 (4 mg/kg) + PF-3845 (10 mg/kg). Paw 
diameter thickness was measured prior to and 5 h after carrageenan administration. ##, p < 0.05 
versus vehicle/JZL184 + PF-3845. (B) Rimonabant (1 mg/kg) as well as SR144528blocked the 
anti-allodynic effects of JZL184 (4 mg/kg) + PF-3845 (10 mg/kg). ***, p < 0.001 versus 
vehicle/vehicle, ###, p<0.001 versus vehicle/JZL184 + PF-3845. Mechanical allodynia was 
measured 5 h after carrageenan. JZL184 + PF-3845 or vehicle was injected 2 h before 
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carrageenan. Rimonabant or SR144528 was injected 30 min prior to JZL184 + PF-3845 or 
vehicle. Bonferroni post hoc tests were used. Data presented as mean ± SEM (N = 6). 
Repeated administration of the combination of JZL184 and PF-3845 elevate 
endocannabinoids and decrease arachidonic acid in the brain. 
 Brain endocannabinoids and arachidonic acid levels were assessed in the brain after 6 
days of repeated administration of the following treatments: (1) vehicle + vehicle, (2) vehicle + 4 
mg/kg JZL184, (3) vehicle + 10 mg/kg PF-3845, (4) 4 mg/kg JZL184 + 10 mg/kg PF-3845, or 
(5) 40 mg/kg JZL184 + vehicle. On day 6, animals were sacrificed 2 h following the injection. 
Figure 13A-13C shows the levels of anandamide, 2-AG, and AA in the whole brain. As in the 
case of acute administration, PF-3845 (10 mg/kg) elevated anandamide levels 10-fold whether 
given alone or in combination with JZL184 (4 mg/kg) [F (4, 31) = 233.3, p < 0.001]. Brain 2-AG 
levels were elevated 6 fold irrespective of whether given alone or in combination with PF-3845 
[F (4, 31) = 123.7, p < 0.001]. In comparison, 40 mg/kg JZL184 elevated 2-AG levels 8-fold and 
reduced brain levels of arachidonic acid by 4-fold [F (4, 31) = 31.95, p < 0.001]. Repeated 
administration of high dose of JZL184 (40 mg/kg) has shown a small but significant elevation in 
anandamide level p < 0.05. Dr. Rehab Abdulla conducted this experiment. 
 
Figure 13. Repeated administration of JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) increased (A) 
anandamide (AEA) and (B) 2-AG levels in the brain as well as decreased (C) arachidonic acid 
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(AA) levels in the brain.***,p < 0.001 versus vehicle (Tukey-Kramer post hoc tests). Data 
presented as mean ± SEM (N = 7-8). 
Consequences of combined partial MAGL inhibition and full FAAH inhibition given 
repeatedly  
 In this experiment, we assessed the consequences of daily injections of JZL184 (4mg/kg) 
+ PF-3845 (10mg/kg) given for six days. Our goal is to determine whether the anti-edematous 
and anti-allodynic effects of JZL184 + PF-3845 treatment in the carrageenan model would be 
maintained following repeated injections. As shown in Figure 14 acute and repeated 
administration of the combination, JZL184 (4mg/kg) + PF-3845 (10mg/kg), produced similar 
decreases in edema [F (2, 22) = 8.47, p < 0.01; Figure 14A] and anti-allodynic effects [F (5, 44) 
= 5.85, p < 0.001; Figure 14B] in the carrageenan model.  
 
Figure 14. The anti-edematous (A) and anti-allodynic effects (B) of combined administration of 
JZL184 and PF-3845 did not undergo tolerance following repeated administration. Mice were 
administered vehicle (1.1.18) injections once daily for 5 days and challenged with vehicle or 
combined low dose JZL 184 (4 mg/kg) and high dose PF-3845 (10 mg/kg) on day 6 or 
repeatedly treated with low dose JZL 184 (4 mg/kg) and high dose PF-3845 (10 mg/kg) once 
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daily for 6 days. Drug treatments on day 6 were given 2 h prior carrageenan injections. Paw 
thickness was measured prior to and 5 h after carrageenan administration and mechanical 
allodynia was tested 5 h after carrageenan. *, p < 0.05, versus vehicle; ** p < 0.01 versus veh 
paw (Tukey-Kramer post hoc tests). Data presented as mean ± SEM (N = 8-9). 
JZL-184 (4mg/kg) with PF-3845 10 (mg/kg) do not elicit cannabimimetic effects, as assessed 
in the tetrad assay  
 As indicated in Table 4 low dose JZL184 + high dose of PF-3845 did not produce of 
THC-like effects in the tetrad assay. Mice were injected with low dose of JZL184 (4 mg/kg) with 
high dose PF-3845 (10 mg/kg), and then (A) catalepsy, (B) analgesia (C) body temperature and 
(D) locomotor activity were assessed after 2 h of drug treatment. The data show that JZL184 (4 
mg/kg) + PF-3845 (10 mg/kg) does not produce catalepsy, antinociception, hypothermia, and 
hypolocomotion. 
Treatment  Catale
psy (s) 
Tail 
withdrawal 
latency (s) 
Body 
Temperatur
e (
o
 C) 
Catal
epsy 
(s) 
Tail 
withdrawal 
latency (s) 
Body 
Temperat
ure (
o
 C) 
Distance 
travelled 
(m) 
  Baseline After 2 h 
Vehicle/Ve
hicle 
 Mean 0 
2.03 38.18 
0 
2.07 38.19 285.25 
 +SEM 0 
+0.103 +0.182 
0 
+0.235 +0.132 +29.228 
JZL184 (4 
mg/kg) + 
PF-3845 
(10 mg/kg) 
Mean 0 
1.81 38.31 
0 
4.51 37.80 259.75 
 +SEM 0 +0.091 +0.194 0 +1.171 +0.133 +22.754 
 
Table 4: Administration of low dose JZL184 + high dose of PF-3845 did not produce THC-like 
effects in the tetrad assay. Mice were injected with low dose of JZL184 (4 mg/kg) in 
combination with high dose PF-3845 (10 mg/kg), and then tested for (A) catalepsy, (B) analgesia 
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(C), body temperature, and (D) locomotor activity were assessed after 2 h of drug treatment. 
Tukey Kramer post hoc test was used. N = 8-12/group.  
Partial MAGL and complete FAAH blockade does not cause cross-tolerance to the 
pharmacological effects of THC 
 We next tested whether mice given combination of JZL184 and PF-3845 produces cross-
tolerance to the cataleptic, antinociceptive, and hypothermic effects of THC. Accordingly, mice 
were treated for five consecutive days with vehicle + vehicle or 4 mg/kg JZL184 + 10 mg/kg PF-
3845. These mice did not display cross-tolerance to the pharmacological effects of THC (3, 10, 
30 or 100 mg/kg) on day 6. Specifically, the potency of THC in eliciting catalepsy, 
antinociception (i.e., tail immersion test), and hypothermia was retained following repeated drug 
administration. THC significantly increased catalepsy [F (3, 42) =52.61, p < 0.0001; Figure 
15A], tail withdrawal latency [F (3, 42) = 65.26, p < 0.0001; Figure 15B], and hypothermia [F 
(3, 42) = 60.15, p < 0.0001; Figure 15C] in both treatment groups. Additionally, there were no 
effects of repeated treatment with vehicle + vehicle or 4 mg/kg JZL184 + 10 mg/kg PF-3845 on 
catalepsy (p = 0.40), tail withdrawal latency (p = 0.34), or body temperature (p = 0.27) indicating 
that the combination did not produce cross-tolerance to THC. 
 Figure 15. Mice treated repeatedly with vehicle + vehicle or JZL184 (4 mg/kg) + PF-3845 (10 
mg/kg) displayed similar (A) catalepsy, (B) antinociception, and (C) body temperature when 
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tested for cross tolerance to increasing doses of THC. Mice were treated with vehicle + vehicle 
or JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) once daily for 5 days. On the sixth day cross-
tolerance to THC (3, 10, 30, or 100 mg/kg) was tested using a cumulative dosing regimen. 
Bonferroni post hoc tests were used. Data presented as mean ± SEM (N = 8). 
 CB1 receptor activity and expression are maintained following repeated administration of 
JZL184 + PF-3845 combination 
 As previously reported, repeated treatment, injection of 40 mg/kg JZL184 reduced whole 
brain CB1 receptor levels by 33.3% and produced a 56.3% reduction in maximal CP55, 940-
stimulated G-protein activity. However, simultaneous repeated administration of high dose PF-
3845 (10 mg/kg) and low dose JZL184 (4 mg/kg) as well as each treatment alone did not 
significantly alter CB1 receptor levels (Figure 16A) or CP55, 940-stimulated G-protein activity 
(Figure 16B) as compared to the vehicle + vehicle control group. Dr. Qing Tao did this 
experiment. 
 
Figure 16. CB1 receptor expression and activity were reduced following repeated injections of 
high dose JZL184 (40 mg/kg), but remained unaffected following repeated co-administration of 
low dose JZL184 + high dose PF-3845. Mice were treated for 6 days with vehicle + vehicle, 
vehicle + JZL184 (4 mg/kg), vehicle + PF-3845 (10 mg/kg), JZL184 + PF-3845 or vehicle + 
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JZL184 (40 mg/kg). On day 6, animals were euthanized and then the brain homogenates were 
used to test (A) membrane-specific CB1 receptor binding by the antagonist [
3
H]SR141716A 
(Bmax values). The Bmax (maximum receptor binding) and Kd (ligand concentration at which 
half maximal receptor binding is observed at equilibrium) for each conditions are as follows; for 
vehicle + vehicle, Bmax = 6.06, Kd = 1.48; vehicle + JZL184 (4 mg/kg), Bmax = 5.0, Kd = 1.58; 
vehicle + PF-3845 (10 mg/kg), Bmax = 5.64, Kd = 1.58; JZL184 + PF-3845, Bmax = 4.94, Kd = 
1.52 or vehicle + JZL184 (40 mg/kg) Bmax = 4.18, Kd = 1.58. and (B) CP55,940-stimulated 
[
35
S]-GTPγS binding.** p < 0.01, *** p < 0.001 vs. vehicle (Emax). Tukey-Kramer post hoc test 
was used. Data presented as mean ± SEM (N = 8). 
CB1 receptor function in the cingulated cortex is maintained following chronic partial MAGL 
and complete FAAH blockade 
 Finally, we examined whether repeated administration of the combination for 6 days 
induce CB1 receptor desensitization in the cingulate cortex, a brain region critically involved in 
the regulation of pain (Zhuo, 2006). For this experiment, the following groups were tested (1) 
vehicle + vehicle, (2) vehicle + 4 mg/kg JZL184, (3) 4 mg/kg JZL184 + 10 mg/kg PF-3845, or 
(4) 40 mg/kg JZL184 + 10 mg/kg PF-3845. Bath application of the CB1 receptor agonist 
WIN55,212-2 (2 µM) induced similar depression of IPSCs between JZL184- and vehicle-treated 
mice (vehicle, 61.9 ± 5.5% of baseline, JZL184, 67.4 ± 5.2% of baseline p > 0.05; Figure 17A), 
suggesting that chronic JZL184 at this low dose did not induce significant CB1 receptor 
desensitization. No apparent CB1 receptor desensitization was detected in mice chronically 
treated with FAAH inhibitor PF3845 (10 mg/kg for 6 d) (Schlosburg, 2010). Consistent with this 
finding, we found that the magnitude of WIN55, 212-2-induced depression of IPSCs in the 
cingulate cortex was not significantly different between mice treated with JZL184 (4 mg/kg) plus 
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vehicle and JZL184 (4 mg/kg) plus PF3845 (10 mg/kg) (66.4 ± 5.4% of baseline, p > 0.05; 
Figure 17 A, 17 B). However, WIN55, 212-2-induced depression of IPSCs was significantly 
attenuated in mice treated with JZL184 (40 mg/kg) plus PF3845 (10 mg/kg) (86.6 ± 5.3% of 
baseline) compared with that in mice treated with JZL184 (4 mg/kg) plus PF3845 (10 mg/kg) (p 
< 0.05; Figure 17 A, 17 B). Dr. Qing-Song Liu performed this study. 
 
Figure 17. Effects of repeated in vivo administration of JZL184 alone or in combination with 
PF-3845 on WIN55, 212-2-induced depression of IPSCs in the cingulate cortex. WIN55, 212-2-
induced depression of IPSCs in cingulate cortex was not significantly reduced by repeated 
administration of either JZL184 (4 mg/kg) or combination of JZL184 (4 mg/kg) + PF-3845 (10 
mg/kg). However, repeated injections of JZL184 (40 mg/kg) + PF-3845 (10 mg/kg) for 6 days 
led to significant suppression. (C) The magnitude of WIN55,212-2-induced depression of IPSCs 
was not significantly different between mice treated with vehicle (N=7) and mice treated with 
JZL184 (4 mg/kg) (N=8), p < 0.05 (D) WIN55,212-2 (2 µM) induced significantly less 
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depression of IPSCs in mice treated with JZL184 (40 mg/kg) + PF-3845 (10 mg/kg) (N= 7) than 
that in mice treated with JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) (N=7 ), p < 0.05. Each group 
of data was obtained from three mice. Dr.Qing-Song Liu has performed this study. 
Discussion: 
 The primary objective of the experiments presented in Part A of Chapter 3 was to 
test proof of principle that combined blockade of FAAH and MAGL represents a viable strategy 
to reduce neuropathic and inflammatory pain. Two significant challenges were addressed to test 
this hypothesis. First, while combined blockade of MAGL and FAAH produces enhanced 
antinociceptive effects, full blockade of these enzymes in combination also produces THC-like 
subjective effects in the drug discrimination assay, catalepsy, hypomotility, and impaired 
performance in a working memory Morris water maze memory task (Long, 2009b, Wise, 2012). 
Second, repeated administration of MAGL inhibitors or genetic inactivation of MAGL causes 
profound alterations in the brain endocannabinoid system in mice, as evidenced by a loss of 
analgesic responses to a MAGL inhibitor, cross-tolerance to exogenous cannabinoid agonists, 
and CB1 receptor downregulation and desensitization in specific brain regions such as the 
cingulate cortex, hippocampus, somatosensory cortex and PAG (Schlosburg, 2010). In contrast, 
FAAH (-/-) mice or wild type mice given repeated injections of FAAH inhibitors, which 
maintain an analgesic phenotype and intact CB1 receptor system (Chanda, 2010, Cravatt, 2001, 
Lichtman, 2004, Schlosburg, 2010). In order to reduce these cannabimimetic side effects and to 
circumvent tolerance, we investigated whether a combination of partial MAGL inhibition and 
complete FAAH inhibition would achieve enhanced efficacy in reversing the allodynia in the 
carrageenan and chronic CCI rodent models of pain. The major findings of the present study are 
that partially blocking MAGL in combination with full FAAH blockade produced enhanced anti-
 90 
allodynic effects in both assays, but in the absence of cannabimimetic side effects. Specifically, 
combined administration of low dose of the MAGL inhibitor JZL184 (i.e., 4 mg/kg) and high 
dose of the FAAH inhibitor PF-3845 (i.e., 10 mg/kg) substantially enhanced the anti-allodynic 
effects in mice as compared to single inhibition of these enzymes. Interestingly, combined 
blockade of these enzymes did not produce increased anti-edematous effects in the carrageenan 
assay. The second major finding was that unlike prolonged MAGL blockade with high dose 
JZL184 (Schlosburg et al., 2010), repeated administration of JZL184 (4 mg/kg) and PF-3845 (10 
mg/kg) did not produce CB1 receptor functional tolerance and maintained the anti-allodynic and 
anti-edematous effects. Finally, in contrast to complete blockade of MAGL and FAAH 
(Schlosburg et al., 2010), combination of JZL184 (4 mg/kg) and PF-3845 (10 mg/kg) did not 
elicit cannabimimetic side effects.  
Experiments were conducted to determine whether the enhanced anti-allodynic effects 
produced by dual blockade of FAAH and MAGL were mediated by cannabinoid receptors. 
Accordingly, we used a pharmacological approach to assess whether CB1 and CB2 receptors 
mediate the enhanced anti-allodynic effects of combined administration of JZL184 and PF-3845. 
The anti-allodynic effects of the combination were completely blocked by both rimonabant and 
SR144528, indicating that CB1 and CB2 receptors play necessary roles in this response. This is in 
agreement with previous reports showing that JZL184 mediates its anti-allodynic effects through 
CB1 and CB2 receptors in the carrageenan and formalin pain assays (Guindon et al., 2011; Ghosh 
et al., 2013). In contrast, the anti-edematous effects of the combination were blocked only by 
SR144528, indicating that anti-edematous effects require CB2 receptors. Previously it has been 
shown that anti-edematous effects of JZL184 and PF-3845 were mediated by CB2 receptors 
(Ghosh, 2013, Lichtman, 2004, Wise, 2012). 
 91 
 The most striking finding of this study is that simultaneous partial blockade of MAGL 
with low dose JZL184 and complete blockade of FAAH with high dose PF-3845 produced 
enhanced anti-allodynic effects as compared to individual blockade of each enzyme in both the 
carrageenan and CCI models of pain. Several explanations may account for enhanced anti-
allodynic effects upon dual FAAH and MAGL inhibition. First, the enhancement may have 
resulted from simply an increase in the total quantity of endocannabinoid levels in the nervous 
system to stimulate cannabinoid receptors. However, the observation that 2-AG levels in brain 
are at least 200-fold higher than anandamide brain levels (Ahn, 2009, Long, 2009a) tends to 
argue against this idea of mass action. Alternatively, it is plausible that simultaneous inhibition 
of MAGL and FAAH may produce augmented anti-allodynic effects because distinct CB1 and 
CB2 receptor-mediated circuits are activated by the respective endocannabinoids. Consistent with 
this idea is that FAAH is predominantly expressed on post-synaptic terminals (Gulyas et al., 
2004) and MAGL is expressed on presynaptic terminals (Gulyas, 2004). A third explanation is 
that along with the increased levels of anandamide and 2-AG, other consequences of FAAH and 
MAGL inhibition may have contributed to the augmented anti-allodynic effects. These enzymes 
metabolize other lipid signaling molecules that act through other noncannabinoid receptor targets 
(Ahn, 2008). In particular, MAGL plays a major role in the biosynthesis of free arachidonic acid 
(AA) its precursor, 2-AG in brain from (Nomura, 2011). For example, MAGL plays an important 
role in the biosynthesis of arachidonic acid in brain. Thus, MAGL inhibition results in reduced 
arachidonic acid, which leads to reduced levels of prostaglandin (Nomura, 2011). However, as 4 
mg/kg JZL184 did not alter arachidonic acid levels in whole brain, this explanation tends to 
argue against the involvement of reduced prostaglandin levels. However, there may be 
 92 
reductions of arachidonic acid in distinct brain regions or spinal cord associated with pain, which 
would not be detected from whole brain extracts.  
 In addition to anandamide, FAAH metabolizes other bioactive fatty acid amides, 
including N-palmitoylethanolamine, N-oleoylethanolamine, and oleamide (Cravatt, 2001, 
Cravatt, 1996), as well as N-acyl taurines (Fattore et al., 2005, Leung, 2006), which activate 
various TRP channels and PPAR- receptors (De Petrocellis and Di Marzo, 2010, Di Marzo and 
De Petrocellis, 2010, Jhaveri, 2006). Thus, combined blockade of FAAH and MAGL produces 
multiple neurochemical alterations that could affect allodynia and edematous responses.  
It is interesting that dual inhibition of FAAH and MAGL did not produce increased anti-
edematous effects compared with inhibition of either enzyme alone. It is plausible that a “ceiling 
effect” had occurred following inhibition of FAAH or MAGL and no further reduction in paw 
edema could be achieved. Another explanation is that anti-edematous effects were mediated by 
CB2 receptors only, while the anti-allodynic effects required both CB1 and CB2 receptors. 
Accordingly, increased anti-allodynic effects may be caused by dual inhibition when both CB1 
and CB2 receptors are involved. 
Importantly, the anti-edematous and anti-allodynic effects of low dose JZL184 and high dose 
PF-3845 in the carrageenan model were maintained following repeated administration. This lack 
of tolerance is consistent with studies reporting that the pharmacological effects of low doses of 
JZL184 (4 and 8 mg/kg) were maintained following repeated injections in the carrageenan model 
of inflammatory pain, CCI model of neuropathic pain (Ghosh, 2013, Kinsey, 2013), and 
anxiolytic effects in the elevated plus maze in rats (Sciolino, 2011). Additionally, the 
antinociceptive effects of the FAAH inhibitor PF-3845 in the tail-withdrawal test and CCI model 
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did not undergo tolerance following repeated administration (Schlosburg, 2010). Likewise, 
chronic treatment with direct cannabinoid receptor agonists, such as THC or WIN55-212, leads 
to the development of tolerance (Lichtman and Martin, 2005).  
 These behavioral phenotypes have been shown to be accompanied by substantial 
reductions in CB1 receptor expression and function in the brain (Romero et al., 1997, Sim et al., 
1996). Additionally, prolonged elevation of the endogenous cannabinoid 2-AG leads to tolerance 
to the analgesic effects of acute enzyme inhibition, significant cross-tolerance to cannabinoid 
receptor agonists, physical dependence, a reduction in CB1 receptor number and activity, and 
disruptions in endocannabinoid-dependent synaptic plasticity (Chanda, 2010, Schlosburg, 2010). 
These findings are in contrast to the observations that with prolonged FAAH and partial MAGL 
inhibition with low dose JZL184, antinociceptive effects are maintained without producing 
tolerance, physical dependence, or changes in CB1 receptor expression or function (Kinsey, 
2013, Schlosburg, 2010, Sciolino, 2011). These data suggest that brain CB1 receptors undergo 
markedly different adaptations in response to sustained elevations of the two principal 
endocannabinoids 2-AG and anandamide. The findings that CB1 receptor number and function in 
the brain was unaltered by sustained MAGL and FAAH inactivation was confirmed in studies 
assessing different forms of synaptic plasticity, including DSI, DSE, and long-term depression 
(Kreitzer and Regehr, 2001, Wilson and Nicoll, 2001). Schlosburg et al 2010, reported 
attenuation of DSI by chronic high dose JZL184 treatment was consistent with desensitization of 
CB1 receptors in the affected neuronal circuits. In contrast, no apparent CB1 receptor 
desensitization was detected in mice chronically treated with the FAAH inhibitor PF-3845 (10 
mg/kg). In the present study we demonstrated that the magnitude of WIN55, 212-2-induced 
depression of IPSCs in the cingulate cortex was not significantly different between mice treated 
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with JZL184 (4 mg/kg) and JZL184 (4 mg/kg) plus PF-3845 (10 mg/kg). However, WIN55, 212-
2-induced depression of IPSCs was significantly attenuated in mice treated with JZL184 (40 
mg/kg) plus PF-3845 (10 mg/kg) compared with mice treated with JZL184 (4 mg/kg) plus 
PF3845 (10 mg/kg). Taken together, these results indicate that chronic high dose JZL184 (40 
mg/kg) treatment, but not low dose JZL184 (4mg/kg) treatment, induces CB1 receptor 
desensitization in the cingulate cortex. These data indicated that sustained partial elevation of 2-
AG and complete elevation of anandamide do not alter short-term synaptic plasticity. These 
results are corroborated by results of acute and repeated administration of JZL184 (4 mg/kg) and 
PF-3845 (10 mg/kg) on CB1 receptor expression and activity in brain. The results revealed that 
CB1 receptor binding and CP55, 940-stimulated [35S]-GTPγS binding were decreased by high 
dose of JZL184 (40 mg/kg). However, low dose JZL184 and high PF-3845 did not alter the CB1 
receptor number or function upon repeated administration. This result is congruent with a recent 
study showing that repeated administration of low dose JZL184 also did not alter CB1 receptor 
expression and function (Kinsey, 2013). Additionally it has been shown that prolonged 
pharmacological or genetic inactivation of MAGL produces cross-tolerance to exogenous 
cannabinoid agonists WIN5521-2 (Schlosburg, 2010). Hence we have assessed whether the 
combination of JZL184 (4 mg/kg) and PF-3845 (10 mg/kg) results in cross tolerance to 
cannabimimetic side effects, mice were assessed for catalepsy, tail withdrawal test, body 
temperature . We found that mice treated repeatedly with dose JZL184 (4 mg/kg) and PF-3845 
(10 mg/kg) elicited no cross-tolerance to THC in catalepsy, antinociception, and hypothermia 
tests. These data are supported by the literature demonstrating that prolonged treatment with low 
dose JZL184 does not lead to cross tolerance to the anti-allodynic, analgesic, and hypothermic 
effects of THC (Kinsey, 2013). As the manifestation of tolerance after prolonged MAGL 
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inhibition with high dose of JZL184 may represent a drawback, the aforementioned results 
suggest that the partial blockade of MAGL and complete blockade of FAAH can be used as a 
strategy to increase efficacy and circumvent tolerance.
 These findings demonstrate that co-administration of JZL184 and PF-3845 elevated brain 
2-AG and anandamide levels upon acute (3-4 fold) and repeated (5-6 fold) treatment. However, 
with acute or chronic dosing regimen, the elevation of 2-AG levels was less than the highest dose 
of JZL184 (40 mg/kg). This finding is congruent with a previous study showing that high doses 
of JZL184 (16, 40 mg/kg) elevate 2-AG 8-10 fold in the brain (Long, 2009a). In addition, 
prolonged inactivation of MAGL with this dose of JZL184 produced CB1 receptor 
desensitization and down regulation in mice (Schlosburg, 2010) 
Finally, we have assessed if this combination produces the cannabimimetic effects of 
THC. The results reveals that the combination does not produce catalepsy, hypothermia, anti-
nociception and hypolocomotion in the tetrad assay indicating that this combination does not 
produce untoward effects of delta-9 THC. 
 The results of the present studies indicate that JZL184 and PF-3845 given alone produce 
partial efficacy in CCI and carrageenan models of pain. However, simultaneous inhibition of 
both enzymes enhances the magnitude of the anti-allodynic effects. Moreover, the 
antinociceptive effects and CB1 receptor functional tolerance that occurs following repeated 
exposure to high dose JZL184 can be avoided by administering low dose JZL184 (4 mg/kg) in 
combination with high dose PF-3845 (10 mg/kg). These findings also reveal that the dosing 
regimen investigated in the present study can raise brain 2-AG and anandamide levels, without 
altering CB1 receptor expression and function, short-term synaptic plasticity, or causing cross-
tolerance to THC. In summary, our data support the hypothesis that simultaneous differential 
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dual blockade of the endocannabinoid degradative enzymes, MAGL and FAAH, represents a 
viable strategy to treat inflammatory and neuropathic pain states.  
 
Part B 
Anti-allodynic effects of SA-57, dual FAAH, and MAGL inhibitor with differential potencies, 
in the carrageenan model of inflammatory pain 
 As shown in Chapter 3A, combined injections of low dose JZL184 (4 mg/kg) and high 
dose PF-3845 (10 mg/kg), produced significantly enhanced anti-allodynic effects in the 
carrageenan and CCI assays, without observed cannabimimetic side effects. Moreover, the 
antinociceptive effects of this drug combination were retained following repeated administration. 
In this section, we describe the antinociceptive effects of the dual FAAH-MAGL inhibitor SA-
57, which is 100 fold more potent in inhibiting FAAH than MAGL (Niphakis, 2012, Ramesh et 
al., 2013). SA-57 elevated brain anandamide levels ~10-fold at all doses (0.125, 1.25 and 12.5 
mg/kg i.p.), but did not increase 2-AG levels at 0.125 or 1.25 mg/kg. , However, this compound 
increased brain 2-AG levels more than 10-fold at 12.5 mg/kg. In this section, we report on the 
pharmacological effects of this novel compound in the carrageenan assay and in the tetrad assay 
to assess cannabimimetic effects. We have also evaluated if the effects of SA-57 are mediated 
through cannabinoid receptors. Finally, we quantified endocannabinoid levels in whole brain. 
Method: 
Subjects  
 
 The subjects consisted of adult male C57BL/6J mice (Jackson Laboratory, Bar Harbor, 
ME). Adult male and female CB1 (-/-) and CB2 (-/-) mice, along with respective matched CB1 
(+/+) and CB2 (+/+) littermates were used to determine receptor mechanisms of action. All 
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genetically modified mice were bred in the Center Transgenic Colony at Virginia 
Commonwealth University. Mice were randomly assigned to treatment conditions, although a 
block design was used to evenly distribute transgenic and knockout mice, by sex, across 
treatments. Mice were kept on a 12-h light/dark cycle with food and water available ad libitum. 
All animal protocols were approved by the Virginia Commonwealth University Institutional 
Animal Care and Use Committee and were in concordance with the Guide for Care and Use of 
Laboratory Animals (Institute of Laboratory Animal Resources, 1996). After testing was 
completed, mice were humanely sacrificed by CO2 asphyxiation, followed by cervical 
dislocation.  
Drugs  
  SA-57 was synthesized in the laboratory of Dr. Cravatt as previously described (Niphakis 
et al, 2012). SA-57 was dissolved in ethanol, followed by addition of Alkamuls-620 (Sanofi-
Aventis, Bridgewater, NJ), and diluted with 0.9% saline to form a vehicle mixture of ethanol, 
Alkamuls-620, and saline in a ratio of 1: 1: 18. This compound was administered 
intraperitoneally 3 h after carrageenan. All injections were administered in volume of 10 μl/g 
body weight. For experiments quantifying brain endocannabinoid SA-57 were administered 2 h 
before decapitation. The doses were selected based on previous literature (Niphakis, 2012).  
Carrageenan pain model 
 Edema and allodynia were induced by giving an intraplantar injection of 0.3% 
carrageenan (Sigma, St Louis) in a 20-l volume using a 30-gauge needle into the hind left paw. 
Paw thickness was measured with electronic digital calipers (Traceable Calipers, Friendswood, 
TX), prior to and 1 h, 3 h and 5 h following carrageenan administration. Data showed only 5 h 
time point, which corresponds to peak edema (Wise, 2008). This procedure has been used 
 98 
previously by our laboratory (Cravatt and Lichtman, 2004, Lichtman, 2004, Wise, 2008). To test 
allodynia, the mice were placed inside ventilated polycarbonate chambers on an elevated 
aluminum mesh table and allowed to acclimate to the apparatus for 60 min before testing. 
Mechanical allodynia was assessed with von Frey filaments (North Coast Medical, Morgan Hill, 
CA), using the “up-down” method (Chaplan, 1994) 5 h after carrageenan administration. The 
plantar surface of each hind paw was stimulated five times with each filament (0.16–6.0 g), at a 
frequency of approximately 2 Hz, starting with the 0.6-g filament and increasing until the mouse 
responded by licking and/or lifting the paw off the surface of the test apparatus. Three or more 
responses out of five stimulations were coded as a positive response. Once a positive response 
was detected, sequentially lower weight filaments were used to assess the sensory threshold for 
each paw.  
Tetrad 
 To measure spontaneous activity, the mouse was placed in an Anymaze chamber for 300 
seconds and the percentage of time the animal spent immobile was recorded. Catalepsy was 
assessed in the bar test in which the mouse is placed on a bar oriented parallel to and 1 inch off 
the ground. The time (s), the mouse remains immobile on the bar in a 60 s time period is 
recorded. Antinociception was assessed in the tail withdrawal test in which the mouse is 
immobilized in a bag and its tail is placed into a 52°C warm water bath. The time it takes for the 
mouse to remove its tail from the water bath is recorded. Hypothermia – body temperature, rectal 
probe (2 cm) is used to measure body temperature (°C). 
Data analyses  
 Paw edema data are expressed as the difference in paw thickness between the 5 h and 
pre-injection measures. Paw withdrawal thresholds to the von Frey filaments in the carrageenan-
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injected and contralateral (i.e., control) paws at the 5 h time point were used to assess mechanical 
allodynia. All data are depicted as mean + standard error of the mean (SEM). Data were analyzed 
using t-tests, one-way analysis of variance (ANOVA), or two-way ANOVA. Dunnett’s test was 
used for post hoc analysis in the dose-response experiments in which the effects of each drug 
dose were compared to those of vehicle. Tukey-Kramer post hoc analysis was used for all tests 
comparing different treatment groups. All the results were considered significant at p < 0.05. 
Results 
Administration of different doses of SA-57 elevates endocannabinoids and decrease 
arachidonic acid in the brain 
 To assess endocannabinoids and arachidonic acid levels in the brain with acute SA-57 
treatment, male C57BL/6 mice were administered (1) vehicle (2) 0.125 mg/kg (3) 1.25mg/kg (4) 
2.5 mg/kg, (5) 5 mg/kg, and (6) 12.5 mg/kg, and sacrificed immediately after assessment of 
edema and allodynia at 5h. Brain levels of anandamide, 2-AG, and arachidonic acid (AA) were 
quantified 2 h following administration of injection is shown in Figure 18A-C. SA-57 (1.25, 2.5, 
5, 12.5 mg/kg) led to an 8 -10-fold increase in anandamide levels [F (4, 13) = 50.26, p < 0.001; 
Figure 18A]. SA-57 significantly elevated 2-AG levels [F (4, 13) = 79.43, p < 0.001; Figure 
18B], but with considerably decreased potency compared with anandamide elevations. 2.5 mg/kg 
SA-57 elevated 2-AG by 2-3 fold, 5 mg/kg and 12.5 mg/kg dose have elevated 5-5 to 7 folds of 
2-AG on the brain. The elevation in brain 2-AG was accompanied by significant reductions in 
the levels of arachidonic acid (AA) on at the high doses (5, 12.5 mg/kg) [F (4, 13) = 14.91, p < 
0.001; Figure 18C], but at the lower doses AA level remained unchanged [p < 0.78; (dose 1.25 
mg/kg); p < 0.43; (dose 2.5 mg/kg)] [Figure 18C]. 
 100 
 
Figure 18. Acute SA-57 elevates anandamide and2-AG, but decreases arachidonic acid (AA) 
levels in the whole brain. (A) Acute administration of SA-57 (1.25, 2.5, 5, 12.5 mg/kg) led to an 
8 -10-fold increase in anandamide. (B) SA-57 (2.5, 5, 12.5 mg/kg) produced a 3-10-fold 
elevation in 2-AG levels. (C) AA levels were reduced at higher doses (5, 12.5 mg/kg) of SA-57. 
***, p <0.001 versus vehicle (Dunnett's post hoc tests). Data presented as mean ± SEM (N = 5-
6). 
Anti-edematous and anti-allodynic effects of SA-57 in the carrageenan model 
 As shown in Figure 19A SA-57 given 3 h after carrageenan partially reversed paw edema 
in a dose-related fashion [F (4,24) = 19.60, p < 0.05; Figure 19A]. SA-57 also produced a dose-
dependent complete reversal of carrageenan-induced allodynia [F (5, 30) = 6.17, p < 0.05; Figure 
19B]. However, it did not affect paw withdrawal thresholds in the control paws. 
 101 
 
Figure 19. Acute administration of SA-57 reversed carrageenan-induced allodynia and produced 
anti-edematous effects. (A) of SA-57 (2.5, 5, and 12.5 mg/kg) reduced paw edema. (B) SA-57 (5 
and 12.5 mg/kg) reversed allodynia. *, p < 0.05, ***, p <0.001 versus vehicle; (Dunnett's post 
hoc tests). Data presented as mean ± SEM (N = 5-6). 
Cannabinoid receptors mediate the anti-allodynic and anti-edematous of SA-57 
 To determine whether CB1 and CB2 receptors mediate the anti-edematous and anti-
allodynic effects of SA-57, CB1 (-/-) and CB2 (-/-) mice were given an intraplantar injection of 
carrageenan, treated with SA-57 (5 mg/kg) at 3 h, and tested for allodynia and edema at 5h. 
Edema was measured immediately after allodynia. CB2 (-/-) mice [F (1, 13) =1.29, p<0.001; 
Figure 20 A], but not CB1 (-/-) mice [p=0.76 Figure 20 C] were resistant to the anti-edematous 
effects of SA-57, indicating that CB2 receptors are indispensable for mediating the anti-
edematous effects. 
  A different pattern of results was found for the von Frey data. CB1 (-/-) [F (1, 15) = 
23.11, p < 0.001; Figure 20 B] and CB2 (-/-) [F (1, 13) =8.13, p < 0.001; Figure 20 D] mice were 
resistant to the anti-allodynic effects of SA-57. In the absence of drugs, CB1 (-/-) mice and CB2 
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(-/-) mice showed similar nociceptive behavior as the wild type controls. 
 
Figure 20. Assessment of the anti-edematous and anti-allodynic effects of SA-57 (5 mg/kg) in 
CB1 (-/-) and CB2 (-/-) mice. (A) SA-57 (5 mg/kg) reduced edema in CB1 (+/+) and CB1 (-/-) 
mice. (B) SA-57 (5 mg/kg) reduced allodynia in CB1 (+/+) mice but not in CB1 (-/-) mice and 
(C) SA-57 (5 mg/kg) reduced edema in CB2 (+/+) mice but not in CB2 (-/-) mice (D) SA-57 (5 
mg/kg) reduced allodynia in CB2 (+/+) mice but not in CB2 (-/-) mice.***, p <0.001 versus 
vehicle; ##, p < 0.05; ###, p <0.001 versus CB1 (+/+) and CB2 (+/+). (Tukey-Kramer post hoc 
tests). Data presented as mean ± SEM (N = 4-5). 
SA-57-induced cannabimimetic effects, as assessed in the tetrad assay  
 Mice were treated with SA-57 (0.125, 1.25, 2.5, 5, 12.5 mg/kg) and were evaluated in the 
tetrad assay 2 h later. Only the high dose of SA-57 (12.5 mg/kg) produced significant 
cannabimimetic effects on the tetrad assay. The data show that SA-27 at 12.5 mg/kg produces 
catalepsy [F (5, 41) = 54.06, p < 0.001; Figure 21A], antinociception [F (5, 41) = 55.85, p < 
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0.001; Figure 21 B], hypothermia [F (5, 41) = 54.06, p < 0.001; Figure 21 C], and 
hypolocomotion [F (5, 41) = 13.61, p < 0.001; Figure 21 D].  
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Figure 21: Mice treated with high dose of SA-57 (12.5 mg/kg) displayed (A) catalepsy, (B) 
antinociception, (C) body temperature, and (D) hypolocomotion in the tetrad assay. *, p < 0.05; 
***, p <0.001 versus vehicle. Data presented as mean ± SEM (N = 6). 
Discussion: 
 The dual FAAH-MAGL inhibitor, which shows a differential potency in inhibiting these 
two enzymes, yielded a similar pattern of results as combination of low-dose JZL184 and high 
dose PF-3845. 1.25 and 12.5 mg/kg SA-57 elevated 2-AG brain levels by 3- and >10-fold, 
respectively. On the other hand, SA-57 elevated the FAAH substrates anandamide, PEA, and 
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OEA by ~10-fold across the entire tested dose-range (0.125 to 12.5 mg/kg). This pattern of 
results indicates that SA-57 is considerably more potent as a FAAH inhibitor than as a MAGL 
inhibitor (Niphakis, 2012). The major finding of the present study is that an intermediate dose 
SA-57 (5 mg/kg), which produced a 10-12 fold increase in anandamide and 5 fold increase in 2-
AG substantially reversed carrageenan-induced allodynia in mice compared with single 
inhibition of these endocannabinoid catabolic enzymes shown in figure 3 from chapter 2 and 
figure 10 from chapter 3A. These findings are in line with the literature, which shows that SA-57 
significantly blocked all spontaneous withdrawal signs in morphine-dependent mice compared 
with single inhibition of MAGL or FAAH (Ramesh, 2013). JZL195, an equipotent MAGL and 
FAAH inhibitor, which has been shown to produce enhanced antinociceptive effects, has also 
produced untoward side effects of THC such as catalepsy, hypothermia and hyperreflexia (Long, 
2009b). Hence, we assess if current elevations in anandamide and 2-AG by SA-57 produces 
CB1-dependent behavioral effects. The results of this study revealed that SA-57 did not produce 
observable cannabimimetic effects (except for the highest dose 12.5 mg/kg), as assessed in the 
tetrad assay. In addition, small but significant hypolocomotion was observed with 5 mg/kg SA-
57, the same dose which produces allodynia. Single blockade of MAGL or FAAH only partially 
attenuated carrageenan-induced allodynia (figure 3 from chapter 2 and figure 10 from chapter 
3A) (Ghosh, 2013). On the other hand, low dose of JZL-184 and high dose of PF-3845 
completely reversed carrageenan-induced allodynia (figure 10 B and D from chapter 3A). Hence, 
SA-57, a compound mimics the profile of high dose PF-3845 and low dose JZL184 in elevating 
anandamide and 2-AG respectively and produced complete anti-allodynic effects in the 
carrageenan assay suggests that FAAH and MAGL represent promising targets for treating 
inflammatory pain state. 
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General discussion for part A and part B 
 Previous studies have demonstrated direct cannabinoid receptor agonists such as THC or 
various exogenous cannabinoid agonists (HU210, WIN55212) produced antinociception (Elmes, 
2005, Nackley, 2003, Wise, 2008). However, their psychomimetic side effects and abuse 
potential have dampened enthusiasm for developing drugs that act directly at CB1 receptors 
(Schlosburg, 2010). The purpose of the studies in this chapter was to elucidate the impact of 
elevating both anandamide and 2-AG brain levels by inhibiting their catabolic enzymes, in 
reducing carrageenan-induced inflammatory pain in mice. As discussed in chapter 2, selective 
blockade of MAGL or FAAH partially attenuated allodynia and edema in this model. Hence, we 
tested whether inhibition of both the enzyme together would be more efficacious as compared to 
individual blockade of each enzyme.  
Advantages of combining partial MAGL and complete FAAH inhibition  
 Previous research reveals that high dose of JZL184 (40 mg/kg) partially substitutes for 
THC in the drug discrimination paradigm (Long, 2009b). Additionally, repeated administration 
of high dose JZL184 elicits behavioral and functional tolerance, cannabinoid receptor 
desensitization, down regulation, cannabinoid receptor cross-tolerance, as well as cannabinoid 
dependence in mice (Long, 2009b, Schlosburg, 2010). High dose of JZL184 also elicited a subset 
of cannabimimetic of THC with lower intensity as compared to THC. However, inhibiting 
FAAH with PF-3845 or MAGL inhibition with low dose of JZL184 (4 or 8 mg/kg) is devoid of 
side effects of direct cannabinoid agonist. In addition prolonged blockade of FAAH with high 
dose of PF-3845 or MAGL with low dose of JZL184 maintain the antinociceptive, gastro-
protective and anxiolytic effects (Ghosh, 2013, Kinsey, 2013, Schlosburg, 2010, Sciolino, 2011). 
However, either PF-3845 or JZL184 produces partial efficacy in attenuating edema and allodynia 
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in the carrageenan model in mice (Ghosh et al., 2013; chapter two, figure 3 A-D). Taken 
together, these results suggest that while both FAAH and MAGL inhibitors individually 
represent promising approaches to reducing nociception but they also have limitations. In order 
to circumvent these limitations, we investigated whether a combination of partial MAGL 
inhibition and complete FAAH inhibition would elicit enhanced efficacy in attenuating 
carrageenan-induced nociception in mice, without the side effects associated with complete 
MAGL inhibition. Low dose of JZL184 (4 mg/kg) was used to achieve partial MAGL inhibition. 
High dose of PF-3845 led to complete FAAH blockade. 4 mg/kg JZL184 elevated 2-AG levels 
2-4 fold and 10-fold anandamide level was elevated by 10 mg/kg. This combination also 
produced enhanced anti-allodynic effects in the carrageenan assay. In C57BL/6J mice, prolonged 
exposure to the combination did not induce any CB1 receptor functional tolerance, 
antinociceptive tolerance in carrageenan pain assay. These findings are important for the 
development of compounds, which possess partial MAGL and complete FAAH inhibition and 
are devoid of the side effects. In Chapter 3B, a novel inhibitor SA-57 that has differential 
potency at MAGL and FAAH (Niphakis, 2012) was assessed in the carrageenan model of 
inflammatory pain. A partial blockade of MAGL and complete blockade of FAAH produced 
increased antinociceptive effects compared with individual enzyme inhibition. Thus, SA-57 
offers a useful tool to explore the effects of complete FAAH blockade in conjunction with 
varying degrees of MAGL blockade. 
 
 
 107 
Chapter 4. KT-109, a selective diacylglycerol lipase beta 
inhibitor reverses LPS-induced allodynia in mice 
Introduction 
 The previous two chapters focused on the impact of inhibiting endocannabinoid catabolic 
enzymes FAAH and MAGL in the carrageenan model of inflammatory pain. In the present 
chapter, we report on the consequences of inhibiting diacylglycerol lipases (DAGLs), one of the 
major anabolic enzymes of 2-AG that is involved in mediating neuronal growth during 
development and as a retrograde messenger, (Brittis et al., 1996, Tanimura, 2010, Williams, 
2003) in LPS-induced inflammatory pain model.  
 DAGL was shown to exist in two isoforms α (120 kDa) and β (70 kDa). Human DAGL- 
and human DAGL- are large proteins of 1042 and 672 amino acids, respectively, containing 
four transmembrane domains with both C and N terminal located inside the membrane (Bisogno, 
2003). Sn-1 DAG lipase activity of membranes from cells over-expressing either of the DAGL 
isoforms was detected with several diacylglycerol. This activity was inhibited by classical serine 
hydrolase inhibitors and blocked by mutations in DAGL- serine 443 and aspartate 495, which 
were identified as residues belonging to the catalytic triad (Bisogno, 2003, Pedicord et al., 2011). 
The catalytic triad of DAGL-, consists of serine 472, aspartate 524 and histidine 650 (Bisogno, 
2003). 
 DAGL-β is predominantly expressed in the periphery and controls 2-AG levels in the 
peripheral tissues such as liver (Hsu, 2012), while the α-isoform is mainly found in the central 
nervous system (Gao, 2010, Tanimura, 2010). Pharmacological studies indicate that DAGL 
activity is required for axonal growth in rat brain (Brittis, 1996). Once 2-AG is synthesized, it 
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activates the CB1 receptors in the same axon (Williams, 2003). DAGL is located postsynaptically 
to produce 2-AG from diacylglycerol (Williams et al., 2003; Bisogno et al., 2003), which is 
produced from rapid hydrolysis of inositol phospholipids by phospholipase C resulting in 
diacylglycerol (DAG) (Prescott and Majerus, 1983). The development of 1, 2, 3-triazole urea (1, 
2, 3-TU) as a versatile chemotype for serine hydrolase inhibitor has been useful for the synthesis 
of selective DAGL inhibitors (Adibekian et al., 2010). In that study, the screening of DAGL 
enzymes against a small library of 1, 2, 3-TUs using an activity-based protein profiling (ABPP) 
assay (Cravatt et al., 2008) culminated in the synthesis of two compounds KT109 and KT172 
that potently and selectively inactivated DAGL- in vitro and in vivo. Nevertheless, both KT109 
(IC50 = 82 nM) and KT172 (IC50 = 70 nM) also inhibit ABHD6 (IC50 values of 16 and 5 nM, 
respectively). Hence, a negative-control probe, KT195 has been generated. KT195 is a potent 
(IC50 = 10 nM) selective inhibitor of ABHD6 and structurally related to KT109 and KT172, but 
inactive against DAGL-. The pharmacological inhibition of DAGL- with KT-109 and KT-172 
or genetic inactivation of DAGL- produced a remarkable array of metabolic changes in 
macrophages that included not only reductions in 2-AG levels, but also decreases in arachidonic 
acid and prostaglandins levels (Hsu, 2012). Interestingly, inactivation of DAGL- also 
attenuated lipopolysaccharide-stimulated TNF- release from macrophages, implicating a 
DAGL- regulated endocannabinoid-eicosanoid network as an important modulator of 
proinflammatory responses in macrophages (Hsu, 2012). Based on these in vitro results, this 
chapter investigates the consequences of inhibiting this enzyme in vivo. Specifically, we test 
whether inhibition of DAGL- with KT109 or KT172 will reduce LPS-induced allodynia in 
mice. We have taken a complementary pharmacological and genetic approach to assess the role 
of these inhibitors in DAGL-WT as well as DAGL- deficient mice. In addition, KT195 was 
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tested in this model to control for ABHD6 inhibition. Additionally, we assessed if these 
compounds mediate their effects through cannabinoid receptors. Similarly, we examined if these 
inhibitors possess cannabimimetic effects by interacting with cannabinoid receptors directly. In 
addition, we have evaluated the effects of repeated administration of KT195.  
 A major drawback to NSAID drug use is the preponderance of gastrointestinal (GI) side 
effects. NSAIDs are believed to damage the gastrointestinal tract through the reduction of 
prostaglandin biosynthesis in stomach via cyclooxygenase inhibition (Musumba et al., 2009). 
Prostaglandins play a protective role in the stomach by stimulating bicarbonate production 
(secrets from the mucus layer and neutralizes the digestive acids) and mucus production 
(Isenberg et al., 1986, Miller, 1983). Additionally, prostaglandin dilates the blood vessels in the 
stomach to ensure good blood flow (Anderson et al., 1976, Miller, 1983). Prostaglandin 
reduction leads to increase in stomach acid production and also decreases mucosal secretion 
(Musumba, 2009) as a result makes the stomach lining susceptible to the action of acid and 
increase the risk of ulcers. As mentioned before KT-109 and KT-172 have been found to 
decrease arachidonic acid and prostaglandin level in the peritoneal macrophages (Hsu, 2012). It 
has been reported that phospholipase A2 (PLA2) enzymes, and cytosolic PLA (cPLA2 or 
Pla2g4a)  in particular, is considered to be the principal source of arachidonic acid for 
cyclooxygenase-mediated prostaglandin production in the gut and spleen (Buczynski et al., 2009, 
Nomura, 2011). On the other hand, metabolic analysis of Pla2g4a+/+ mice or Pla2g4a-/- mice 
showed complete loss of prostaglandin D2 and only a modest reduction in PGE2 levels in the 
peritoneal macrophages (Hsu, 2012). However, treatment with KT109 decreased prostaglandin -
E2 level in Pla2g4a -/- macrophages as compared to KT109-treated wild-type mice or untreated 
Pla2g4a-/- mice (Hsu, 2012). These data together indicate that DAGL- and PLA2G4 
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coordinately regulate the production of this prostaglandin in the peritoneal macrophages. 
However, it is unclear if these compounds will produce ulcerogenic effects in the stomach. 
Hence, based on these results we have evaluated the role of DAGL- inhibitors on gastric 
hemorrhage. Therefore, in our final study we have examined the role of DAGL- inhibition on 
gastric hemorrhage in mice.  
Materials and methods 
Subjects  
 The subjects consisted of adult male C57BL/6J mice (Jackson Laboratory, Bar Harbor, 
ME). Subjects weighed between 20-30 g and were housed 4-5 per cage in a temperature-
controlled (20-22
o
C) environment. DAGL +/+), DAGL +/-), and DAGL -/-) mice were 
on a mixed genetic background of C57Bl/6 and 129/SvEv and were obtained from Taconic. Male 
and female CB1 (-/-) and CB2 (-/-) mice and their respective littermate controls, CB1 (+/+) and 
CB2 (+/+) mice from the Center Transgenic Colony at Virginia Commonwealth University 
served as subjects for the mechanism of action studies. CB1 (-/-) and CB2 (-/-) mice were 
backcrossed onto a C57BL/6J background for 13 and 6 generations, respectively. Mice were 
randomly assigned to treatment conditions, although a block design was used to evenly distribute 
transgenic and knockout mice, by sex, across treatments. Mice were kept on a 12-h light/dark 
cycle with food and water available ad libitum. All animal protocols were approved by the 
Virginia Commonwealth University Institutional Animal Care and Use Committee and were in 
concordance with the Guide for Care and Use of Laboratory Animals (Institute of Laboratory 
Animal Resources, 1996). After testing was completed, mice were humanely sacrificed by CO2 
asphyxiation, followed by cervical dislocation.  
Drugs  
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  THC was obtained from the National Institute on Drug Abuse (Bethesda, MD, USA). 
Diacylglycerol lipase beta inhibitors, KT109, KT172 and the negative control KT-195 were 
obtained from Scripps institute CA. All the drugs were dissolved in a vehicle that consisted of a 
mixture of ethanol, alkamuls-620 (Rhone-Poulenc, Princeton, NJ), and saline in a ratio of 1:1:18, 
except diclofenac, which was dissolved in saline. Each drug was given via the intraperitoneal 
route of administration in a volume of 10 μl/g body weight. 
Lipopolysaccharide (LPS) pain model 
 Allodynia was induced by injecting 20 μl (2.5 μg) of lipopolysaccharide (LPS) from 
Escherichia coli 026:B6 Sigma (St. Louis, MO) (Naidu, 2010) into the plantar surface of one 
hind paw of each mouse (Booker, 2011, Kanaan et al., 1996). Animals were tested for 
mechanical allodynia 24 h post LPS administration using calibrated von Frey filaments, ranging 
from 0.16 g - 6.0 g (Stoelting, Wood Dale, IL), as described previously in chapter 2 and 3 
(Kinsey, 2010). At 23 h after LPS administration, mice were placed into Plexiglas cylinders on 
an elevated wire mesh screen, allowing access to each hind paw by the filaments. Mice were 
allowed to acclimate to the test apparatus for 60 min prior to testing. Paw withdrawal threshold 
was determined by using the “up-down” method (Chaplan, 1994). The plantar surface of each 
paw was stimulated 5 times each and a positive response was scored if each mouse clutched, 
lifted, or fluttered the paw upon 3 of 5 stimulations. 
Cannabimimetic behavior assessments 
 Mice were treated with vehicle or 40 mg/kg KT109 or 30 mg/kg THC and tested on the 
tetrad assay used for assessing cannabimimetic effects of THC and other CB1 receptor agonists. 
Prior to testing all mice were acclimated to the test room for at least 1 h (Martin, 2003). Baseline 
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catalepsy, nociception, rectal temperature, and locomotor activity were assessed. Mice were 
injected with a 30 mg/kg THC 30 min prior or 40 mg/kg KT-109 120 mins prior and tested for 
catalepsy, nociception, rectal temperature, and locomotor activity. Catalepsy was assessed using 
the bar test, in which the forelimbs of each mouse were placed on a horizontal bar during a 60s 
test in which time immobile was measured. Hypothermia was determined by change in rectal 
body temperature from baseline. The tail immersion test was used to measure antinociception. 
The distal 2 cm of the tail was immersed in 52.0 °C water and the tail withdrawal latency 
determined. A maximum cutoff of 10 s was used to minimize possible tissue damage. Maximum 
percent effect was using the formula [(test value - base line value)/ (10 - baseline value)]*100. 
Locomotor activity was measured in a 5 min test in the activity box. 
 In separate groups of mice, the cannabimimetic behavioral effects of treatment with 
vehicle and 40 mg/kg KT-109 were evaluated in the tetrad test. Baseline catalepsy, rectal 
temperature, nociception, and locomotor activity were first determined. Two hours after 
injections. Mice were then evaluated for catalepsy, nociception, rectal temperature, and 
locomotor activity as described above. We sued Anymaze boxes to assess locomotor activity.  
Gastric inflammatory lesion model 
Gastric hemorrhages were induced and quantified as described previously (Kinsey, 2011a, Liu et 
al., 1998). Male C57BL/6J mice were weighed, then placed on a wire mesh barrier (Thoren 
Caging Systems, Inc, Hazleton, PN), and food deprived with free access to water. After 24 h, 
mice were administered KT-109 (40 mg/kg, i.p.), the nonsteroidal anti-inflammatory drug, 
diclofenac sodium (100 mg/kg, i.p.) or vehicle (1:1:18 parts of EtOH, Emulphor, and normal 
saline), and returned to the home cage for 6 h. The mice were humanely euthanized via CO2 
asphyxiation, and stomachs were harvested, cut along the greater curvature, rinsed with distilled 
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water, and photographed on a lighted tracing table (Artograph light pad 1920) and photographed 
(Canon T3 Rebel digital camera with a 10x close up lens). Basically, each photo has a reference 
in it, along with the stomach. That  ruler is used as a reference to compare with the stomach in 
each photo. Then photo-shop software is used to trace the length of each hemorrhage and  a 1-
pixel-wide line is drawn on each photo, using a color that doesn't show up in the photo (like 
bright green). Then the  pixels of bright green are measured in the photo using photo-shop 
software, thereby adding up all of the hemorrhage lengths together (each line is 1-pixel-wide, so 
the total number of green pixels is the same as the total length of all the lines. Then the process is 
repeated on the ruler/reference, tracing a 1 mm segment in another color (like bright pink). Then 
the same count of bright pink pixels is obtained to find the number of pixels in 1mm. Finally, 
the, total length of hemorrhages are calculated by [pixels of hemorrhages] / [pixels/mm] = total 
mm of hemorrhages (Kinsey, 2013, Nomura, 2011). Image files were renamed, and an 
experimenter blinded to treatment conditions quantified the gastric hemorrhages, relative to a 
reference in each photo, using Adobe Photoshop (version CS5), as described previously (Kinsey, 
2013, Nomura, 2011). 
Results:  
Anti-allodynic effects of KT-109 is maintained over an extended period  
 Intraplantar administration of 2.5% lipopolysaccharide induced allodynia. In the time 
course study, KT-109 produced anti-allodynic effects in 2 h, which was sustained for 28 h and 
finally gone back in to the baseline level at 48 h [F (1,80)= 73.37, p < 0.001; ( Figure 22)]. There 
is no significant interaction between time and the treatment [p = 0.090].  
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Figure 22: Anti-allodynic effects of KT-109 are maintained over an extended period. (A) In time 
course study, KT-109 produced anti-allodynic effects in 2 h, which was sustained for 28 h and 
finally gone back in to the baseline level at 48 h. *, p < 0.05; **, p < 0.01 versus vehicle 
(Bonferroni post hoc tests). KT-109 did not produce any anti-allodynic effects in the control 
paw. Data presented as mean ± SEM (N = 9). 
DAGL- inhibition with KT-109 but not KT-172 reverse LPS-induced allodynia, negative 
control probe KT-195 does produce any effect 
 To test whether DAGL- inhibitor KT109 and KT172 reverses LPS-induced allodynia , 
mice were given an intraplantar injection of LPS (2.5 mg) into a hind paw, and 22 h later were 
given an i.p. injection vehicle (V) , KT109 (1.6, 2.5, 5, 20, 40 mg/kg), or KT172 (5, 20, 40 
mg/kg) or KT195 (20 , 40 mg/kg). Subjects were assessed for mechanical sensitivity to von Frey 
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filaments at 24 h. Figure 23 A shows KT-109 significantly reversed LPS-induced allodynia [F (6, 
56) = 22.98, p < 0.001; Figure 23A]. However, KT-172 [p = 0.37; Figure 23B] did not reverse 
allodynia. KT195 [p = 0.47; Figure 23C] did not produce anti-allodynic effects in this assay. 
Neither KT-109 or KT172 nor KT-195 affected paw withdrawal thresholds in control paws. 
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Figure 23. Different doses of KT-109 but not KT-172 reverse LPS-induced allodynia. (A) shows 
KT109 (2.5, 5, 20, 40 mg/kg) significantly reversed LPS-induced allodynia. (B) KT-172 (5, 20, 
40 mg/kg) could not reverse allodynia. Neither KT-109 nor KT-172 affects paw withdrawal 
thresholds in control paws. *, p < 0.05; ***, p < 0.001 versus vehicle; #, p < 0.05; ###, p < 0.001 
versus control paw (Dunnett's post hoc tests). Data presented as mean ± SEM (N = 6). 
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DAGL knockout mice show anti-allodynic phenotype 
 Complementary pharmacological and genetic approaches were used to evaluate the 
impact of DAGL- blockade in alleviating inflammatory pain. Accordingly, we tested KT-109 in 
DAGL- (-/-) and (+/+) mice. DAGL- (-/-) mice treated with vehicle showed an anti-allodynic. 
KT-109 reversed allodynia in DAGL- (+/+) animals but did not further alter nociceptive 
responses in DAGL- (-/-) mice. A two-way ANOVA reveal a significant interaction between 
treatment and genotype [F (1, 50) = 5.93, p < 0.01; Figure 24].  
 
Figure 24: DAGL knockout mice show anti-allodynic phenotype. (A) KT-109 completely 
reversed allodynia in DAGL- (+/+) animals. (A) DAGL- (-/-) mice treated with vehicle show 
anti-allodynic phenotype but KT109 did not elicit any further decrease in allodynia in DAGL- 
(-/-) mice. *, p < 0.05 versus vehicle /WT (Bonferroni post hoc tests). Data presented as mean ± 
SEM (N = 13-14).  
Repeated administration of KT-109 does not lead to tolerance 
 In this experiment, we examined the effects of repeated administration of high dose KT-
109 (40 mg/kg) in the LPS model. As shown in Figure 25, repeated administration 40 mg/kg KT-
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109 significantly attenuated LPS-induced allodynia [F (2, 13) = 5.68, p < 0.001] indicating that 
prolonged inhibition of DAGL- does not lead to tolerance. Repeated drug treatment did not 
affect the paw withdrawal threshold of the contralateral paw. As expected, no allodynia was 
observed in the contralateral paw. 
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Figure 25: Repeated administration of KT-109 does not lead to tolerance. (A) Repeated 
administration 40 mg/kg KT-109 significantly attenuated LPS-induced allodynia. There was no 
allodynia seen in the contralateral paw. **, p < 0.01 versus vehicle (Tukey-Kramer post hoc 
tests). Data presented as mean ± SEM (N = 5-6). 
Anti-allodynic effects of KT-109 are not mediated by cannabinoid receptors  
 As KT-109 inhibits the biosynthetic enzyme of 2-AG in macrophages (Hsu et al., 2012), 
it is unlikely that its anti-allodynic effects involve cannabinoid receptors. Nonetheless, to assess 
direct or indirect interaction of KT-109 with cannabinoid receptors effects, we tested it in CB1 
and CB2 knockout mice. KT-109 produced anti-allodynic effects in CB1 (+/+) and CB2 (+/+) 
mice. Its anti-allodynic effects persisted in CB1 (-/-) mice [p = 0.90; Figure 26A] and CB2 (-/-) 
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mice [p = 0.20; Figure 26B]. Thus, the anti-allodynic effects of KT-109 do not require 
cannabinoid receptors. In the absence of drugs, both CB1 (-/-) and CB2 (-/-) mice displayed 
similar nociceptive responses to intraplantar LPS as the wild type controls.  
 
Figure 26: Anti-allodynic effects of KT-109 are not mediated by cannabinoid receptors. KT-109 
produced anti-allodynic effects in (A) CB1 (+/+) and (B) CB2 (+/+) mice. The anti-allodynic 
effect was not reversed in (A) CB1 (-/-) and (B) CB2 (-/-) mice. In the absence of drugs, both CB1 
(-/-) and CB2 (-/-) showed similar nociceptive behavior as the wild type controls. ***, p < 0.001 
versus vehicle (Bonferroni post hoc tests). Data presented as mean ± SEM (N = 6). 
KT-109 did not produce cannabimimetic effects in tetrad 
 Additionally, we examined if KT-109 produces cannabimimetic effects in the tetrad 
assay. C57/BL6J mice were administered a high dose KT-109 (40mg/kg) and assessed 2 h later 
in tetrad test, which includes: spontaneous locomotor suppression, antinociception to noxious 
thermal stimuli, catalepsy, and hypothermia (Compton et al., 1993, Martin et al., 1991). KT-109 
(40 mg/kg) did not produce catalepsy [Figure 27A], increased tail withdrawal latencies (p = 0.79) 
[Figure 27B], hypothermia (p = 0.44) [Figure 27C] or hypolocomotion (i.e., defined as time 
spent immobile; p = 0.86) [Figure 27D] indicating that KT-109 is devoid of common 
pharmacological effects produced by THC and other CB1 receptor agonists. To verify that the 
tetrad assay used here can be used to detect CB1 receptor agonists, we tested THC as a positive 
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control and THC has shown to produce catalepsy, hypothermia, antinociception, and 
hypolocomotion. 
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Figure 27: KT-109 did not produce cannabimimetic effects in tetrad KT-109 (40 mg/kg). KT-
109 did not produce (A) catalepsy, (B) tail withdrawal latency, (C) body temperature, or (D) 
hypolocomotion. To ensure that our model can detect compounds that produce effects on tetrad, 
we tested the d-9 THC as our positive control. ***, p <0.001 versus vehicle (Tukey-Kramer post 
hoc tests). Data presented as mean ± SEM (N = 5-6). 
DAGL- inhibition with high dose KT-109 does not elicit gastric ulcers in mice 
 NSAID is believed to damage the gastrointestinal tract through the reduction of 
prostaglandin biosynthesis in stomach via cyclooxygenase inhibition, which leads to increased 
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stomach acid production and decreased mucosal secretion (Musumba, 2009). Levels of 
arachidonic acid and prostaglandin decrease in parallel with 2-AG. Hence, in this study we 
evaluated whether KT-109 produces gastric hemorrhages. As shown in Figure 28,  high dose of 
KT-109 (40 mg/kg) [p= 0.80] did not cause any significant hemorrhagic effects in the mice. In 
contrast, the classical NSAID, diclofenac (100 mg/kg) produced a significant increase in gastric 
ulcers [F (2, 22) = 6.20, p < 0.001]. 
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Figure 28: DAGL- inhibition with high dose KT-109 does not elicit gastric ulcers in mice. The 
photographs show gastric hemorrhage in mice treated with high dose of diclofenac but stomach 
treated with KT109 does not show any hemorrhage. Unlike a classical NSAID, diclofenac (100 
mg/kg), high dose of KT-109 (40 mg/kg) did not cause any significant hemorrhagic effects in the 
mice. **, p < 0.01 versus vehicle (Tukey-Kramer post hoc tests). Data presented as mean ± SEM 
(N = 8-9). Dr. Steven Kinsey has performed these experiments. 
Discussion: 
 KT-109 has high selectivity for DAGL- over other serine hydrolases, including 
DAGL, but also inhibits ABHD6. To control for ABHD6 inhibition, we have employed 
KT195, which is a selective inhibitor of this enzyme (Hsu, 2012). KT-109 has decreased 2-AG 
levels in peritoneal macrophages upon acute administration (Hsu, 2012). This compound reduces 
levels of 2-AG and the downstream lipids AA and prostaglandins in peritoneal macrophages as 
well as in Neuro 2A cell lines (Hsu, 2012). Concomitant with these changes in lipid metabolism, 
DAGL- inhibitors have significantly reduced the LPS-stimulated production of the pro-
inflammatory cytokine TNF- (Hsu, 2012) in macrophages. The present study increases the 
understanding that DAGL- inhibition plays role in nociception by demonstrating that KT-109 
reduces LPS-induced mechanical allodynia in mice. A complementary genetic approach using 
DAGL- (-/-) mice reveals an anti-allodynic phenotype indicating the DAGL- plays an 
essential role in attenuating LPS-induced inflammatory pain. In addition, KT-109 did not elicit 
further anti-allodynic effects in the KO animals, which indicates that KT-109 is selective for the 
enzyme DAGL-. The anti-allodynic effects of KT019 were independent of both CB1 and CB2 
receptors. In addition, KT-109 did not produce cannabimimetic effects in the tetrad assay 
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indicating that the compound is devoid of common behavioral side effects produced by THC and 
other CB1 receptor agonists. In addition, the anti-allodynic effects of KT-109 did not undergo 
tolerance following repeated administration. Finally, unlike the classical NSAID, diclofenac, 
administration of high dose of KT-109 did not elicit gastric ulcers. As this is an acute assay a 
very high dose of diclofenac was used to ensure that gastric hemorrhages are produced. 
Diclofenac is capable of producing antinociceptive effects at a lower dose hence, it is important 
to do an experiment to observe hemorrhagic effects of diclofenac at a the lower doses.   
 The results reported in this chapter represent the first study to demonstrate the in vivo 
effects of these selective DAGL- inhibitors, as described previously we have also tested the role 
of the negative control probe in the LPS-induced inflammatory pain model. Here, we have 
shown that high dose KT-109 (40 mg/kg) completely reversed LPS-induced allodynia, low and 
intermediate doses (1.6, 2.5, 5, 20 mg/kg) produce partial attenuation. On the other hand, KT-
172 (5, 20, 40 mg/kg) has failed to attenuate allodynia in mice. These data were surprising 
because KT172 showed near-equivalent activity against DAGL-β compared to KT109. In 
addition, equivalent potencies have been shown by KT109 and KT172 for DAGL-β (Hue et al 
2012). Additionally, the structural similarity between the compounds suggests that they might 
produce similar effects in vivo, though it has not been confirmed whether these two compounds 
bind in the same pocket of the enzyme. Although KT109 and KT172 have shown structural 
similarity with each other and similar potency for DAGL- but the downstream effectors for 
both the inhibitors are yet to be elucidated. Activation of different downstream signaling 
pathway could be responsible for KT172 inability to produce anti-allodynic effects in the LPS-
induced inflammatory pain. In addition to pharmacological inhibition, we confirmed a role for 
DAGL-β as a target for inflammatory pain by demonstrating that DAGL-β (-/-) mice displays an 
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anti-allodynic phenotype in the LPS model of inflammatory pain. Another important finding is 
that repeated administration of KT-109 did not lead to tolerance of its anti-allodynic effects. This 
effect is consistent with knockout the data. The present study also shows that cannabinoid 
receptors are dispensable in mediating anti-allodynic effects of KT-109. Although the 
mechanism of action for KT-109 is not completely understood, we hypothesize that involves a 
reduction in the LPS elicited production of prostaglandin. We predict that inhibition of 2-AG 
synthesis will results in reduction of arachidonic acid, which is a precursor for prostaglandin. As 
a result, the prostaglandin levels will go down. However, suppression of TNF- production that 
was observed upon selective pharmacologic or genetic disruption of DAGL-β by Hsu et al 2012 
is less understood from a mechanistic perspective. Regardless of the precise mechanism by 
which DAGL-β inhibitors reduce TNF-α release, this finding has potential clinical relevance, 
given the demonstrated clinical value of TNF- blockers for treating inflammatory disorders like 
rheumatoid arthritis (Parameswaran and Patial, 2010).  
 The tetrad data indicate that KT-109 does not produce cannabimimetic activity, further 
confirming the finding that there is no direct interaction of KT-109 with the cannabinoid 
receptors. In addition, as 2-AG is reduced, there is likely to be decreased endocannabinoid tone. 
We require more studies to confirm this. Finally, we have shown that high dose KT-109 does not 
elicit gastric ulcers in mice. NSAID is believed to damage the gastrointestinal tract through the 
reduction of prostaglandin biosynthesis in stomach via cyclooxygenase inhibition, which leads to 
increased stomach acid production and decreased mucosal secretion (Musumba, 2009). The 
impact of DAGL-β inhibition reflects a direct effect on DAG which is not converted to 2-AG in 
absence of DAGL- activity. This reduction in 2-AG in turn decreases the production of 
arachidonic acid and prostaglandins. As reduction of prostaglandin production leads to increases 
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in stomach acid production and decreased mucosal secretion (Musumba, 2009), we have 
evaluated in this study the role of KT-109 on gastric hemorrhage. Our result reveals that unlike 
NSAIDs, KT-109 does not produce any gastric hemorrhage in mice upon acute administration 
indicating that despite reduction in prostaglandin levels KT-109 is devoid of ulcerogenic effects 
of classical NSAID. Although it is very promising that high dose of KT-109 does not produce 
gastric hemorrhage upon acute administration, the effect of prolonged blockade of DAGL- on 
gastric hemorrhage is yet to be evaluated. The biochemical and the behavioral data together 
support the idea that DAGL-β can be a promising target for the development of analgesic 
therapeutics. It is relevant that this isoform does not play a major role in the production of 2-AG 
in neurons. Thus, DAGL- inhibitors would not be expected to disrupt neuronal function or 
interfere with endocannabinoid-mediated neuronal processes.  
 
Chapter 5. General Discussion 
 Direct cannabinoid receptor agonists have long been known to reduce pain and 
inflammation in acute and chronic preclinical animal models (Kinsey, 2009, Lichtman, 2004, 
Long, 2009a, Russo, 2007); however, the psychomimetic side effects produced by these drugs 
dampen enthusiasm for clinical development (Lichtman, 2004). An alternative approach that 
promises to retain the beneficial effects and to minimize the untoward cannabimimetic side 
effects associated with CB1 receptor agonists is to inhibit the primary enzymes responsible for 
the biosynthesis and hydrolysis of the endogenous cannabinoids (Blankman, 2007, Cravatt, 
2001, Cravatt, 1996, Dinh, 2002). Pharmacological inhibition of MAGL and FAAH elevates the 
respective endocannabinoids, anandamide, and 2-AG in brain and spinal cord tissue (Cravatt, 
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1996, Kinsey, 2009, Long, 2009a). Blockade of FAAH and MAGL produces antinociceptive and 
anti-inflammatory effects in vivo in carrageenan, tail withdrawal, CFA, CCI, LPS and formalin 
pain assay (Ahn, 2009, Guindon, 2011, Guindon and Hohmann, 2009, Kinsey, 2010, Kinsey, 
2009, Lichtman, 2004, Long, 2009a, Naidu, 2010, Schlosburg, 2009, Sciolino, 2011, Spradley, 
2010) (Sasso, 2012).  
Irreversible (PF-3845, URB597) and reversible (OL-135) inhibitors of FAAH have been 
demonstrated to elevate anandamide levels in the brain (Ahn, 2009, Boger, 2005, Fegley, 2005) 
and attenuate neuropathic pain (Clapper, 2010, Jhaveri, 2006, Kinsey, 2009, Lichtman, 2004, 
Russo, 2007), inflammatory pain (Booker, 2011), and collagen-induced arthritis (Kinsey et al., 
2011). Similarly, MAGL inhibitors attenuate nociception to radiant heat and acetic acid-induced 
abdominal stretching (Long, 2009a), as well as reverse allodynic and hyperalgesic states in 
neuropathic (Kinsey, 2009) and inflammatory (Ghosh, 2013, Guindon, 2011, Guindon and 
Hohmann, 2008) pain models. However, these inhibitors are not fully efficacious in producing 
antinociceptive effects in neuropathic and inflammatory pain models.  
 It is also important for drugs used to treat chronic pain conditions to maintain their 
antinociceptive effects following chronic administration. The consequences of prolonged and 
complete inhibition of MAGL contrast with the consequences of prolonged and complete 
blockade of FAAH. Repeated administration of high doses of FAAH inhibitors produce 
sustained antinociception and without loss of CB1 receptor function (Falenski, 2010, Schlosburg, 
2010) and FAAH deficient mice display a CB1 receptor-mediated hypoalgesic phenotype in 
thermal nociceptive tests, in both phases of the formalin test, thermal anti-hyperalgesic and anti-
inflammatory effects in the carrageenan model (except in chronic constriction injury model) 
(Lichtman, 2004). On the other hand, complete blockade of MAGL leads to tolerance, physical 
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dependence, impaired endocannabinoid-dependent synaptic plasticity, and CB1 receptor down-
regulation and desensitization in select brain regions (Chanda, 2010, Schlosburg, 2010). 
However, partial MAGL blockade with low dose JZL184 maintains its antinociceptive actions in 
the CCI of the sciatic nerve neuropathic pain model (Kinsey, 2013) as well as in formalin-
induced and carrageenan-induced inflammatory pain model (Ghosh, 2013, Sciolino, 2011). [3H] 
SR141716A binding reveals that mice show normal CB1 receptor expression and function 
following repeated administration of low dose JZL184 ( ≤ 8 mg/kg) (Kinsey, 2013). Although, 
antinociceptive effects of low dose JZL184 are maintained following repeated administration, it 
produced a partial anti-edematous and anti-allodynic effects in the carrageenan model (Ghosh, 
2013). Similarly, the FAAH inhibitor, PF-3845 only partially reduced mechanical allodynia in 
CCI and carrageenan models (Ghosh, 2013). Thus, it would be advantageous to develop an 
approach to augment the efficacy of FAAH and MAGL inhibitors in reversing carrageenan-
induced allodynia, but without the occurrence of CB1 receptor functional tolerance, dependence, 
or cannabimimetic side effects. 
 DAGL- is one of the main biosynthetic enzymes for 2-AG. Inhibition of DAGL- is 
expected to reduce 2- AG levels with therapeutic application similar to those of cannabinoid 
antagonists (Di-Marzo et al.,2008) which have been shown to aid in weight loss (Chaput and 
Tremblay, 2006, Cota, 2006, Di Marzo, 2001, Pagotto, 2006), inflammation in rats (Lu, 2006, 
McVey, 2003), and Parkinson's symptoms such as dyskinesia (slight tremor of the hands to 
uncontrollable movement of the upper body but can also be seen in the lower extremities) 
(Brotchie, 2003, Di Marzo, 2000). Yet much less is known about the physiological effects of 
disrupting endocannabinoid production in vivo due, at least in part, to a lack of selective 
inhibitors for endocannabinoid biosynthetic enzymes. Two DAGL- inhibitors, KT109 and 
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KT172, have been developed recently (Hsu, 2012). These compounds have shown to reduce 
arachidonic acid and prostaglandin levels parallel with 2-AG in peritoneal macrophages. In 
addition, these compounds have shown reduce TNF- level in the macrophages. We have found 
that these compounds produce anti-allodynic effects in LPS model of inflammatory pain. The in 
vitro data showing reductions in 2-AG, AA, PGE2 and TNF- from macrophages (Hsu, 2012) 
and in vivo data showing the antinociceptive effects in mice, make the upstream enzyme DAGL-
 a promising target to for the development of analgesic therapeutics.  
Inhibition of FAAH or MAGL reduces carrageenan-induced inflammatory pain 
 The first goal of this dissertation was to test whether inhibition of FAAH or MAGL 
produces an anti-allodynic effect in an inflammatory pain model, and if so, through which 
receptor mechanism of action. To assess this question, we have employed an inflammatory 
model of carrageenan-induced allodynia that produces increase responsiveness to non-noxious 
stimuli and edema, an accumulation of fluid in the paw. The positive control diclofenac, a 
classical NSAID, attenuated edema as well as paw withdrawal thresholds, demonstrating that this 
model can be used to detect drugs that produce anti-edematous and anti-allodynic properties. 
After establishing an inflammatory pain model, we tested selective the MAGL inhibitor JZL-184 
and FAAH inhibitor PF-3845. We hypothesized that elevating endogenous cannabinoids 
following inhibition of their appropriate catabolic enzymes would inhibit carrageenan-induced 
edema and allodynia. Inhibition of these respective enzymes partially attenuated edema and 
allodynia. These findings are in line with previous literature showing that irreversible (PF-3845, 
URB597) as well as reversible inhibitors of FAAH elevate anandamide levels 8 to 10 fold in the 
brain (Ahn, 2009, Fegley, 2005). Importantly, PF-3845 is highly selective for FAAH, unlike 
URB597 that also binds to other serine hydrolases in peripheral tissues, including several 
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carboxylesterases (Alexander and Cravatt, 2005, Lichtman, 2004, Zhang et al., 2007). Less off 
target effects make PF-3845 a better therapeutic compound than URB597. Acute treatment with 
PF-3845 results in FAAH inhibition up to 24 h and maximal anandamide elevation up to 12 h in 
mice. In pharmacological assays, PF-3845 has analgesic effects in the LPS, CCI, and acetic acid 
stretching models of pain as well as anxiolytic-like effects/ digging behaviors in marble-burying 
assay (Booker, 2011, Kinsey, 2010, Kinsey, 2011a). Similarly, the MAGL inhibitor JZL184 
reliably reduces nociceptive behavior in inflammatory and neuropathic models of pain (Booker, 
2011, Ghosh, 2013, Kinsey, 2009), blocks NSAID-induced gastric inflammation (Kinsey et al., 
2011b), and attenuates anxiety-like behaviors (Kinsey et al., 2011c, Sciolino, 2011).  
Having established that inhibitors of FAAH and MAGL produce anti-allodynic and anti-
edematous effects, we tested cannabinoid receptor involvement in mediating these effects of 
JZL-184 and PF-3845. Our pharmacological (inhibitors) as well as genetic (CB1 and CB2 
knockout) data indicated that anti-edematous effects are mediated by CB2 receptors and anti-
allodynic effects require both CB1 and CB2 receptors. It was interesting that the combination 
mediates its anti-allodynic effects via CB1 and CB2 receptors. Previously, PF-3845 has been  
shown to mediate its anti-allodynic effects via both cannabinoid receptors in the LPS model 
(Booker., 2011) and JZL184 has been shown to mediate its anti-allodynic effects predominantly 
via CB1 receptors in acetic acid-induced abdominal stretching, tail withdrawal assay, CCI 
(Kinsey, 2009, Long, 2009a). In our studies, either rimonabant or SR144528 have completely 
blocked anti-allodynic effects and several explanations may account for this observation. As 
shown in Figure 28, one possibility is that administration of JZL184 or PF-3845 elevates 
endocannabinoid levels in the CNS as well as in the periphery.  The antinociceptive effects of 
these endocannabinoids require activation of CB2 present in peripheral tissues (Hohmann and 
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Herkenham, 1999) and CB1 present on CNS and PNS regions associated with pain. CB2 
receptors on immune cells, triggered by endogenous cannabinoids, may suppress inflammatory 
responses in the peripheral tissues such as paw or dorsal root ganglion (DRG). Indeed, CB2 
receptors are expressed on activated mast cells (Facci et al., 1995), which infiltrate peripheral 
nerve tissues during an innate inflammatory response, such as that initiated by carrageenan. On 
the other hand, elevated endocannabinoid levels in brain regions such as periaqueductal gray 
(PAG), rostral ventromedial medulla (RVM), associated with pain activate the CB1 receptors to 
activate descending pain inhibitory mechanisms. In situ hybridization showing CB1 receptor 
expression on dorsal root ganglia nerve terminals and CNS regions associated with pain such as 
the dorsal horn of the spinal cord and PAG (Hohmann and Herkenham, 1999) supports this idea. 
Moreover, Walker et al. (1999) showed that the electrical stimulation of the periaqueductal gray 
(PAG) area as well as formalin injected intradermally into the hind paws elevated anandamide 
levels in the PAG, supporting the role that endocannabinoids are released in response to pain 
sensing pathways. In addition, Hohmann et al. (2005) demonstrated that intracerebral 
administration of inhibitors of endocannabinoid metabolizing enzymes into the PAG potentiated 
stress-induced antinociception and led to concomitant release of endocannabinoids within this 
brain region. These enzyme inhibitors prevent the rapid degradation of endocannabinoids, which 
allow prolonged action at these sites.  
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Figure: 29 proposed mechanism of action for anti-allodynic effects of MAGL and FAAH 
inhibitors. 
JZL184 and PF-3845 inhibit MAGL and FAAH and elevate 2-AG and anandamide level 
respectively. Endocannabinoids are released on demand in regions associated with pain but are 
rapidly degraded. These enzyme inhibitors prevent endocannabinoid degradation and thereby 
reduce nociception by stimulation CB2 receptors in the immune cells (neutrophils, macrophages) 
and CB1 receptors in the dorsal horn of the spinal cord, and in the brain (PAG, RVM). 
Simultaneous partial MAGL and complete FAAH inhibition reducing carrageenan-induced 
inflammatory pain  
 Another major observation of this dissertation (see Chapter 3) is that partial inhibition of 
MAGL combined with full inhibition of FAAH produced enhanced anti-allodynic effects. Two 
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pharmacological approaches were used to test the impact of dual FAAH and MAGL blockade in 
the carrageenan model. First, we have used combined administration of 4 mg/kg JZL184 and 10 
mg/kg PF-3845. This dose of JZL184 partially blocked MAGL and elevated 3-4 fold 2-AG level 
in brain (Chapter 3A Figure 9). This dose of PF-3845 fully blocked FAAH and increased AEA 
brain levels 8-10 fold. In the second approach, we used a novel inhibitor, SA-57 that is 25 fold 
more potent in inhibiting FAAH than MAGL (Niphakis, 2012). Both JZL184 (4 mg/kg) + PF-
3845 (10 mg/kg) and SA-57 have produced enhanced anti-allodynic effects compared with each 
enzyme inhibition. On the other hand, these inhibitors produced a relatively small magnitude of 
anti-edematous effects produced by intraplantar carrageenan.  
As reported earlier, prolonged blockade of MAGL and FAAH produced differential 
analgesic tolerance. MAGL inhibition over six days with repeated administration of high dose 
JZL184 produced tolerance to its analgesic effects. PF-3845, on the other hand, maintained its 
analgesic effects upon repeated administration in the CCI model (Schlosburg, 2010). Hence, in 
the present study, we selected a dose of JZL184 that partially inhibited MAGL and a dose of PF-
3845 that completely inhibited FAAH. It has been reported that JZL195, a dual MAGL-FAAH 
inhibitor, that equipotently raises both 2-AG and anandamide levels, produces greater 
antinociceptive responses in tail immersion assay and in acetic acid abdominal stretching test of 
visceral pain than inhibitors of either FAAH or MAGL alone (Long, 2009b). However, this dual 
inhibitor also produced cannabimimetic activity similar to THC and other exogenously 
administered cannabinoids, such as spontaneous locomotor suppression and catalepsy (Long, 
2009b).  
To the contrary, partial blockade of MAGL combined with complete blockade of FAAH 
in the present study did not produce psychomimetic effects as assessed in the tetrad assay 
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(Chapter 4, Table 4).  Similarly, SA-57 did not produce effects on tetrad at a physiologically 
active dose (5 mg/kg that produces anti-allodynic and anti-edematous effects) except mild 
hypolocomotion. Importantly, this combination when given repeatedly did not produce tolerance 
to its anti-edematous or anti-allodynic effects. These findings consistent with previous findings 
showing that repeated administration of low doses of JZL184 (4 and 8 mg/kg) maintain anti-
allodynic effects in the carrageenan and CCI pain model (Ghosh, 2013, Kinsey, 2013) and also 
maintain anxiolytic-like effects in rats (Sciolino et al., 2011). Additionally, it has been reported 
that chronic exposure to a high dose of the FAAH inhibitor PF-3845 did not produce tolerance to 
its antinociceptive effects in the acute thermal tail-withdrawal test or the chronic constrictive 
injury of the sciatic nerve (CCI) model (Schlosburg, 2010). As tolerance produced by complete 
and prolonged MAGL inhibition with high dose of JZL184 may represent a drawback, the 
aforementioned results suggest that the partial blockade of MAGL and complete blockade of 
FAAH can be used as a tool to increase efficacy and circumvent tolerance. The observations that 
combined inhibition of FAAH and MAGL is more effective compared to inhibiting each enzyme 
alone and the prolong inhibition of partial MAGL and complete FAAH maintain the anti-
allodynic and anti-edematous effects in the carrageenan model, suggest that this strategy can 
serve as a powerful pharmacological approach to treat inflammatory pain. To test this idea, a 
novel inhibitor SA-57, which has differential potency at MAGL and FAAH (Niphakis, 2012), 
was characterized in vivo. The other major finding of Chapter 3 is that SA-57 completely 
reversed carrageenan-induced allodynia, though produced partial anti-edematous effects in mice 
similar to single inhibition of these endocannabinoid catabolic enzymes. Similarly, SA-57 
significantly blocked all spontaneous withdrawal signs in morphine-dependent mice compared 
with single inhibition of MAGL or FAAH (Ramesh et al., 2013). Although SA-57 produced 
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antinociceptive effects in the carrageenan assay and blocked spontaneous withdrawal in 
morphine-dependant mice, at higher doses (12.5 and 5 mg/kg), it produced a subset of 
cannabimimetic effects in the tetrad assay. It will be important to have a separation of dose 
ranges for  the antinociceptive and anti-edematous effects and cannabimimetic effects. In 
addition, the effects of repeated administration of SA-57 have not been evaluated and should be 
assessed in future studies. An alternative approach in the future would be to examine whether 
repeated administration of a dose, which is inactive upon acute administration, produces 
antinociceptive effects following repeated dosing. 
  Why are inhibiting MAGL and FAAH in combination more efficacious in reducing 
inflammatory nociception than blocking these enzymes individually? A possible explanation is 
that MAGL and FAAH inhibition elevate anandamide and 2-AG, which not only activate CB1 
and CB2 receptors but also activate non-cannabinoid receptor targets. In particular, MAGL has a 
major role in the biosynthesis of free arachidonic acid in brain from its precursor, 2-AG 
(Nomura, 2011). In addition, FAAH metabolizes other bioactive fatty acid amides, including N-
palmitoylethanolamine, N-oleoylethanolamine, and oleamide (Cravatt, 2001, Cravatt, 1996), as 
well as N-acyl taurines (Fattore, 2005, Leung, 2006). These different lipids activate various 
transient receptor potential cation (TRPV) channels and peroxisome proliferator-activated 
receptors (PPAR-) receptors (De Petrocellis and Di Marzo, 2010, Di Marzo and De Petrocellis, 
2010, Jhaveri, 2006). Thus, combined blockade of FAAH and MAGL triggers multiple 
neurochemical alterations that could affect the magnitude of reducing inflammatory pain. 
Another explanation is that dual enzyme inhibition produces enhanced anti-allodynic effects by 
merely increasing total endocannabinoid brain levels to stimulate cannabinoid receptors. 
However, the fact that 2-AG levels in brain are at least 200-fold higher than anandamide brain 
 134 
levels (Ahn, 2009, Long, 2009a) tends to argue against this idea of mass action. Alternatively, it 
is plausible that simultaneous inhibition of MAGL and FAAH may produce augmented effects 
by activating distinct cannabinoid receptor circuits in CNS and PNS associated with pain and 
antinociception (PAG, RVM, dorsal horn of spinal cord), as well as in immune cells. Consistent 
with this idea is that FAAH is predominantly expressed on post-synaptic terminals (Gulyas, 
2004) and MAGL is expressed on presynaptic terminals (Dinh, 2002). Also, these enzymes may 
be expressed in different neuronal circuits which can result in augmented anti-allodynic effcts by  
interactions between two separate synapses i.e., via crosstalk between distinct anandamide and 2-
AG-regulated neuronal circuits. Regardless of the precise mechanism for the augmented 
antinociceptive effects upon dual FAAH and MAGL inhibition, our findings of Chapter 3 taken 
together indicate that this approach offers a promising strategy to treat inflammatory pain. 
Inhibition of DAGL-, a major biosynthetic enzyme of 2-AG 
 It has been well established that FAAH and MAGL are the primary hydrolytic enzymes 
of anandamide and 2-AG (Cravatt, 1996, Dinh, 2004, Dinh, 2002), both of which activate CB1 
and CB2 receptors. The final goal of this dissertation was to assess the effects of blocking 
DAGL- one of the two major enzymes responsible for 2-AG synthesis. KT-109 represents the 
first selective DAGL- inhibitor and decreases 2-AG levels in peritoneal macrophages and in 
Nero 2A cells (Hsu., 2012). This compound reduces the level of 2-arachidonyl glycerol and the 
downstream lipids AA and prostaglandins in macrophages as well as in Neuro 2A cells. 
Concomitant with these changes in lipid metabolism, DAGL- inhibitors significantly reduced 
the LPS-stimulated production of the pro-inflammatory cytokine TNF- (Hsu., 2012). The 
suppression of TNF-α production by selective pharmacologic or genetic disruption of DAGL-β 
could be due to changes in endocannabinoids, other arachidonic acid–derived metabolites that 
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are not biosynthesized by COX enzymes, such as leukotriene B4 (LTB4), or a partial versus a 
complete reduction in prostaglandins. The results presented in Chapter 4 demonstrate that 
DAGL- inhibition produces antinociceptive effects in the LPS model of inflammatory pain. 
Specifically, KT-109 reversed LPS-induced mechanical allodynia in mice. These data are 
corroborated by the complementary genetic approach in which DAGL- (-/-) mice treated 
displays an anti-allodynic phenotype. In addition, KT-109 did not elicit any further decrease in 
allodynia in DAGL- (-/-) mice. This finding indicates that KT-109 most likely mediates its 
effects through DAGL- enzyme. The anti-allodynic effects of KT109 were independent of both 
CB1 and CB2 receptors. Importantly, KT-109 did not produce cannabimimetic effects in the 
tetrad assay. In addition, repeated administration of high dose KT-109 did not undergo tolerance 
to its anti-allodynic effects.  
 Finally, unlike the NSAID diclofenac, administration of high dose of KT-109 did not 
elicit gastric ulcers. The mechanism by which KT-109 reversed inflammatory pain is yet to be 
elucidated. As depicted in figure 30 the plausible mode of action can be the reduction in 
arachidonic acid, which serves as the precursor of prostaglandins, leukotriene, and other related 
lipids (Kite., 1983). Accordingly, LPS is predicted to increase prostaglandin levels through 
induction of COX2 activity and KT-109 is hypothesized to reduce the available pool of free 
arachidonic acid in the paw and hence reduce prostaglandins and other mediators of 
inflammation. We will measure 2-AG, AA, and prostaglandin levels in the paw as well as in the 
spinal cord in future studies. Nevertheless, cyclooxygenase inhibitors or NSAIDs the most 
widely used medications in reducing pain and inflammation, exert their effects by inhibiting 
COX-2 which is the enzyme responsible for converting arachidonic acid to prostaglandins.  
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Prostaglandins are produced in the gastric mucosa where they exert a cytoprotective 
function. Hence, decrease in prostaglandin cause serious GI adverse events. In our study, we 
have shown that the DAGL- inhibitor KT-109, despite reducing prostaglandin does not produce 
gastric hemorrhage in mice (Nomura, 2011). The in vitro data showing reductions in 2-AG, AA, 
PGE2 and TNF- from macrophages ((Hsu, 2012) and in vivo data showing the antinociceptive 
effects in mice, make the upstream enzyme DAGL- a promising target to for the development 
of analgesic therapeutics.  
  
 
Figure 30: Proposed mechanism of action: Anti-allodynic effects of DAGL- inhibitor, KT-109. 
KT019 inhibits DAGL- and consequently reduces 2-AG production, which in turn leads to a 
reduction in arachidonic acid. Reduction in arachidonic acid in turn affects the prostaglandin 
production in the peritoneal macrophages. Although the suppression of TNF-α production by 
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KT109 or DAGL-β knockout mice is less understood but it could be due to changes in 
endocannabinoids, other arachidonic acid–derived metabolites such as leukotriene B4 (LTB4), or 
a partial versus a complete reduction in prostaglandins. Thus, upstream blockade of biosynthetic 
enzymes regulating AA production leads to a reduction in prostaglandins and other pro-
inflammatory mediators underlying inflammatory pain.  
Integration of endocannabinoid degradative and biosynthetic enzyme inhibitors  
 
 The purpose of this dissertation was to test whether inhibition of enzymes regulating 
endocannabinoids biosynthesis and degradation would reduce nociceptive behavior in mouse 
inflammatory pain models. The results reported in this dissertation support the following 
hypotheses: 1) inhibition of the endocannabinoid catabolic enzymes MAGL and FAAH blocks 
carrageenan-induced edema and allodynia; and 2) the 2-AG biosynthetic enzyme DAGL- 
reverses LPS-induced allodynia. In the first part of the dissertation, we have shown that 
inhibition of MAGL and FAAH increased 2-AG and anandamide, respectively. These elevated 
endocannabinoids reduced inflammatory pain through CB1 and CB2 receptor mechanisms of 
action. Hence, elevation of 2-AG and AEA mediate the anti-inflammatory effects through the 
cannabinoid receptors.  The second part of this dissertation shows that inhibition of DAGL- 
produces antinociception, despite the fact that it reduces 2-AG levels. Although these two 
approaches are seemingly in contradiction, DAGL inhibition produces antinociceptive effects 
through a distinct mechanism related to reductions in arachidonic acid. Arachidonic acid is a 
major precursor for prostaglandins (Vahouny et al., 1978) and other ecosanoids. Therefore, 
reduction in arachidonic acid leads to reduction in prostaglandin levels and reduction in 
prostaglandins play a major role in attenuating inflammatory pain (Ricciotti and FitzGerald, 
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2011). Another question that arises is that if reduction in arachidonic acid occurs following either 
MAGL inhibition or DAGL inhibition, why does antagonizing cannabinoid receptors completely 
block the anti-inflammatory (allodynia and extravasation) JZL184 and PF-3845? A plausible 
explanation is related to the different magnitudes of  reduction of arachidonic acid levels in 
animals treated with JZL184 + PF-3845 or KT-109. Inhibition of DAGL- inhibits 
arachidonic acid by 90% (Hsu, 2012) but partial MAGL inhibition and complete FAAH 
inhibition did not reduce arachidonic acid levels in whole brain (Figure 9) upon acute 
administration. In contrast, repeated administration of low dose JZL184 + high dose PF-3845 
reduced arachidonic acid level by 50%. Therefore, a different magnitude of arachidonic acid 
reduction might be responsible for involving two different mechanisms in attenuating 
inflammatory pain. However, these results strongly suggest that alteration in 2-AG biosynthesis 
or degradation play a major role in reducing inflammatory pain (Figure 31) and support our 
hypothesis that endocannabinoid regulating enzymes represent a promising target to treat 
inflammatory pain state.  
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Figure 31: Integration of endocannabinoid degradative and biosynthetic enzyme inhibitors. 
JZL184 and PF-3845 block MAGL and FAAH respectively. 2-AG and anandamide levels are 
elevated. They in turn activate the cannabinoid receptors and reduce allodynia and 
extravasations. On the other hand,  KT-109 inhibits DAGL-, reduces 2-AG level, arachidonic 
acid level, and prostaglandins level, and as a result reduces allodynia and extravasations. 
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